var title_f36_25_37264="Calculator: Bedside Index of Severity in Acute Pancreatitis (BISAP) score";
var content_f36_25_37264=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"BISAPScore_form\" name=\"BISAPScore_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Bedside Index of Severity in Acute Pancreatitis (BISAP) score",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"BISAPScore_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           BUN &gt;25 mg/dL (8.9 mmol/L) (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"BISAPScore_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Abnormal mental status with a Glasgow coma score &lt;15 (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"BISAPScore_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Evidence of SIRS (systemic inflammatory response syndrome) (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"BISAPScore_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Patient age &gt;60 years old (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"BISAPScore_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Imaging study reveals pleural effusion (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          BISAP Score Interpretation",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0-2 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Lower mortality (&lt;2 percent)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           3-5 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Higher mortality (&gt;15 percent)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       <b>",
"        SIRS",
"       </b>",
"       is present when two or more of the following are found: &nbsp;",
"       <b>",
"        1)",
"       </b>",
"       Temperature &lt;36&deg;C or &gt;38&deg;C &nbsp;",
"       <b>",
"        2)",
"       </b>",
"       Respirations &gt;20/min or PaCO",
"       <sub>",
"        2",
"       </sub>",
"       &lt;32 mmHg &nbsp;",
"       <b>",
"        3)",
"       </b>",
"       Heart rate &gt;90/min &nbsp;",
"       <b>",
"        4)",
"       </b>",
"       WBC &lt;4000/mm",
"       <sup>",
"        3",
"       </sup>",
"       or WBC &gt;12,000/mm",
"       <sup>",
"        3",
"       </sup>",
"       or more than 10% bands found on blood smear.",
"      </li>",
"      <li>",
"       Please see appropriate UpToDate topic reviews for further information.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Wu BU, Johannes RS, Sun X, et. al. The early prediction of mortality in acute pancreatitis:  a large population-based study.",
"        <i>",
"         Gut",
"        </i>",
"        . 2008 Dec;57(12):1698-703.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"BISAPScore_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37264=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function BISAPScore_fx() {",
"with(document.BISAPScore_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1.checked){",
"Score = Score + 1;",
"}",
"if (cc2.checked){",
"Score = Score + 1;",
"}",
"if (cc3.checked){",
"Score = Score + 1;",
"}",
"if (cc4.checked){",
"Score = Score + 1;",
"}",
"if (cc5.checked){",
"Score = Score + 1;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 0) && (Score <= 2)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 3) && (Score <= 5)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f36_25_37264=null;
var title_f36_25_37265="Breastfeeding side by side";
var content_f36_25_37265=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Breastfeeding side by side",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Side-lying position for breastfeeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Caroline E. Brown, DEd, CNS, WHNP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37265=[""].join("\n");
var outline_f36_25_37265=null;
var title_f36_25_37266="Outcomes of ART by stage of procedure and maternal age";
var content_f36_25_37266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58270%7EOBGYN%2F62286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58270%7EOBGYN%2F62286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Outcomes of ART cycles using fresh nondonor eggs or embryos, by stage and age group, 2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 455px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In 2006, a total of 99,199 cycles using fresh nondonor eggs or embryos were started:",
"    <br>",
"     &bull; 41,369 in women younger than 35",
"     <br>",
"      &bull; 23,376 in women 35-37",
"      <br>",
"       &bull; 19,775 in women 38-40",
"       <br>",
"        &bull; 9346 in women 41-42",
"        <br>",
"         &bull; 5333 in women older than 42",
"         <br>",
"          The above figure shows that a woman's chance of progressing from the beginning of ART to pregnancy and live birth (using her own eggs) decreases at every stage of ART as her age increases. As women get older, the likelihood of a successful response to ovarian stimulation and progression to egg retrieval decreases. As women get older, cycles that have progressed to egg retrieval are slightly less likely to reach transfer. The percentage of cycles that progress from transfer to pregnancy also decreases as women get older. As women get older, cycles that have progressed to pregnancy are less likely to result in a live birth because the risk for miscarriage is greater. Overall, 39 percent of cycles started in 2006 among women younger than 35 resulted in live births. This percentage decreased to 30 percent among women 35-37 years of age, 21 percent among women 38-40, 11 percent among women 41-42, and 4 percent among women older than 42. The proportion of cycles that resulted in singleton live births is even lower for each age group.",
"          <div class=\"footnotes\">",
"          </div>",
"          <div class=\"reference\">",
"           Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2006 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2008.",
"          </div>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Percentages of ART cycles using fresh nondonor eggs or embryos that resulted in pregnancies, live births, and singleton live births among women aged 40 or older,* 2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 441px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Success rates decline with each year of age and are particularly low for women 40 or older. The above figure shows the percentages of pregnancies, live births, and singleton live births in 2006 for women 40 or older who used fresh nondonor eggs or embryos. The average chance for pregnancy was 23 percent for women age 40; the percentage of ART cycles resulting in live births for this age was about 15 percent, and the percentage of ART cycles resulting in singleton live births was about 12 percent. All percentages dropped steadily with each 1-year increase in age. For women older than 44, the percentages of live births and singleton live births were both a little more than 1 percent. Women 40 or older generally have much higher success rates using donor eggs.",
"    <div class=\"footnotes\">",
"     * For consistency, all percentages are based on cycles started.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2006 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37266=[""].join("\n");
var outline_f36_25_37266=null;
var title_f36_25_37267="PUPPP abd thighs";
var content_f36_25_37267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PUPPP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 479px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHfAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1reeMH8aa7E4PfNR5KjGeKQ5OCDWdxrQmXPRq898XXovdW8qI7o4PlB7E967LWL77BpU0xJDgFVz6mvNId2/kAM/JJ6ms6suhtSjd3LseOC3Wr9thgNoG4DgZzVALlcjp19jWjZoqRDkBsfMRWKOpKyLUfp3PBIq2qquTjA+tRQAqoyB6YqbapTB4FUItwqBHz0JzzU8alQ23kHvVcPxHyoC9T6iplYY+Vt2egz3ouKxYhZ1KlOR/FnpirG7MjBTxmq0Z7kc45qeKQLGQFwq9MdqYEgG9Cshw54yOKsRf6oDduxxVeJnddwOCcfK3arCkKgTGMf560CH8Few9qRx2HXuRUeTyQucds9aVmOOcAnk4oGSKemRyeakxgAY4x0zUIOecY9xxT2XpjPPWgRJGQWx0OM4pxIH3e/c0xB2GaV2BHyjIoCxIrlOAMe+aXzPVeO1RlF5znOf1okbC47+uKAFT947E8VaiI4A6e9VLRGSIAkFu5xVhc8Y4HU49aBNEhJbdsY8cZxxS5O4DHTr700tgBV6ntQVIAOOO3NAiUEE8HOPWkdRMpDjOOQMUwHaF6Z7jgYp6sRjPGfegA8oBg3TB4we1S7i7YXGMUzBXJYZBIxnsaTiMHsSfzoDckB+Y4x+VK2XI689u1MJ+UY7037xHJ9vSgRKiIJFz1U8Yp7A+ZyAFHFJEoY4x9cU6UMIgehyOi0xMHJVemOeg7mnxsSuSCCetNkG36ehGacpJA7CmBIBzx1pvzlTvC7vY0zcSxBbkelSLj3wBz70AIEAxnrnGaB1HqOtIRyeTgnOMdKdgBOnGe9A0I+OSOSeMVEWJOfTjFPOWySMY7CkIyCOnqaQDMFuwFDZ2+jCgg5wMHjg+1NfOScLu6Ajii4DXzgc5HXOMZqKRscYyT2pxPLcZx2JqBgcEkk/jSBDXfLZP4YqJ2Xpxkd85ocAdOcH8qjYnOeOKZQjsQuDx71ASR34qSVh2GfeoPl3fN1HIFILFeWPbG6ox3E5zVSRipOeT61YunLY2nHr61Ulbjc2GFIspXD54UnHXpyax75jnGAPWtS6JHPQj+dZd8+Oo5J9aQztzyQMU/AVc45zTwox07VBe3C2ttLM+dsaFj+FdRwHF+ONQ8+8SzjY7Ivmb3Y9qxYQGAyMn1Iqs0zz3Us8g+eRi3PbvVqyyeSMgHj3rlk7u52U42jYsRjAAGTx09Kuww4YSLgHuPWq1uWYuCDjPBxWjA3HAGF7HvSNF5FiLBG7JPH8R71MiM5QZBjzz9KjXa6EO2ARkn0qxbx7E2KMrjg0ySeEqZNqgAIMkDoafMqjBxlugx2pApUnIOfpSgYdz0J4GaY0SxZjBLsBgYwKdbKAA288nIJ9agBZ5gFxsAyfWrSBg2SRgjPPrQDL0ZVhtI46ZPb2pS2M5OVFVlYLnceMZ4p6YZFKlgG5HrTJsTK2AmBuyfwqVzuHHSo1duB0I6n1oLnHYZ6mgBVDAfJ8wJ61JuOSSF9iO9R7wwVkpI8gDqD0INAyYHGCcinrtVwrHk8gD0qAscc5A9acn3VOMEd/WgRNI+3qwI9e9MEm4A5/GomiEww/Kg8A08gKflwRQGhOH28r17U+IYYsCcnrk1GuGXpzilQk4BwoBx9aBFhMAnIXHv1pJGJ56UhULHtLZamgklVKrgjtTECSfOvHU4BxmpXJcYU7T3NMRGBGFwPpUqBVzg5PrSAm3ZUYOMd881GCCfWgDqxPXgU1GJOScqOKBEoAPUA/zqSNVDHnKADCkUxc8449M0L1wScHuKAJQRkjke9PLts43Y9agV0cgKQzjr7VIvI4yB6jimDQrKSowxOeppVGCM5zjikbcB3wKVQSN3OB2oEPAO4EnDY7U7uSTz6VGQSeh+lOVffrTAUh8jpjv600sVHydfejjjJGe1NKgH5cZ680CHNhsYzz60nRuvTt6U2Z1jUO/C+1QQXEUzM0WcnvnrQOz3LBB4Pb0qInPJBAHQUFsDr1NIT8pHXA70hDGwwJBB9qryZXouM+lR3F1HbkrjAJ5btSiQMpK45NIuw1yMZJwTntzVK3mSUNjJKnGKvOMe4A9qqn5Cdq4HUH3oZWgm4buM1WkkMrFkGOcfNxipnfOARzUDnnHv39KQIqXXGDwSOoFUy/cEfh3q3et0CnBz+GKznbP3gu0VLLSKdwx6en+eayL1jwM5961Lg8kFgc81l3uG98nqaQM9IJ4xkZzXLfEK+EGnRWqEh525/3R1rpgDknqRXmfjS8+1eJDGDuW3XYPr1NdU3ZHDTV2ZRyqqoJBbt7Vo2kYWBtpzxkVnRRlhK5OSPlX+tamnP8A6PkglV4HvXMdyWhbt0U5XknrVuFwHOByvFQwSIcKnHbBqeKNZN4BwRxQNF2FD5ePlAJ5yOTU2wqpYthSMDNVrd2JCNjcP4Vq6oAXBPyhfzpoQu5o1RcEgj72acqMrLJg5H+c0x5ApjTbw3GeeKsxgleVzzyKAv1FCuZUIOVzk8c1Z5BIC8k9aYF2sDg+uOlSM23gAnHJzVE7j0b9f1qUAZ2gFd3OB2rMZpZpx5PyqpB6da0Ivljwo468+tJDasKrsJgpB46mpz86kdOMUwEBenU8c0sEqyA7eSOCRTJbHBFTIHA7Zp4Gep4x+tQugaQMc8ds8VOo6cjFACBUJDcexFNQ8dD15p27AG3p6Ypo+Uc5BpDH5GMZ/CljCjnv6VEeRgcml3ZOKALCkZ/rTg2zGeQeoFRqSfTb7UAg9CADTEOjYkvv4GcLU6lRu54PANQ/w887RSJyOWOB2xQInLbjuO4Z44pQSpbnn9BVO/uhbwMVJJPT2pNKuHu0BkfgdutF9bD5Ha5fBy3J+YcZpwIUYbJGeecU8uqKuTx0HFLcLn3I6HpQRcXPzArk+47VFJOkZ3vnB4yR0qWPYw27wXHUZrN1dMx7OQvqKCoxu7MvxXKM7BAhH+yec1ZVhtJPGOwrlbMMso2FiF457/WuislcRKHAJ96SbZVSHKXCC4+TIyOlBGwDPSmxhiBuXDdMCpVU8AjIxVGYxckZGSPQUvU8dSO9SFFyAPTtVS68xZQyOQAcEDmgErlnaM4JGKjztyQMg9qeD13jB6detMYqHJGc+lOwjP1YsbfuPQelU9HiOAxOFPODWxKodCG5B7EVCExzgAe1T1uaKXu2JeZAeny018IMEgZHWkj3Fs4wB1xVTU1Lx5RsZ4oJiruxBeWiyoxG7J9utLEggh2H5j0qKCV44ysxI5xk/wA6llZVjBJA7jmjzLd9hdw3fMOPTFVZWLeZnAwcDFOeTup+X2703PJOM/pQSV2LBc5B+lQTZLDORxmrOTuyRg46+30qpIzBmU8AdO+aRSK0pOBkDg8c1TkIDGr0jBlByAT+NU3IA4wfepsUjPnXuOcHNZ14SOOM5rTn56dM9Kzrv1znpnHakDO/mmWKCSV8AIpYn6V4vNcG5vJpznMrlv1r0nxpcmz0Gfruk/dj8a8yhKrGwycDC5HrW1V30OahHdl61YfY5CD83OT+NX7RvItFLHAI3fWquQI1hUDa3B47U+8O94IwCUJ2kZxgVizsSNXTI/3aOwDFuc5xitOGJVzg5Gck1QtRtALKQqg4A71d+0xgRjBy4yPX6U0S79Cyikzb88DtipFASc7W3EDoTxRDnPbbjPvUNjG/myyyHJY4Az2qhWLsiho8EjPtzU9vGEh2BiMDGcZNMjRixYk4IGBU1uJEzuOR2z1oF0EhlZmdXDMq4GW7mpYjGWG8HaRjPqaVdzqVfG4+hpBhdsZJ6cY7U7ATLuB+UAU1CUJYuTvOCppGLkhRxng/SpUA3EAMR60CE2SGUuHGzsKmhVIkO3jJ6e9NwFG4LlunrQgO4nAC+9ArkyjIz60qNtXJY4Jxz3NRb8YHGfQGl34AbBJoGSE4bGMDvQGz2qFnBbax5NPZzu25OMdu1ILDiCee+fWlRwMrjmm4yc9OPWkcZGOAaALGRtwCOe4pPmA7UxSMYBAA4pVYY6/TNADwSNwxlscZpIEcKwY5JOaevByevqTUEM0/27YE/dY646mmNLR2JLiFJIGjcZzTNIhaCNoyvyDoPar045xt+pppAC/KfrRbqLmdrExaPcpY8DpVhRgqeoPqe9UBHvVS+cdcdjUtvLIw/egKOw9KCbFho8sWHy+4HWqt1bmZCAx6cGrQkbOcDb6+tOx0z0J9KBJ2M6z01YyzM25sjHzf54rUUmIYx8o70/ywwOMY9acYz5eFxg9ieKqKCUnLcr3MUkiqyOV2nJGcZqeJT9n2M53EdcZqRWGzay4PY45pWyoHcEdaLWFfQW2QQRBEOWx1NND5GBz3yB0pVXdgjrUCzETmMIVQnqvrQhWY/BYliSSOwqnqMzxAhQQR6D9K02+UZ4BPoKik8uRfnUH1zTaGnZ3MfSZppGyynaTxk9K0QAFLNyPemXMZjiAgAAPXA7VXu7ry4sn5iuM4NRsU/ed0TuCP4htI4X0qBfKeYqVyy8ZPSiO585IzGMxv1HenNtVz9OKBWtuV763M4yAQBWfPEslv5U3U8ccVpzSAoC7kAjtWLd3ZnPkrjg8YGf1pOxrDmZZVQihVOMDpSHAJC4FV4PNiH70ZJ9+RU+4sBgdRzmglqzGFDgbgfzzVSQlCSQM56Y6VNeiWJWZGz657VQiJkD565zz3oGlpcjcDcxJO6q02QueOD+VXpl+Q84I7+tUZHKDkfiaQynNnA9D055rPu1ZELnkDnFaU/wA4wTkdKzr1v3XB5GQBUgO+JN1ma0tFPq7D9K460BZoUI5Ylq1/GV19p1+cFvliQKPrWVpWPtKs/RUAFaTu2Z0laJrttSRGk6KpIApNJX7Spnfgbi4FR6nMi2wTPzyHauPWtCxtmt7FU4C7fmPvUG5MtyRCxPdto71Ytg3miVz0GAo7Gs2FA2okrwIR0A6k1ba5IWWUsAsfB9CaQ7GqrDG3cxC8kirMQYSfKcxsMEVV0+FjAjE5VsE5HWtS1ZCvysF7YqkiJeQ4zIpEeAp6D1NWLZt+VI+73z0NQ4V2CY3Kh5NWh5cZMRCsSM4HpTJ0tZEWX+0gcMvUnpipx8xO7DemBxim4YA7eFHQdfwpsayu678oM9BTFcmjcYEmQRmnAsVdi/yN90UwxhFYIeGOeaWIKAgULtHB470ALEGKtknI9KQkdUOPb1pYOAzAkg+lNZUBwSAcfNQPdihfmYEknGee1TA/Lt6YHrTEizHjnGPWmxj5scE+9AbjuAwAwxB5NSF9pHUZOKYxCgnGCe1KmWHzYPv60gFfnqc/UU4Njkn6Uoxnng05hlcgDigAHJxnApyHPHOOoppTqUHI6e9OXIQE/ex0HagQKw85UOSTyfpVhcq20HA60xB824AHjNIj75CjHj0pgywXYdCOeDVcK4I3OxLHHHarDIVwDwPUVRF65u2hEbcchgOKbQRV9jS3AKBgbv5U6J8qQclupOMgVg3M1yJF3Mc55BFbNlsW3Esznr3oTu7BKHKrlreEQFlznjp0qVFIUdz7niop4vMEZSQBM5xjg1NtARQc7RjFUZkkfzN8q7TjkVJzswCMenpVdA6scHC8jpU8T98cdsd6FoIXgjBPTpT+CgDDjsc02RArA4IHX2HtR06dO4NMQ4ttAAwR0yKeiB1POCeMd6x76+e3PyDeo7AZIqxYzrMA+0qxGOaE1exTg7XLN05jh3KMiqlreGYgMF3HoMcVdZdwKN0JqBIY4GOEGR0pNagmrWHTrKsWY13noRnpWPe20m4KgyW6ird5f+Rnb1A79jVGC9NyRhgwPB4qZWehpCMkrotW9uLZAzsQAOaraleGGEyRoCOvvWjJ86bJFyPWqFzb7yB0TGMH0ptW2FFq95GbZ3El5aAsdrDqMVFb2ciXJkyQo7etaMdutuoyAqetDrtH973qLFupvykK4YjIwR2NLFhSw6LnjIpxT5iCOe30qIhlYqCSPamTe5nX4lty0vmZUDkHnNRRS+bEHU8Y5q5exiaJgobBX8qyoo5I4iqcIDmpemxppJFxts8RjbnPOaoSOhVjgnbwx9aS3kc7ieP605wCj55J7Ubk7FSQoyj5sselZl4cY4wemauLEbeJnftk+9Vboh8YPfOT0pA/I43WpvN1K6cFss7VLZIVuYYwOSN7H2A4rNuW3zyyAcZ/Hqa2NLAlvHkz90bM+lWyYaIW8OdRtlKLj7x+tdJ5iiBiyjO3JxXMahxerhsuxUYHYA9a6IHMDDHG3APrUGj6EGlEt5sxGWdjyOmKi1FvLjgtww3yvuOOO/WrenuIYhCwGdu7GelUr8j7aJX24iiJAzxmixaWp1kMqwQIoIC8fn3p9rEwbzV99o7Z7VQspPO06CUjDMMnNaEEcnko27aOBmq3M3oPa8MRYkYIGataRN5qq7YJPT3rL1WXy7cshUsc9RVvQk/cKc/d5BHQmiO42ly3NR+JRg5BBOBTi4IAXGcADPamKODu+8TSYyflXg9c1RiOYFhwQT6gUq/KxjVSDjOT3NMdsDKqxI4AFTqxZQCcEDv3oGMb5QDw2R0zVQIzXI3J+6xjJ7mrUpKoxVdzAce9JvDxKHGHJ6CkUn1HR5inKjlWGd3YU8bFcsOWxio2J7jp6VGWBPyt2yfrQF7ljep9iBnHvTC5UlyDtAycU2LaQeuBzk05DjIAAX160gLCjegOMMadzkbRTAFOCAQT2p4XejAttPqKBDwCOQ3+FSx4bIBw1VbjzFt38sfPjC4/nUWiJMsbiVgzZ+gp9bDUbq5eZGy2wn5hx6VTgspYrkTb88YC571obu2O3rxSg84zn0p2TEpNbEpB2DcD82PpSeSp2sAx2nrUF5M0UG44zjhe341etWRrIM+BntTTuyHdK5AV85t3l8AHnv7VYjjBj2kBSOxqOVjsfypPmONoHalSVkt2a6yxxyaGh2bRaTcoAY8Gn2/mMCDtCAdB1rKtr9ZZhsTEa/LgnJ+talxPFCAxYEM2FweTQnpdCcWtB20sxGTg8Y70SLKVAiIGDz61Lav5sO9k2kdcmpxFu+ZQB+NUtdSb2K88hiUlhu45ANR2M7MrNLlVHHuaebV5JzI77o+wNNYumIxECg5zjjH1osx6NWHS20N6Sy4x2IPUd6kjt4Ywq5XC89ealgKRptQYAPQVHfRK0DFV6HPFMV+g2ScbSYjuHSsX+1GW88thk47Dp+NaMKQzW7LGGXB+Y9c1EdPVZV2/MzdSegqWm9i48sdzG1MPPtO0bzxgVNpduttGXkUDA9elXLmUW4fEYBTkE81m6dqJvd6PCAM5+bg/lU6XNbtx8jbQqY96g9OAarmUku0qgBfQ9aWSXyIcuysQvQjmsm8vWuUxAoU4zkfw02zKMGy9HNFcJ8hBAPIxzUDqUYgk5qlaRS2sIkcMwPJPrV5xkKw4yKkqUUnoNJDEd8nB9aiutscfmOTgDJIpWHljLZAPQ+9NYLPuWQ5QDHFMVrMiWRPs6tkBT3IqpJHuVs/d60ajsS3Oc7R0xUe7/QgwXc2OM1JSRTXJUsi8AnpUYJ4yMYqxNu+zEJjfj7oqrKxjtlaUdKQ9yrOd8TK+CTWbIARt9uhrRk5Tf1UjNZ8xAcsDkUrjseebzukBxgkAn15rc0QhbWVwOGcnjrWAT+7Z15IfOPwrZ0psacNuQwBIrR7ER2JLVRdxSPjLCXGPQV03ysse8Y+Xn1rm9BkCWMxIIO8En8a2Lu78q33oo3rwAT3rM0d76CW4VtXlTPG0D61B4i3CeFWJjQ5zgfpU0KIL3I7qGY5xk9qh8RsXureIYBPfPSg0V7nV2cO7TrcIQoC4xTridbcxohLfwgD1p+nbfsaxueFUY96x7icnxFDFnI6+gFPYziuaTL2onNrGWQsXbbjr+NbWloYLRFK8AdMdapyW5NxEMjA7ntWlJJ5NuSxUgDCj19DVRFJ8ySQ5Mu77lKgY2j1p4VtxBxz3J6e1R2ErTwAuSrcMGA6068WZopNjKJCP3Zp9DN72ZNFkZCHI21lCUxXoheb5M5/H0qxEZI7fEr9Fwzd81iyy41JQASmP881Mmawje51LBMrsx8w//XTcgFSMjPGcVS84WsI4y7H5TnpV6RGRAUIyeSc9DTMmrEbgrux1POajA4ZeoxzTpWDFV4DKO1RXlwLeMscbug/xoY4pt6Er8CMY+UtirAPXjAxwMVV06X7VArsCxHOe1WgpAABznv6UMHdOw45bpnjqKlVTj14oiTcrfNwaGBHXp+VFhXE53AN0I4qSLCJxjB9KaM4xzUijYoyOPQCgCRfcce1Lgsw6fNTVODgcE9+1IHXcA59uapbCIYbiO5EqGJxsbaAw6+9aEOGTax2rj06e1Z10BEQ0ZByRkY61qQxiSIMrfgaEOXcWBdpIweOahvI5JsJGAQT83NWo8JM21hvI/Kq8ZlW5O/GzpwelMUd7lSysXtXLZBUnPDd6vSJjEuQxHXPr7VIrNkjgsOCOmakYExfd6dqVkhubbuws7szy7clccdM5rUePacrxgdaz4Y0QgqqoSMZ9Ktwl1QrK6uSSQV7VUV3M5NN6IfGdw5+UgdKpXszxZaNenY9KuFGdsggP6UyWNJQQ/LYwadrgmkZEV27PkhkJ645rS82QKpyZFbjpgfjUCQ28TBWbDngAnNSpGbeOSWXDJ0wDSWhbaexKrZjY7Qg6gDvTQwkiBKkSdDjtTLW5E27aCOfTpS3G0R/uyd68kDpTItrYivIRLGUzufrz0rMhsTayNJMFAPPHNTR3JCt5g3SDtnHFUpL+V5XQoTGeQPpUNo2jGW3QivbgTSYIyB15qjbxuty7SZEbcjHarMMSvMxbCnjK561bvIhFD8o2ioSvqXzKPuorXDszoittBPU1bB2qM4571g2czrMyuWID8ZrWaRzKzHHk8AHHU0J3JnFrQW8P2gKrdEOcVBIwjRxu5Hp2pxO3c2Sf6VUnbe+cbVHGKbJiZMV000rhwSM4ArSLqkLMwwo+6Khjt08wsMqT2p+qyC3g2gDGBmpWm5o/edkZv2tnkkGB8vUmorrdNEsZPfmq1shYtzhXYke9W5m8q3LAYI5yf51I3ZOyKt03lKEBAG3HXvWTG3zMM5yavzzNNCpAGCOTjmqUcZBKnGWJKijqN7HnsRzHOFOPlzn6VrWEnk6aXOMY6eprDhwfxQ5q8JP+JKMH5jWrMImnp7FNOcZw0hJGfXtWtcgeRbW/Bbcu73FY7YTTLZ1b5VIJ9a17sqTbS8ZRSxwO1SzZFi5RZbpI4htIZSxz2qlroL6zEmMcDBNWI3xZ/b1OXbAI74Hao9YfF7YzkgLnBHrUlx0Z14lENkCB91Tya53SHS+1cXAzkZXb9K3iyG3JYjBXv0rnPDULLqVwVUE5x1zj0pvcmn8MmdxHGqh95baSMVS1SR5EEZ+VTgD6Ul7dG3jDbgQBgjHU0CEzMhGWHXPbPem9dCYq2po6Sg8hAGOAcZzWhMu6QsCDz+VZH2hbZBBGOS2Dnua1kK+WWB7cg/0q1qZyTvcqaioMIUMBnqMdTXP6dAbjUHZiwwcZzxwa3b4qsZlJ6KTXOeGZTNfPnhVJOT3qHrI0hpBs6VbWMynzlICDcDngmppJQwJwSvp0xT/NEnDcMexrN1CXy4yMgZ7+lU3bYzV5NIsWk6zTu4wAOn4Vk61cmOchsHe4xnoBS+HC01tI7PkZ+8PrVfxAvn6ra26r8z8/UVEm2jaEUp2N/QgyWhYkjcPTip7qTGFBxuOOOwqS1/dW+wnIWq0mWuFwAPXHT6VeysZN3k2M025MNyYWfeOoJFbEzDHJJGOazwiI4U7RI5AzjrV5kYA9P8aSTSCTTdwBAwBx9e1SckYLEA88HrUEgyBnI9qmVcqACAaCRA/UBRmsS+mkgvQS+QW4JrYkjYRMqN85BAOayba3juYTauWZxwWPX60paqxtSaV2zaitvPjSR2wRgrg81oCRVTauTjvVO1j+z26xMSSvGe5qdeE4x3xVoxlq7EqZ8xmAAyKFZsEBgD13EVXWQ5GOTU8XLEyc4pksmT5sAAbs9fWrZV41Bx8p65rOuEcyI8ZBPpirpnKIjSABR1Jpp2E1sSbsqSAeP096gt42ikbJJG7PPUGphGAC8ZIDDJ5pIzhiuePanYC2cBg78nHUdaSZpGUNCFOPvZ5yKhhYjAUE/UZzUzRkRkoNueo9PpQTsQyQq8gdkGcDBPGKJU3LwQQR+dSJJsU+Zj6uapC4IeQl1KnoM9KBpMkh4XOCBnpUs6F4GDEDvx2qISgDJDA4zntTFdmbY5Uv3xRsg1KlrBFgvh33HGWH61DOggX5gSxPy4HStFwjxqAzBR0wajLmRyDggd/89KnbQvmd7mFplpOs0kkhY5bIPXFXpx5x8vg/3iTVmeTbIY4AygD5j6VRVWRjLJIGc9l6EVNktC2+bVkcMCwMWkKHHb0FEki+WQCNpHHeo9QidlABBU8nHFZsErfPCP4Tw1K9tBpc2tyIXMktyykkImRVromWIU9uO9Pt41IdwAXHNV7seaqhiFYYJGeAaWw3ZslmJigZ2GD/ACrM1F1nRS7YYjHtUzmTJiYbgTleazbpZEfcSAgzkdzSbKitRsYTy1IG4r0wacxEimNuFYYpsToAyx54/KjJ6seo49KQmZ1xKbeWNMHYTjmoL0sf3i8DHXHQVcuITOd5ycc7feopkEtuduQCMc0rFXR5Zat88eT6jB71YB/0KND0LkY9KoxHY8ZzwDxViVmEJxjiTP04rU5qb0Ogv5Numpx90gcdq0rmUJpDOo3OE6+1Yt6+6xR1YlRtLLWm587Rm8k87PyqW9DdMnsSsmk20C4O9h07Vc1FBcana27bQEG85HpWboTgyW0IYEBDx6Gtd4/N1BHXGFU80i2+puB1mieFCpwvFYWgN9n1WS3wDIckmp9Gm3Xt1En3UGME+vNR6cgk1ia4KqFQ446n60AvdTRo6qP9IhiAJDvkj0xXQ2MeyLA5JHA7AVz1y/mXkRB3EdD6ZrobMxyldpw69s8VS3IlskUtkkt+OgZQSMjIzWqJUUKmfn7c9TUcjLES7DjpxxmsWW6/0mPZ1ZiTjtij4RL39S9rfFpLt4JXnJ7VjeHH8q3kf7wIIz3FXNeMn9nI4BbByw9KfpMUS6Zv4UMCSAKWrZasoa9SbQb8ajI7MpDISp3egpvia4EdnJjA2+uOpqj4Z5mnkz8xbg+2areKJRJcQW2CcuGOe9T9nUainVsjX8P/ALjSlZxzjO2ordnvNciuXBxECoHb3NWLUbMWyrnKBj7elTRWckEasCM7stz0FOz0IvZt9zXndSMdQBVZ/l5XBPuKXzARnHOc1Huw/OCtUzFGdcXrJqkQbIB966QlpGRmYgAcg1yF6yvr1scLhByPU11ayAxDAIyMnNEdb3NamiTG3V0IFY5yx6elZVjdSTagxaTnA7cVduwGjcN0AJzjpWT4UHnSXBZvuvnOal7oumkoNnWzRhowAcEjPHUiswQLBfPLlypGfo1aUkjYwo4Poapzkt8mcZ/KraM4N2sW97uAeQe4FSDI+UH6gVXt24wcYxjrU5IzjjJoTJYZXvwatQuAiqwyW5Jz0qomFU5GfUUyCSQXJyo2diCKbC10aEkscbZkLe3/ANakSUXWI/mZBmsXVfOBJRx83IyeaZpk3lMsbS5YZLc1LlZ2KVP3bo6eKeCJPL3bgBz3NTKY2TK9AcGqEjQzlSIv3mASw6A1PCzBWGTyelaIxaQ69uZAFEaEY/iBpLe6nRlEi7lJ+9g4FBZf97B5PpRuDkMuWAzk56fWgNLWLF2yXGVYFQeh96ykg2SGSR9wXgH0q25Dj5CA2OvY0Q8IPmLc8kihgm0h8TFWJkG8dqo3bPIzeQrZPQdhWgihxn+HJ75oaSGIkbM46kcflQ1cadmV4kKwL5v44rOudQjhmVE6vzg9quX9/E0UihHUL0296x/squRM42rjOCetTJ22NIJbyJ90skpLkhGHr1qVIzsJACKKajK6DaBmkkUyp5eSMc5HFITB9zH7uAOmapOiGbHygk5yKtTPhJEXnHGfWsqMbpGkfIK9MnFIqK0J3LJlRjAOMiqrfNk56cmg3O4PhtwqSNwIjzgnsKQO60ZHhQ+Sypx+NZ126yh2QcL196jnE815v6xrTrlz8qrg+/pUtlpWKljGUjzIfvE9RUzoJCCBnHNTYBVfl96jZG+6OCe1Am7u5TmnXLIvYcmoEXbHtZscdKneILIxIAHGBUbgiNnbDnOAvrQCseP8k9M4Oc+lWWfMQOeGwc1WDHPbntT4TvhKkcjitDlps27aQSwSxMcnAxmtHS5QBPA53AAAEjpmsTSXxeA9FZf6VeSUwz3ZTqCD1pNXOlMtaCWg1XbIcvyB3FdWsixrJ5fLMCwUnpXMWSqdWEi8BlDD05FaDvIuqZydgTPHekynuWvDpV455yoV9xJ9KuaUhWSWT+F2J56VlaHHJM85LsN5J47c1vEC3ifaeFXLKfSkXN6tE0f7yQup+5xirekzSiTeBwScY6CsjTRI0GUyWbJ+ma6HS1EMZUEgkc5HSiO5E9ESX8ge1KyKNzGsO3xNrJTAARQBz61q3twuAg+bJPIrL0g5nDnbuA2g9OKfUUFaLZf1ZpDYGHgsflGP61VlP2XRcuRuC7Ac9eK1RApYuRu4xyevvWTrcSzW7xDlQOg7Gk11HB3aiR+GN9vaDcMsQctWXr8xjv4ZFbhhnBrQ0+YppBIJZlHbFYSMNTijhlOJ1PHqRS3SRtDSTkdxp4BhWcAEsAKsGQscLnH86q2Q2WscTEZQYB+lSk4UkqCvXmqOR7lhWJbFEhxtA/GoVBIOMgAYzQXO2mCRjv5f/CSL5jFUCjHua6ttqLhc9Omc1yd5IiahCsoxGcAcd/WuiRyUB4JI7UkaVNbEhJKMpX73XNZ+lRrYXMiS42scj2q6dwA+YE+lO2K2HZRuAxyM0MI9magcZVgQwPY0SqCc7ev6VnQO0c2CRgnIBq5kkkFiSexFBFrACI1yOamDcDd+lQqpzg4/PFP5zyevpQA8sc4UZGciptpyOuDUSJxjOe+6lUnADHGPWqTESPEGOZFBIHWo1t40lZ9oHv608spB3Z5PSlyWTaCOOlPQCSMlRxznqD0qYSAEAL9MimxMgA6hgPwpE+bIYsynnrjFMTRMI5E+cIQT97jGanRXAD7hk8cCmeexdCrNs+7sz1pHmLMNmW/A8UyR7lUJbqxPfg0m3Ct5alc9WPSkDhlwSc59MUwswDZYnPGBzigQ+J40B/edT6VBqDykFogu0DAUd/eo3gBbzFYsSc5J4/Kkldy/zvlccDHWl0KSSdxiF5owWUbz196bdI6oFYcdlp6SOqkoevrVRJ5XlJlYbRwAKT2KS6jokEQwTyajlfAP3ic9+MUrOC2OppHTfgdCT+dIfW7IDLw28keuKrzB5gFRRgjgnrVyeBLfaW+Zj2qrcXUayKq/xcYFIa7opxW6W4K5BPPalK5U4/8Ar02aB5JlZ2YHqBSsnPLZAHep1G+5XweR0J7elNChvvDae9SyAAgcU23RpLht+fLAwAO5oAjkAQenoBUROxlznaO3rS3cbyz5bCKGzwetJPINu7jIHTFAPyKE5Xzny+STnaaSVMoQAfrUduzSzGbaBnpmppGCxuT1C0imrOx40QCKRGKN9fagkg+g9KJc4GOMdRWhwRdmWYm27ZEJBXJFaZbzI2lXO1o8Vk2xDRyR5wcZU1e0aVmikibBI7dqDrjI1/DjLO7bnwVGFxVm8le0undTuQoOc1jaXM9peS4GFBwCPrW3dkyQTuThivA6jFJo0i9dTW0hFS2jmhIJbsT70rzudXKk5Upkr+NY1vcNb2Fsc/IWGcHpzWsy+V5lzKBsA4I71Ldy9maWgHyZXjVflB49q2ri5CZTgN0HvWJobl4TL0L559avXIDMJD0GeM9KeyM3bm1KkspW8VUbjZkjr3qzZOsV5vPy57EevtWRYeZPeTmMjDNheK6KKEopLqBJ0FJbltpaMu3BMYaTOSOmKybaPzZJhKflPTBrQ3NJCNzAMSM02R8gqqgEcdP1p2uZc1iiLMQwiONsbic+9cpaYtdVGFPyMcs3ua7GUlQwbk461yesgLqJz0JBHajRGkJNppnZxMPKU5PPWrBdBGwHLL/DWfYuXt1x84wOlS5YklDgk4/CgyLcU7eWGYAHqBTWbOSxGemKgc/L831J96VGDKdw5oGUtVtvtBiKH54+R71r2UzG2QkcZ2nJ796rLtZyEwDUu0qEK4AJwBSKvdWLq4IzGMnuamjyQAeTRbMvmCMo3Tlh2p0iZfMeOucUyGyTbkbsDd79qmQjAJ6+tNjUgbiMMD07GlVyFIfG7+9ige5OpXuMnrilVc9+M+lRp2ODzUkKldzDByaYgYHcSMY6cUkYO4FwCPzqwWLgDrnHB7Um0EEdB6UCuI4OQc8elCqC2FPuc8ZqUoAA2PfJpgiPry3aqSAVCMjblh0qZBGUYdGFQGMox+YDnseaesWw98fkabYEq8L1OV7CnB9gG4/MTwDxiq2/+FQB7+tKHycuOR056GhCsTxDfuJPOe/SpLiGNY9xZQMZ61XWUL0OfYf1qK5H2mMZZgBxxxii4rak/wC7Rl2fOpGeDTZpWMgWONCvqewqp5ZXbsYhE4xmpVYAEZPpSvcGgf3yM9B6VFI0cKl5GUDFTYDEdTxVa6kQMUcrkZyP6UvMcSpb3SzTthPlA5J6e1Wbm7jt1JXBYdSf6VWjuEyUjwVzwdvWo7+HzlCglTjk4zSLaV9RYpzPvlYk5OAD0FVvLb7WJCBx1xUiwFDsLEKvO3pup1x8sLHcEHrQO+uhCGEszdyvANRyAuSF6dPxpbeNIkLFixPPBp4JKEruAJ445xSJb10GW8PB8zoDyR3FRI++eYoSIwABVlgcEEk84waomFzPtVkRMcjueaWxcdbkd7cCONT5eGJwM81SvJCwZR8rOODV7UI0JVQwyOeudtUb8orwbfmYnPvj1pMpa2I4I1QAdu9QXjq0ixghc5OParKhtxUthjjt0rNvPnvxIrcAFTxQLd3PLdgLHOPXrUTZU4bvVq7j8ud1Azg1WfNannjIWENwgycj5SPY1cs3EF45HAbkVRnG5dwHI61JCwnTBPzAdR2NBvTdzUlmxdo+cBwCRjrzWvqUjLaxYbkkDFc3DKz2/wAzANGcnHetSeVjaQzA4QgKc84NJm8XqasoWWC1hJALHnI6Vtyp/oRizk7cCuceVZLO3lT5XVhV953W5hV2J3Lzipdi1rqa3hWQyWRBPKnHSti8VjG/zADGDjisLSC0Vs+PvqT04rR0y7N3DJHIDuBI9aQpb8xn+H28u6uINx+VsZPUGuqMgCAlvmH41yrRmy1QEYaKXgn1NdCHBTjAOOBnmhBU11JvMfeuCCvejzWXII561CsmQcgA+9LuJySMimZgWOzByzfyrn9dgDxrcKpLKMEHmtuQ4OAdvrmq7BmikRlyjjHWkXF2I/DcgksEBbDRnbjPU1sqdqjCkcc5rl9NtZ7VnQfdJBx6VtQ3ySZiKgMRg54zQhyV3oXH4jJckBxj8aiQucKTu7VGXIAXOVHGc0F2jkBQZIGQPehkI1lhbrtxz3pxOWBPOOM9KWG4Mluny7SeSSaMfN83OAOR60Ar3H27tnA+6OtXIf8AWEnkjkZ4zVe28sTIkhOXHQVorGicKcY6j1poH5kkMuYhuQg9x1oCDpgevWnqcoDwQfQdKb3Jx9KZNxdv3QBj15zUg4Ge/wBaahBJz19KkABIzjFACbz0IAz+FPBIIPoMZpypzwAQfWiRCuCVz7+lAChjgqBuX370v3iQq85wCTTFG7rwf6U85Ck7MD881fQB08aRJvZ9nPAPelKnaTkFD3PWow+1SuA2exqUkBSzEkgdOlAEYILLsYBiOhokchcEAfUUgVS2SMk8cmhlVs4zgc+tJbDY2NlBbYefRjxSswPUj1OKaV6Enj0pOBjZjFDExZCoQDP0JpDNEiku2wDg8VGo3cIdo/2qDCsiEMVI7nOcUg9SO5utjokLcnnI64qKa385zJGPmxye9Stjnpg8LigsDD5a7gR3A7UdB3tsRRxMjKN6k46nmobiUQFtn7wnk4qOZzDkRkseOvOaRBFHGGk4dzyPWkPzEWYlssNpxyKYpM+RMFUA8DrxVjZFu2gnc3Slii2nAx6j3oC5WIMc5VQDEBwfek2EtxwCR3qx5B+17jk54AApt2TBCSAu/HFIFqMMmJW2MQB2qjOdxZmBDe3enxMzIvTJ6tSTIJA2CM+wpMoyI/Me4ZyPlzwCO1WXRA4dsknvmpIVWMfPjBOMmoZ5d7OpUKP4aQ27soyzDMjD16VVnxEqsCCxGTTZGEbOeWIbv61GQ7ndIeMYxjrSB+Rxnia1NretgED0rDYA8969E8cWOSz4OR3rzx4zu2881s1qeZEYVBGex4qupENx84Ozirm38PrVeZCwIGc0I0i7MX5kkYoOByQPStTTLiKRGt3P7thxk9KxLaVkdQ55Bw2fSrWxRIyduqNnoaLHTF3Nm1jkCvCmW8s/d9R6iptIvN1wYZx0+6W6iqWkXzeZtk+8Op9adqCFJjPEOOvA6etSap30OsMzRNhUO1hncO9GnXq2hdZJCvmnIJHIzVTSLpLyBc8nGCMdxTLpondfL/1kZB2GpaKi76M30tQzCUsxB5C/4VdIUNEpba38OfX0NU4XIiQHIGOlKSJZznI443HnNBN+5pSZBPO44+77e1V3kYBeWXA5xUMk5D7QACwxk0qTAl0cFmz1Ppii4l3J5ZNzAkEAjgGi2KsOUyu3qT0NQupdd2cBe4pocIc4/H1oEWAVkiJIy2DwO1RTSAhSF4BFRowIkZHGSeVPaopZ3SM8lpFHakCNFmDcgjAxipYVLYwx5wTzVSG4V4FbBxjJGO9aNoF8gZyS/IHQimO5cgOyUFsYIOSO1WtwkcsvA7jFVIl4wRgkdKsqGUgsPwpkslVAzgxjBx1NW4QVZdx4Pt1qtAw8wAA7ScZ6jFXHJjkGcH+lMHcsK0ZnEQb58dPSphGAwyTgGqe0lw5AL45OKnSRwowM++aAt2JduCMEZB65pygkZY4z61CWfC4U4zyTTxIku1WUAqaBFtJNwOxBx1NMDlGIcD/EGq7fMOoxnjHaphuPGdwA4GaA0JVmI4AzkYFJg9DkEnpUagAHdwT0pDkjgkHsasCZShkIxgD2pJW6gkbRnFRk7Vyc59aV3JXYAuOoJpiHEO5LNjYvtShiPQjGevak3OyBTwe5HGabKXwNyYUHnJpXsOxETtbGcg/y9Kc7fKQMEdcUyTOcYwvtTZDlSg+UH35qAtcaZOfnPB4welSxhEBCqFUDNVdw3AAA46mnB2AYAACmhtDfORjhPmCnn60iy5DBRxjtRsHyrnaT6CnfZ2Ay2MZ60g0KKeZIWLED0FL5QOGDHC8Gr0sIQDceveotuFIJAB5oC4woyR7yfkI6nvTfMRGWTO0D07U4FmUA8ADjB5p8kKsD3Qc8mgPUha8+SRRhSOQ3ese9viXWIglivLVoTLwVhVSc9R6VVWyBYPJGN554qXcuPKtSOElI41Zg2RzjrUdzI+4CHgDqRVlY0RiGJy3H0qteSJGAsSDP1xRYOpVmuUiEYCk5PTHNVp5wxyqkMR+VIkTzzGWYcdhSSxHBJ3E9AB/Klcp2Kcf32yGwOd2KbM2VXaOKvgRxxhpomkRTlwpwRVHapcHkDrz1pCN7xJZJc2z45OK8e1O2NtdOpBHPFe8XcO+Js9D0ry7xjp5SRpNoxmuiS6nlre5xLkYxnmm7eM5pzoQcUh6dTxUlla6TCl0Hzd/cUkE210d8GPgNnpj/AOtVnjGKqTp5RJ4MTdfahGkZ20LkuLeUTwtgE5BFbYZZ7RmIBDr0J6GubtZVbNrMQQ3KNVvTrg2kxhm/1fvQdCZqafOLCYDJMLjg9RV7UCwlS4QnnjKjmqU1uGtXXhk+8uO3vU2mSie3ME7fNH0x1xSauWn1N+x1FJ/3WcNgEe/1q67KSDnIHAArl50U3UclmypLzjnhvatq3uHIV5l2nuPSosN6bF55HORkAY4b0NOeUui5ckdCR1zVaaSPKg5JbjIFI77Cw+XGOueaRN3sW1cKuFds9/ekE+5ArLkLxk9xVKOTYpVAADznPrQW+c4yPxoAsuyiTcueMk4pyqXPXDHpVFm54LA9/SrdozNt3ZG1ccd6AuadsM8lcnPA961YDxyuCD09RWXbENHhMqT+laUJcYDH2z600Lctw5HAPvgCrSZwQxyB+lUojhwSQDj1qZHyCp6ZxxzTA0rZkiGG6nkegpDIzN1OCfzFVoy2085xxUiMT15BHXPemVYuRhmLc9OSPanrIpww+6R9M1WiO595yMjBx3qUjjaACD3oCxYMgY45/CpUQCPO7k9CKqqflGGHSpCSGwjA/SgRYXJOCOPfgmnKGB4+UZ4NQkk8EZ5xz0qRJk5BXJzg4oJaJzjjd9RUkR5cPtCkfKfWonC+WWGdnv2ppOcFTx71YE8ojCDaGxjp6U0gbRgHOOc9KjY/Mp3HjrS5LPg9ucetK4hR04Jxjj0ojVo4/mOdx3EmpI0dizKAADjk4FEy7PlJ3MRnGc/jRa4JleRslQBnPHJ6U2QhuG7eg60rKNvfcOmBQow20nDH8aQ9iHGVPHPoP5UmxgM/KSDjA7VY8rvgk9eaaoKud5G09MDNAuYYFyxPUL0+lRTztKTFGwDKMVYkcuFVCVQc8cZqAqhdn4G7uD1/GgE+41svEC7AkHGcfnSSD5ByGOOvtT1bbkkLkHpUSnOMfd9DQMBtByRke9RX02YQobgDnBxxU5jZjkgKv161WnhXOHYil0GtyC3OExkqMZziiVxGrbGUp1HqfrTUGCSWwD09MVRvAZRJsYqvTOcZqSutxj3IjhdiwIzjjsKqjFxNG7OcYPHYU5rcLGsbc8cmnbMRbcYB6HpSKuh0TASOQAFHANT2EzK1x5W1rkx/ugeue+PeqQDgqMkqB3FOt7FLqeR5JjGkQ8x3Xt9Ka3E7W1JdHjvI70iSN1hbJmLrwR3zWRNgSuFHyZO36Z4rdd7aZCkmpXrpjGGQ4rIaMFlA5XPBPFOSJW9ztMjla5fxTponhdlXtnpXUMucE8GoLmLzYiDjvW7POPAtVtmtrhlPas5uOufr616L4w0ctmRVOQe1eezRNE2G/Ks2VF3IT160Y3DHb+dOdcEZFLxjjrQUUJ4ijHAyueMDkVOJftUAyT5q9D6ipAm5cEfWoLiN4GEkXQcmnuXGdjR0+4Z4xEzbW+6h7GpGnNrNFKyFSo2kA8Ee1ZZm3DzYxwcb1HY+oq9DcC4QpKAVPAPv2pWN4yNuby5IlkicA53A57+tT21zJHIY7oZWTBBrCtHCFoW/dt2VuQR7VoWlwyyCGX5sjCt/KpaLub6sHjBGGCfd560skgMRIxzxxWQoxNujZgD95QeDzT7RgjyYclSfXikFtC7vIA6nA4pyzHaQcZHH1+tVJJNp29CfXmhJPMXJO1gcEGlYRaRsqeeeozV3T5HGMkbQMH1rHD8gryD0z6VctpcjIblu3rQ9Sb6m6kg4wSp9q0IpmkYEnAxn8qzbZAUBPQ9verNm3lMwl5Xs31oRZrRtnABGKuKy7x8wU4/OsiKRGcH05xnrV1Ccgc9eMUBY0QV2DDYbtU0MYkXnaD14rOXKtgnjOKtC48mMvt3MOevvTEXjkNtIUep9Ke0wJ+Xn2x1qKK5SW2LMmJM4pkM2Sei4HXGaoaLg4PGPm61ImApJ4A4zjNVC5Jygz7g1YEgCjPBHXHegGWEI5KcgVJ5QwCMZ6+tVEuGB28MuORSCQ+aTll44BPFBOpcJYHB3KKTewIHvUW8smSRg8Zz0NIXB2kMpxycCgCzu3MoGM+/8qljB37VIBFUhKMnHQ989DTnlVOxJPvTQi/FMhDZVhtOMkYBqJ5I9xZkUSZwG7kVW+0Bsg5C+pNQh1Dgjv6mnewral8/eGOR3zUYXJB9B97uKY9x5YQoyqG67upoEoZiVIwffihhZlgyoihiDu7DNQw3HnyOAhUdBVWYea4cyEKo4UGmxyCMYUc49akfKXH245znHcVCNvLFcZ7AdKTzVb5v4h29femtcAEnOABjjnmhisxJSRyOQvTvUcr8qfuqO3vUDzDDEkr3phfJzu9hSLSJzN5gCnOAOM8VXA3OA5+mKZvJHJGe59qRXCNuVvmHTvRcdh8i7X2qvygdzjNVLz5xtTBKmrfmZLMSTnjJ7GqbKu9sHLk9RSBeZCoI6/MxPOTgU29JSEAAe9WGi24L4z6VXuwHGAvHcd6Q7oq7wGVXznrkc/nVzTmiimlWaOUxumCEH3qpRRq7bg2O1ah1a7VcLIowMD5RTQpa7Ecg0wIwAuwDx0FZCLsyOdgz1647VpnWb0DmVeP8AZFZUrFmLMAMnkn3odugK63OyWQFiP50bjkj+Hrmo0TkmpyA4wSK6DzjH1m0E8LcZOPzryvxJpnkyM6LxjNe1PErLtzXHeJdNVw+0damSD0PHZCVJUimjA5/nWzq+mmN2KjiscjgqR0qCk7jlYH2pkkgbjjaeKhlJQjHI7Uiqz8npQURNG0RJjPHfFCylcuvQjmrG5c4H5VVuYWQ+ZEcexpp3KjKxoxyrcRgFvmzkH0pWJbBJ2zIefSsiObb86DIz8y+nvV1J8MjZZ0PG7POPf1pNHRFo2LW/GCsgKsfXpV2K5hdyj4DDnGOKw/LfBkjcHHbsas291E+Fxhx1z1BpWKuaEsp3c9GB59KaJMnJ5Gc/Wq8k2MEnbnv61Uv9VtbJS91PHEB2Y/N+XWixHN3NcTBt4DdQCD6+1WrWYDacAc5HtXmt145tYmItLeWbBPzMdqkfzqKD4gMHxNYkL/syZ/mKtU21sZ+0Vz26OQCBCOmKsRznZjduxzjNeTaf8SrBYmS4julGcr8oP9a1bX4kaIchpZYz2LRH+lR7ORoqke56UkisNoJAHPJrThnD7W3nK8cd68ytvHOiynKalEuezkrj8xWpF400cKD/AGnaEE45lFJxaL50+p3vnlsnk49OKetwoC7ST2wf1rhR420VJONVsyOg/ejIqaLxdpDkldTtdo4J80UrMpOJ3UNyASATjqOatebvC5yPQe1cGvibTAozqVrjOQRKuf51OvijT8lft1tnsfOH+NPULo7qOdQApzn0FKtyQwU8jGDg9K4j/hKtOjBD6jbblOeZl6U3/hMdEXbnU7PPr5w6UaiujuzPtVipyenJ6UJcKAPWuBk8d6Agb/ibWj7Rk/vM4FVn+JPhtcH+14CB6E0+WQuaK6npqXW3IX5sdqc1ygwPuk9R1rya4+K/h2M7heSSbeCUjOKpSfF7SeRBBeS4ySQoGfaqUJMXNFHr5ussNrDj1FPa5GeoyK8U/wCFtJj5NLuMHoZJFGabL8XgkSuunfKxHJl+7n14p+yn2JdSPc9pe4Y8enPNMN55aklj1444rwyT4wzGRtlnbKARuLSlsZ+grN1P4sajKH8o2SxjptRiTn61UaUn0E6sbH0ImqW0pO91cD3BxUy3UBXzYuBjivj3w94w1fRrm5ls7pU87LOJF3DPbANa1x8SfEsvI1Ly8D7oVRn8KfsnuJVVbY+sDd2yR+YWwT2pn2wMS2QCen0r5Em8b+Ip48ya3OG+6F6c/lxVJ/GGutkHWtQCk5wZe1J0mHtUfY5uxtBVgCeueahFyEXDMVA5HFfHk/irUmhQJqWp+aPvs1yeT7DtxUb+LNelPy6pfL7LOcdKXsmL2qPsF7tf4T16GoXu0xkuufSvj9vFGutydYvj/wBtmqL+39YEhk/tS+DMMZ85uf1o9i2CrpdD7HjvIliYhssOntUS3e48HPc4NfHsviHWZUAk1W9K/wDXdv8AGmRa1qkBBj1K9RuufOb/ABo9iw9uux9jT3LBQqEBjzyegqnHdxwNuDnP8WTjk96+TJfE+uyn95q18SOP9cwqpLquozH97fXb567pmP8AWj2LH9YVtEfWlzqMCPue6jUZycuKz7vxHp8bB59StlPTmZQP518pM80ije0rA9Dkke9REYPIoVHuL6w+x9TSeNtCjPzavYp64lB4qk3xC0APj+1bcj/e4r5mIIPIroPC2l2l2NRu9UaU2djb+ayRcM5JwoH40/YoXt32Pf8AT/F+hXs6KNYsowx++8nStCbWNNVN0Wo200OSSwcDH1rxTS9E0W3ttDsNRspJ7/WFLmUSFTbqfuEDv7/jXA3sRtryeDdny3aMkdDg4/pR7FE+2Z94AjbwaiklKH0zSbtgOD1pjne2e1MxJknzjvVe+tvOBI5GKsIgVQO/ahW+YgDgevc0BscPrmklkYlcDHpXnuqae8UrEKa9wv4Fl3AKOhrk9W0VSrMVx2HNS0J6ank3l5bD9vWmuSBgCtvV9NaCRjjvWIzYY5NQUpXIwgU7j1FNLmQccH2FPkO4Yz0oUALgmgaKc9tj5o8BuhB/iqCGTYdrKAuefatEjepO5QF9e9QS4cFdgzjqBQmXGQ0XLQuFSQICeD/CfY1OHViJGC7hzWVIs0IbywHXGdvXFYOras9rL5dozI5GGBHAHtmrUeYvnsa/ivxG1sn2WyfbckfO/wDzzGOn1rgpJXlcvK7O56sxyTSzSPLI0kjFnY5JJ5NR81rFWMHK7FB9aOKSiqELmlBx2qa3tZ5yBFBLIf8AYQn+VacfhnWpNhTS7whun7o80XCz3MX8KCOM8Vu3HhXV7a2M89hciJVy52j5fwzWMiKcE575AoWoNNDEG4gZA9zSYOeakKrjuuR6UoCYG6QjvgL0oWg2iPHTpg0EYPr9DU4ijJGJlweny808QR4P79BzjJU4FG4rFYjgkHNKqjaeR7etTmNMkh1LZ5G04o2ANyygDHVSKfL3GQMckZ5B70gxgEnk8EVZ+Ut8wQgnPB/nSKikqx2AAYwG5PuKdgISxGQxJ6fiKkSRlbbuPOAcnginLGuWKnnIA+YHI/xpwgc4yrMOgwAc+3WmtAK+5iCOGxx1zx7UqlipUA8nkYqwLcMsOx1Ic9SpGDjpmk8kFQwTGCFwH5znvmiwEIHJBU59McimjGTjPHSrAA+bfFKcHcxBzgVGvkg4dZFb6/zpWQEYjPLDoBkn0pyKSw+XPfNTpFCSuJidzHdxjaB7980hXzAQHbYM7fYZosAwQyNnCMSoye56U0xSKF3IRnkcdaejPsC7mVQMgcD64p/7xgcl3T1wSBn0p2AgEecndgDr2/rTQBt53c9DU6ksVGTu6Y/pQygPgh2DDhh3PalyoCEptUjGTQQACDnPapGYYGSck84GKaGO/DngUWQDQCnHAJ49aQZCkgY7H3pWYgYwTkUg2jnJJovYAwzruVeBxntTSpyRinDBbqcY/Km5zgHuOtTcBxYBNpA3bs7gTx7U3oPl+9StkHDZOPam5yent170hB1IBY8Cug8FSamNXaPSYYZzLGVminAMTR9TvzwBWADg5zgiuj8GXNsF1XT7m4S1OoW3kxzucKrA5wT2B6U0B01x/wAJFF4jllgbSrnUJ7ASW5i6RxAkYiyB82M15rIWMjGTO4kk56k969Xn0yOwv/D2qahqFnDa6XZRpJsmDPI65+VQOuc15bfzC4vbicLtEsjOB6ZJNAj7o292GalRADnORimxtwRnvUkeQwDGshiY3YweO3tS4CsB696JCFGB+QpjZ29O2aAJSi8k8n3qlcwiUEHH0qQOcnJyPSg9c880wOL1zSvMJyg5rz7V9LaCTco478V7jdQLcRlSBmuQ1vRwVbK9ahoFoeSumB0P1qMKxbDHit/WNMa3kOBjmsSVG57fSoKTuRtycAcCkG1WJbnNAwBzmm8kYYcZoKGXCFxyQoPGMVg6zoIvZ02SCNxxnGQRXRElhtbn0pjBVI2g7vX0pp2G9TzXV9Ol025MM2DkZVgOGFUc4Fem63Yre6TcKUUuqFkPoRXmffJrohLmRmyS2glurhIIEaSVzhVUZJNen+FPh8sbJLqQWWU87MZUH+tXPhx4WW1gS9u13XUq9Mf6tT2r0yyjEUmNuO4HtWFSo72RvTpdWU9N0OOBQkSqmBjIXFdDb6ftVT5j5XgE9DToNq5I5Yc1ewDGoQfODknPFY3fU6UiOTTQEYusbZ6KVrA1P4b6Bqtx5lxpcKSPyXiJTJH0rqkkLOpccngfWrcLnefX3oUrbA0up5sfg94d80D7NOAMltshOaY/wY8PHhVuFx6SHn616pGWDc9Tnn0q5BsMeDnI65HWq533JaS6HjzfBXw+3BkvFYjbu35yar/8KM0bCkX14vPIJHP6V7ioQjJIVex9DRPFHKAWAH0FPml3FyxfQ8Ik+A9m6t9l1aYSZ53oDgf41nzfAufzJRb6oDngCSM/MM85Of5V9CpbrliMYP609AUYIQm0DgYp88hOEex84y/A7UwxCarbNheC8RGeOntzmoG+B/iAtHsu7BlAJJIIC+3v/wDXr6YhjjYZPGMj5hmnfZoQp27kb1U9aftJA4R7HyvP8FvFkQQLb2MrNkkrJwPcnHSsq8+FvimFC/8AYkjAEjMTgkn6envX10I23ldwJx1YYNSxxjpuGO/FV7aRLppnxTceC9fsA/2rRb0Ko+Y7T8p9cis+bTLqD5LiC9TK7iXRh+hHTpX3P5CvjdtPJGPSopbC3mx50Mbkjadyg/nT9q10JdJHwn5bxsd4YHGNrqDz6HHUVC0Rf5UR5DgsrE8qOOSK+5ZPCmiSDZPpdmy9f9Sv51yeufB/wpf3v2uK2e3Yks8cEhVXz1yO1P21xez6HyEkOVyeARhRjk/QUnlvHgLKoPJwW/Q/4V9b3fwb8Ky2CxpZGI7cBxId1cPr/wACZ0V5NF1FMuMeVOM9+zdqtVUS6T6HgIaSPDeW24dDnI29DTAyFhhhjOSGHp2xXa6/8O/EmjA/atJdlHSS2O7PPt+dco8TwkrIPmzwskeT/wDWq+ZMhxaKjKA3PBP5H/CnRsGBUALlcdeMjvg1KISS+Y3TGT8g3Ace9M2tIwCMkuQQAflx781VxER4PAwQOCe59aY2dwz1zncKkK7WA5z0II70FRtwRgnoc/e/wpbiIznop4Hc+9NGWye3rT2QeXlT9R6UjAhSAfk6ilZgNIyeD7+9IRkAjpjvTlxwWyB1yPSmtk5IpCAnIHZf1o4yQw70uD0HfpRu6DuOM0ANOMcda6XwTZ6dcNqdzrdo1xZWlv5rBZGVg2cDGCMk9Oa5peox976V0Hgu41KLVHi0uyF/50ZjntWXKyR9wfT60IDd8PyeEdX1SOx/4R+aGSYlYmN07Atg4Dc8ZrK8Sabpx0aHVtIgltVW5a0uLeR94RwM5Vu4rq4tO1OyYy6J4NSxviCBcy3IkEWe6g4xx3rhdY1h5dMtdIW2jt4rV2eUq24zS9C7H9KBH2uFwNy96esmThhmoVYg89KdxnIrIZKy55HBoyBjGcChSGyDx3pAOPY0AMdVAyO9RrkNg8jtUknDfX07UnDewoAY3yv8oqK4iWaPacZqwy4X6d6hYkNntQByGu6V5isCnHauC1TTmgdgF4Jr2q4hWaM59K5DXNNOCWXvxUtD2PKJ7fa2O9NKkLgDPrmumvtObexC8ZrGmtzHu61A0zOKFeRkk0saZ+tSEHd7Uzdwo9DQMfJhVKgZHtXOeH/CrTeJ5ZJkJsoGEgz/ABk9F/CuhOXBxjnp9a6rR7YwwKCP9o/lRzNLQqMbs2tLiMZGQcEdjWrFgOCRgf0qvbfLEuRgYGfrV1IzyWzyM1nc646FiDGSdvI4z61ci2525GT0HsapRMdpVh+VWFGJFxkknNDLNB8RJ6kd/agMRgZyCOlPOXO9Rx3HvQE+XOMKPfvSsIkgfdg7skg81et5PnUK3CnnvkVRKjbkAqw4+tTRYQgtgN2bNPYRrwyRzRMZAAP4cnrTWgeP94rEBhkjHSqTyCOM7Vymc59Ks21+kqZkwFIx0qtAcXuiXfkgEYboDTldgfnAOKcUR0Dqx56rQkICHIOOvpiixLYol8lyzcoe57VKU+UPnOT2qrIeCpwVz0z0pySsFAA9uDQFiZwwbHUUZVZGV93TdmlVeODj1yaFZSQhGGHcjrQITeCSSRViOT+8Ovp0qF41A+YHB54NN27ScPgdfrQBM842PgcjGMjrSFyyKGAHqBzxUIjV8hyemc9M1CbvfII0iIUjkjgii40r7FljvXCKAB3pCrsqlgAwpvmOUAUgqpyahbUvnCGM5JwMrQFn0LREciEPGpPTmua1vwXomsI8d5YQSqfvNtAb8xzW4kxc4C4NTMDnLenQ0XYmrHi3iH4HaRcea+kXM1m3JSI/OmfcH2rzLxF8KPEmmb0jihvYlBb9zgYHsp5zzX1bMdhBRQR3qFDDK7N5ZDHrmrVSSF7OL1sfDt9ZXenP5N9bzW7EfdlUj9CKrMjAhd2R0PHOB2wa+3NW0LTtSjaO9tIZkYFfnQE4rzjXPgxod+HfTzJYydvLbKk+pBq1W7mTpPofMm/HHByOvTNSYDhAuDnk59a9D8Q/CXxDpwd7MR6jApLHy+GGB6GuAu7Oa2naG5ilgkBztlXacc9q2U09jNwaepXwCFw3UYORjFN2HBcEemc8/WnMpVAdowTgHv8AlTd42lcbj6+lBA0ksBgjA69qauRnHXp9ak+8NuDu9RTOh5OcdOaQgJwu3bg5znHNdZ4Bkdotas7adbe+urXbbuz7ckHJUN2JFckcg810Xg+wsLk6jd6oks0Fjb+d5ETbWkOfXsB1JpoDtdB/tDUR4dvoJi9rDE9rqYaUYVVJ+8CecjvXll8sS3k625zCJGCH1XJx+ldSus+FlVgvh+6Ab7wF8wB+vrXJzFWlcxrsjJJVc5wM8DNDEfdhPBz0pofa3zDj0p5GRz1ppTcp9RWQwc55Q05JQykcVEmRx0FP2BfmH4+1AEwGCScEd6RsZ447imA7uepp64J56DvQAFect1/nUbEAkDrTpmJ4HFRMpGDQA3leR+VRXcKTpyMn2qyF3DpzSeSVA75oGcrqGmABsKDx1rjtW04o2SPwAr1maBSvI7VyusWm8so5FS0SeayWO4kAGs6a2MbHOdvqa9Hi0cPyRmsjxBo/lxEqOMZx71NikzldIt/PvVBwUHJFdnZIGjPTBbH1FYmiW5gRuobrn3rpbeEJGiHI7/Ws2dVNWRoQpk4HIXrmtG1jV0Bz3HFY0R4lAZsnritCzJW3Cs4BJzxUnQlcvpFtLA424yDRj5sjgqNxHpSRyIYyQxKBuSaepb7Uu0gxsOSaYJFwzr5eYwWb7wB7/lVuCUNBnaCxH+c1lTSGC6RFXAZSAK0LfHlfOcueDiktwaSVyVGVmI6ZH4VJHKpmCFMg96qaZcxyTyROpx0Bq2E8sny1HBxkHtTWwNW3LksQBVAqlQMmlWFVIwuAeOB0rOM0jMoVxtB+bnFawk4XaMgrnINNaktNIaFOD1YZ44p8EjIzsxO0+q9KIJ8v5YBLDjk0sqbnx1BB96ZPqNdtwx1Hv0NNjIBAAOaTy/7oI2nB560hDYIB5PTjpQhkqs45znAxzU5nUpgfeIxkdqojertuJJzjinZUDoSSewAouFiysjKjeZIGx0HoKIZhIhZdpGeB61TQLt4Y578VJvUBQig+pA6UgsWd2CAep6YppdQuTndTFl6kkMT3qu7NMhDnaAccUAkW1niaIogAVeuO5pDGu8McAL0GeTWbDbbImAkZsHkE1KNwfPOAMGi/cbS6F8SrsD7O+MNStIxbKt8gH1qmCW3ZyGPJx1oEbEZB+btg0xWH/ahJI6sBgHAxTJCq/c7+3NQ3EbRgjGD1z3qJZW7tuwcA1I7dSypxwe3PWlLFfk6kjJ4qLBIydo3c0hMm0ZfKnqemKAItoTcpXAPOR61j694Z03VkcX1rBMGG3LJzj61sM4JLEg9gexqcbSvy/WmmD8zxHxH8F7OZXfQrl7WXH+qk+ZGPueteUeJfAmv6Cztd2TSQxjJnh+ZK+vJkJbjr19DVWWNJVMboGOOeOtaRqtbmcqUXsfE7pgkozYwODwc1Ew2tz1BwfUV9T+KfhvofiAM72/2a8JyZoOC3se1eM+KvhfrOhq01tGNQt1ySY1+ZQPUf4VtGpFnPOlKJwDBSp5znpgV1Pw7dLe71K5jtxc38FqWtoDnEh/iBA68du9cu8UgO0owYcMG4wa7nRPDPijSWNxpd5Y27ypgkXKZI69606mdu5TbxTelzv8NaRvzzmyfP/oVcdO5kmdyqqWYnaowBz0Ar1LyPHvfWbP8A8CIv8K8xut4uZvNYNNvbeR3OeTSYj7lVhzk8dqlydpI7CqRODg9alilycAcViBNhe5PHSnKeMHFRtnrR1HvQA9gVOQMimHLHNPTJwM80xxjk0wHoCBz+NKVyeDmo1Y7cnr3FPiyQelO4DwNrk1KSCue9RgZPOSBRJ90kfTikBHNymB+NZht1ZyGFX1Dbju4H86cY8j5RigDNW1WMjjIzWbr1oq2ksrYwoz7V0KoQfm6Vz3ji58jTIoUI3TPjGeQBzS21KiruxxtmPm5Gd3IH+NaSFmdWc9Bz9apWPLyHt0qyDmeNeeDnAFc7dzuiraF+NMNkfxDJx3NPRXaQBRhV5OKbEWLMoxwSBk0tr8s7A7jtPIpGkdCyZdj/AGaPK5GOnWrkMvk243g5+7071XkEQkVycuPlFTwTmUqojByT155oK6GhHIJlQkAgjgmrMaFScZznJxVKJuSGKgg/KQOlSK8pumLHOR0poz6jAqpdKSDknkit07Ngx1wM1krIoA81lBLdKuLL5bIFUMrcFielC0Ketihc7nnZEYqpPGDV5br7P+7bJlP8XOKWKOLyyr/f6jA5qaJ1mQNuUsOp9KFEbd1YtWjF03Bsr3bHanJcBuY8FAP1qvCcJlHU7j0HanLsjVkjG0HkmquZOzJlIBcszEvzj0qNVOS27ctNMqrhQ/73txwRSvKAANoX1xQFhrIScrke/Y0fMAAQfwpfN+U4OTUkKhG+Z+cZHGaQxmGBwuFUck+tDLhTkEDGfY1J52wZBBbsDTorkSA+ZHtHTkUCKwy4AwcE8DFSuqopDtjPQZqYNF0YcnpVOQ4bIPGetA0Nhk2syCNlX0Pf3p8jAjPI749aYXAHcZ9RTGb5Scg46ZNAdSRJSAwGTnqcUv2kIoyFxjtUIIUHruPH+8aj8wZwVHA5pXHYk89nPzZJI9c4qMkKuMcN1xUnmBmC/j06UjojrhQdwwT70gGbnVQeqnjAHanSSs42q/B71GTjOcDHXNS4QMpz8x6+1AbDYY9q/N1pRJtxzkmmXNySFjjbYRycjrUBf94BkFT19qAtfcvx7GY5JHPBqo7xmdgDnA/OkEpHygEgcD0qItukIbAJPancCTCLJl8c9qhmCjqM5H5VFes2wNECJAc9ODTYbkTR+jdD7Uk7Da0ucZ408CaP4hMkrwCG6bj7REMH8fWvC/F/gfVvDjNJLGZrIZ2zR87R/tDtX1FN/rGG3A7VZW4e8Jtk060lOMFWjyCPxrWFRrcyqU1LVHxOWPqcdetJngA19ReL/At5Kr3Oh+H9FWfktFLGNrfiDxXzLqcEtvf3MVxF5UqSMGQDhTnoPb0roTvqjikmtz7b2bmOcZ9qeqHrggD0qVEHUmlYqAcVmTcapCj1pOnIximgckt0p3LcdjTGIX3EbeB+lTIpI9femLGODjpUgbgYPT9KAEIwRjFIW2rweaUck5NNkwccdPegSI2lJPWpIjk1X2jOfXtSq5DY6e4oKLTgYyppwyqjODTYjkDJ6c0rnI4piB1DDIzmvPPiA7f2vaxk/Kse7p3J/wABXoSEKpz0xXmPjOQXHicrnIjQD9KiWxpS+Iq2w2EhvvE5rR0+Nl+eQgkjb1qmgyN4IIUf5zVuONmt1UnHOcj1rnO1MvJhZcEc4yPU1CkpW4JHyjd9fwqBIZPMWQsWI5Gf5VMn3mVwCxHJFDNY2LkDJLMiup3L0x0/GtFYxGMg4BP61lWn+jHcpJwfm75rUgljlOOobnBFCCfkS4OdwxnpjmkuHeOFpMknHX0p4PTdgKDj61Ddh5ASi4OPu9AaGTDVjoXad1ZlLJgEZ9avmVEli3HBH3Rng1Wso9sbqpGCMilVROojeRS+flwOgpbFuzZqn94qt8uTzwelQQgZbyvvZ5yMjFSxKIlAbA9D1FSmLYN6EFDzxVmW2w2xRBcN65zyatXJjhXcx6nqKoTZd2KjDkYDg9frT13vA4lGXB6GhaFWvqy8Y9oGTkdu1MfDf7JxzxSedlEQ9T+NR3OSwKOCuCD7U2StyeHZGi713AnqKHZGk/dMTjrx0FVIHkX7xOwdAOamQEqcjCselSFgCnkg8DrQZTtGF+b3FK+9eFHyjt3oaN+Ny7cjOOtMQwk7hkHBPUc5qQAncR8oPAHrUSg78jrngHpT8YbaQTjJBGD+VADWGEYEjKnnJzzUaLvGR9SfSnD5dynueRUhVPLUltjN0FAEajarcknt3xTW74OcHn1p0wCK2xxvHPTqKquwCkbuM5HvUspCyDaxbnJ6io0lZTxkDvxzQ7F+p57VEZCOOA3fFAycybl54A9qimmyCCcHtxUUjggAHPFVmf5xnJz3NIEiwX3rxyB1NODhhyTx7daqhyeCMDNKp4AbGe9Ay3Ex9CxPAwDSmRQxyMDqTUcdyY8heO2QO9RzSZxg55zQKxbleJQmRu3dx2qtKgMZKYDZ64qFZCRjOD14pzPlsAHj8jQLYr+c0kRLn5t3JqbTpy01zbrIscs0WI2Y45zyM1UkCu5YNjBwQR1qxaQwSGea4TfHAm/YDjcc+tVEJbGjbrLMtjOsi7YkMdxl+gz3/CvGfif4Rg1pJLuwjRLyMnDDjzF7A16npSwXU/2eeHKy/Krg/cP9a5/UdqSND12kqT2ODVKbWqIcE7pnfPKc4zxSH1J5PaoyABz1NIGJ9ie1bHn2JVyx9DUm3aMimIeOOtNJOcdqYD2ckfLxSxsQCD/+umcDnrQrAsR75oBkx59qaRkDFPxke9IeBx1ptiGCIcnrShB94dBTWJJoEnO09aQxQ2SVHbvUo+7zziouFG7vQ0hP19aAsE7ARn6eteR6jcm5129l9HI49BXpWr3ItrOV88KpbB7YryqBWZ2k6+YS2ffNZzNqO5sQABCAQwIzx3q3YzedakNxjnPtWfZh3B+YBUHNaFsFKKAcc9McVidatYeZyh+U5DAEA/rUwGVVkbDbs4Pp6VHHboJQwzleg9KlZGEsbCMNjrig0i9ieSIpGHUvnP3VFSafIY2fBJZRyKmQFlBByM8HNNtpFa54fkDGMc+9Firt3TLschdQzZA6nNPkLurKAQoXIYHrSqp24DDrnHY0Yy2CuMfxdjVGd7MitTLHCrMMgnkdzVmO3Pnu5JCnkYP6VXSKZZGUZ4ORV0ZKgE8jg/WpS7lyl2HcrEo+aQA859PatK0wYl24wexNUY0JlXHCkY9jUtvEEUKSQM5IFUtCW9C4IcMMYA/iUU2QEn5cnHAzUqMpmCsg4Xhs0/yyTxgt6ZzTM7kCoF6ZDULzn5QPr3qZQwyrgdOoGKRh7D60DuQbBG4A6n0HFWdiuAORtGRjjNM4LnIH9aNgIKZPOc/SlYCaJYmTdt2n3qN0JXCuWXvg9KYUIj2cZPUEmlji8nKo33uTzmiwWEdeVA+YHsPSodhVx3wOxqZ2KnMfY9aQyBmycjA7UAROpVWEhx3HtUanCZwGwOBUjFlQlj17DvUAZSSCTzyfakMCWyTu6DBFQkEZ/vetSy8tjHf9aiKsCTnJ9B2pDRDJkAgfLimcEBsDnpnqKex5DEgjq3fFRMCgwc4J6Z7UFIaSNzDnB9KhfBOSMAVNt3Dd6DucVBISrbF5PXnnIpDF3BCRjPHWmoSSNuDnnNMBJdWJ9vpSu21cg4A9KQDw7Fwp6dTiklLISTyvpUMc5L5HPtjrRM7ZYgDDdqYWEeTa5A6GmGZumcDNQu+QMcHpio5WPmZ5x/Ki4MleRe7cA1eso723vylukZfZlkZhtZTWM0iYJyc9hnvUulQQXUs8l5JIkMSby6EAj600TLY6CT7fGG+y6fZ28hBHmLICfw9K4S8mYSsrEFhkMT65rftE0a9uBbxy36yEnZuKjcfTpWPrNlb+Ql5ZSSmFnMTLKPmjcc84q2rmadtDv8HIP6VIMY7Uqlep+8OKbKAATnFbHnpkihQBg0xyMkg1AZMY5H4U8BmXPJouNIVnyMAVJEvGSOT2pigcVOOBkUCEZ2GSTk+9MSbg8dKY0mSARwaa47jp6igdiypyM0ip82496jgbI9DjpUwJ/EUwEkI2gdqgYhRknHpT5ch+OlRzDKE+1IEcz4rvMWcq9yCK4qy69cccitrxhc4JQMKw7M8kZG7aDWcjaki9pYwrAk9+K07MhpMDseQfastMqGcdQOMd61LRcojqB845xWR1pl6OUF1QDLP+gqRoypPfB6+lQwg+YvynHqOoq06/McqN2Pz+tBQsKMbYjJALZB6VPAkchGAMjkt6fSog0kbqByvVsc4NTRxBDiPOH69hTDYuQF33BwCvGAeDSSbmdo12kFc9eaZG2IyMcdNx5zUoQYX5SMDgjqPpTF1uOimdpkDKPLAwfarUKn5hI3ynoVFV40OAwbj371MrHdgMOfeiwN3J14YKpOOgqbfjbkhc9d1VQzB1GAR0NSFiEyMHjgd6CS7Cq8YKqfSo7uSeKF3tkBcHJUd6itZZJGLFAMcZYVbOZH4TKnqRRe6HsxYLtJ1TJxIRxT3Awd5II9qiEEZmOFVWXkY6inldw/iGP0NNaCdhQAuG9e9SorMy7+PekjjDKSX4PTPBoMQGQ5YD0B60CEYxI2ZM9ODiqs10qsXGAO5qNgxOx8NEOQSc4qCaBXfCsee3+FLU0SS3L1u6zKTjaByM0jAAgK2dx64x26CmQyeUrIofp8x6A1WyzONxG0HIzS2Fa5YlYn5AAexFRRAIeAcdCKkmKliwxk9SDSK8QJ3Dj19aBWCR94ZiBtHQDrUDOPm/kOlSyFSGIwEXv61VZSyg87TxSY0OZs5HUKOBVRiUzkfP2qaXKDAB2nkGoXIGcev50mUtBrsfLAIG7rgVWywG4kbsYxU27cACQDUUhJxn/wDXSQyu5x1Hamux2Dtj0q3CofIJ4qlM4DMgYEA9aY0MMgycdew9KQyYTA6monZSSARjpUIkO3B4OB0NSMleMjBB+Y8gZqKZ2OQVycck0kkw3Kc9DnnrTZLhSoGAW754poTK2QBkkA54FTabd/Z53iMX2iOZfLeJerD2+lV523DIbgDIHrVjw+7+Ze/ZWAvWhxBn1zzj3qluRJ2Rfnih0kfa7fTL7zQCVacgoh9eK5zUNUjk0qG0t43UhjLMzHl3Pce1bGif2qmpoZhci3BJnabO3b3zmuOvWRbiYgDyy7bQfTPFW/Iyv3PZ1wuSefWoZJMNjJ/ClbJPHApGT5i/p29a2Z54wDJ5J4PerCtge9VhknCY+lWEHGG60FXHiPnNSFgFAPSog4DZ5560rjdg9qZIx8ZJFJGRgA9aRzzx0ppGR6UikSMCpGM49qfvAXgk1CsmflI/WnhSGyTwaAY4Hfzg59Kr3beXGx6+pq1s+tU9VkWO2YE9B0oA8u8UTNJenngHpiobYltrbRyBVfWJDJqD7evIp9tllQZw3Tis2dFLY1F2mNSvStDTZlCOCPlUA/j7VnwA7Qh4bGRjv71ashECxQEEVmzpibC7WXcnODnrVi1n89XDDBxxnrxWXANhwN2/OSO1Xo1KSIMBsE/NnoKRWg+VhG4ZQzEHoO1asDeaikgKx/hJqgyrLwq7R65zzU8RbsFQrgA5znFMN0WArfMmR0yCeKkgJK446dz0phbzUVyNj9SM01GOeDg9fr7UxFlAEJVMde54+tSpjOPlAHQVFGvmZJODjkdqliTAJbbkDv7UMRYjwQW2sM8H60u3ngg9uRUcbFSQDz1PNKhz95STnOCelAi1FtXCkZ465zU1tJJuZJFGwfdIqvGuArAEA9atwFd7dlxwT0OaaEx247mZVAbpkmnrJljGQSCM7s96jYfxKR+HNRtIxUkgkD8KAtcSQM/G4A0qyymHa/JXpxjNEeShcrjGMA96ccOpfaVHUc96BkQAGQMY64FMZerEEcfd96lC7gSM+3GKkWIAsxOFHtQF7FfGVAfO0c4qNlVs4XgnjjFWJyo+Y5/Lg1GpAZSMHnoKQyPYSQM7M9B3FN2kZLZzUkjl5iir2+96VDJGy5YMNx6k9KQ0NU7QAFBPqf50hYyBVQc+5qN3GRkk47Cs2O83XkkBiddg+8eAfoaTGlcvshMh3Ocnt6VWbB3Ac9uRjNSfOV3Y5P8AFUEkoUfMeR196kYjNhQcEe1Qsxbng/1pxlO4cYUc1WmkQ5K8YPOaQ0StJ5bsFJz0qjcFRuG3gnJIPOalLblO04x7VVnAAJLHpxTKGMwVWyp3VA0oPPOz1PelMm6IAjHXkmq7qPKJ3dOnPFArkk00aoCvQ8Yx/SqEtx+8JAP55JpkspViV4GPTnNUJZDnIHWixLZckueDwMemaovcsH3RkhweCDjFV5JGwQenetQal4eEeG0u6JHU+eef1q4xuZylYTT7651TUbWzvbu4lt5HCspkPSsK8f8A0uZUxhXZRznoa3bbWNBtrqOa30q6WaI7lJnzj9a5y4lDySOm4LIxbn3Oa0toYSnbY9zjB7n86kJ7frUYBzwalcbVBOAa0OUagCNu/On+YsgYDqKhMnG0/lUWwodwzQFupISwbBpVZ89aaG3n+lPJ2nmgp6k4UMATiqzFlb5vu1Ju2jIIz6UrqrEHqKCbkUI3NmpXbnB6CowCjcdDUmBjpz9aBjjLgVia/LttHYnHFajEq3IGK5vxZL/o79AMUMGebXMm+9kJ54OKt28gK+mMZFZu7deH1IPTtV62ILDdwA3NZHRR0RtRsAFOcADir1u4WUqF5zxjvWZasCrxsPu9Per0bFJIzg8k5PpUWZ0I0VzuU85Iq0jx7VLA4JxiobeVpYN20Dg5pwmxOEK8eppFW1LUkvlY8pFdicgmrunvGwbcMOfmZT6VnhsMQCBVm2lDOpRcnoWNNMe6sTFiN27kNxkdhQrsSSpHzfniklKs4CggdcZqHLq8bKuck5zQCLtu8kcbhySCck062klWY7v9W3OOtVLd5CZAqg885PFWIpNmFZvnJ4460DNII0h3Bhjvk1ISYxjHPWq6bUjaNud5yfaljbZJ0JAHTrmmQWkuHjmcux2EcDGRU8MykncFEeMg9zVTckilztQ9QDTVlI3GUfLjAA69aLisacDq0RYcpnA28Y96fugIHzYzxn3qqGVYlEQJB6kdaesaOpLZJU9O9MLItGFugfcCOvaopEZAAMnmnOflXdxtwF2mldzkDJx7jvQIYmUX5vu5zz/KmkPIo3gYB/hqUSFioUKU7knmm3MhWIiEZXPPFAx8kSJFmWQEnsKqTRbH3JjIGMg9Kp73kmLSY8tf4alU8Els57dMCpuVy2FMjLlioJPtmiWXMaq2CQMnNATcMrwPXNRmRRncMv0B9aARXcMwyV6+nFQZ74GB145q9J85UqqhfX0qhLht23I+lIolZnZQMAbR1x0qpJ8zDcPlHPzDvTzI+0rkFelQvIWztyPr2pDGy85BIBI4FVGfjJxx2NSyEsVUcs3f0qpKMZ34HHT3pDQx3HQj5utRtJsGDgk9PU0yRwSTg7l7VCzEkAkbiMfSgGMZ2CEnOSevrVWSQhQeh96kuHZEbHNZ0sjfKAB1p2E2MuZQEyTyTz61QllKnIbmnyuEzu5wazpGLS4HB64PaqSMpSsLJKACS3GelX7bQb27tluHMNtbuMo1xIE3fh1rHYYb5uTXR6paR+InhurK/tlIiWNred9pjIHIHYitEjmnNvYrXPhy+ELyW72t0qDcwt5QzAD261hO+BwefSum0vTV0TUYr7UNQtI0gO4pFLveTj7oA9a5nP2m7kdRhXdnC+mSTQ0ZrzPf4yCuaaXyfbvSqpH0qM4Rs8YrQzuOZOM5+lAYdCD+PNNkLEcHAqL6dRQxkhBXLKaFORz9TRGx5UiiQZHHH86A8gEuG9qnD5HOTjnmqI/yKliZh8vWkgtctK4bIxg9ahcsrE/w1KmABtx70rAGmBGMSLux2rj/ABtII4GAHFdiQUPHTvXBePJx5RXuaT2Ezz+3kJujnHPp61pxErnIGDjOKxbdv9Iz0rXtmDIw6nufSszppmrBMoAYDJP+NXxMjRtnO3pzWTan94oI+Q9z61sQQhM7iDv6r1GaTudMbWL0DCIOCTtByParSbZC7EZxjBqiAzyc9uDu71bjBSBUbqOPwqB36kheTOVUYPX2qzGwVPlyQDkEH371UQD+DoOuTV22QEAAngdCOgpiuSsxc7kwO2B3FL5m4EE4B6YqE4VsIQM8jHQGnrLkIrLk45x0oKHK5VhuXk8ZHep43xtc49uO9QoNzqTgipkXg9D7Hv70ATrIWI3everVu3yMGGMHG7NUVAXgcYOcNVhWO0Eg9en9aYiwDhVKgZx0PSpEYOp3hRJjJ7/lUb8R4YjJ74pAM9FAHHHagRdjOI0jc7znt2oedoomZQrNn8cVWVWIwo56e9OYMD8wGR1x0oA0bd0kTcFZGP8ACeamAiMyb9/vg8VmLKyAleWPUZ7VA0jmfETEKR3/AFouCjdm5OoBbyvuj0qB5PMkxGpGB1zxms+FmQZDt9O9OkupVi/dxhueB0obBR1Hzpw2QRzz6GofKLDaATgdBT4pXKkyn5vTFAciQNzgdOaQ7tAxZISpBBI4GcVVZQnyxjkEkd+ana4UzNvfcMc+gqrKw3OYyxGME0gQ2SQxxkMSxJ6VBk7t3O088/ypGkU7yOoHVu9MJO4AkD37Uy7aBI2S20AYHSo0KnYvIY9/WnPhSAzDB5/Cq9xJuVgijaDj5aTGhZjhsgYBqvKDLyDx6e9KXLYLZHbnvTROIwc4xUoCB4znJXBPcVSuV2k9eORVieRfLYcned3J6e1Z91KNxAG0duaAILh+DhuB6VnSuFUVNK4KgA9Ofas+dxnaTkiqiTJleZ9xY4zxVcuuCFPIHLUtw4jjZzx9arQu0kTtzz3rQ5Zu4wkHJGPc4rebw1GbOC6k1ixWCX7jMrde46da5wZLZ9K39K0zWb3TJYrWAtYysGJkwF3DoVJ6H6U0YDf+EftScDX9N9sK1P0LT83HZgGwGHfnrT08K6rbx+ZNbMY15LIwfH1xXS+HtNwQxA7HpTsS2d35mCB2prrwCetR5I+90p5cDAHSrJED5BB/Go/mzx0pZCOgpAeopMY5eeR1p68tj+dMQbRuxSGYBuOf6UDHSxndxxSheB61MrBhhsZqBuGyKBEqEhhkAUrlsjFRK+5qlJwM0wY4n5ADXm3j1SDn2r0XOU+9k968+8djjOPpSewjzuJsuM9jitS0kEbpk8MMGsxgN30NXIWCyAA55qDopuxtQBSCuBlq2LaR0t8EZZOma563J3hwec/nWyr4Xaoz3GDSOlbGqhW4QkkjsQKsvICi7lyVHJrNt5SELbjjOGq0vAZVOcDA561FmBaBBZfl69+1XbdskgjI28NWeCDxIduOSfSplmMUq7ed5A68Y9aBrUtPv5HQZ5z2NSqTuwOSO3r9KJNm3KszZPPtTUXBzv8AbPUigCQkIPmJyBxg9amQqUG89f4T2NQl920M4OFwT0pYgG4TAI65NMotBgTjkkd6nj3SBdm4dsHtVdNwVcjOe9WYTukK4PIzuH8qBDyflILdexpokCxZcAkdAKV3+UjcG9aYEJXKLlu4oEid5maJWiwoxjrS+cGhAc7j3FV8jhGGD15pGXDc46cd6B6WJ1c72AYDjOKktgFUg7QScnFUVclgMkL6GpomwpZsDJx0oGy2HUn5WJxwR2ppAlDEOfl9+tCbAoeZshsEAGlUgOu0qy9cGgkRtoGMbQ35mkbapA6kcjJqVvKyQrAE9BmqjJtYkHtnBpWGSMSxKgKD1JFNZVCEb8tjtTGO0HDYc8YxUJ3MRk/72O9IYhjT+LnPT0qtIdpIzk5weOBUuSA2AeTVdpN3UnHegaIAzZO849MUhmwSeq0rEM2TwwHGBnFN8nPXGSfTApFCu4K5bBJOeeKzpnHPTaD361PcIeATjnB+lUpT8pTnC/rQBHOwIJzwPQVmXEhJC45q08uWAzwOw61QuJScsBgZwDQJkNzKM5UcY4qjIcnb1Jqadskt2A4FVpW2knPKiriZTZnamSzpGpypOcelTpAEtWOTnHT0qO1iEkxkbnk1oyIXt3XGRjj2qzBrS5igEngV3V5pd3rv2e40uRJbUQoiw+YFMRA5G0n1rnLKwZtucmvQ7HQdLsjFBdG5+1Mis8kZG1CR0x3ppHO5CeE/Dt5pl9Hc3jLbwpy4MgO4Y6YHrW1aW6qzFFwCSQPbNTafo3kalBBOTJBJko4PDjFTqm2RlPIBIA9qqxNiAtvHb86YWIByaRGHrg01jkgDJ7E0x2HMxAyBU0QDrk1Eq4PPQdqVDhcDjNK4Dpmy2FPBp6oFQEnJohj5OaSdgo46UwuDyDHy9aZklgccVEhZj1PWpoxtbI70hk6IAuT1ofJPp/hTC4IwuM+lPXLKNx96YhHT5SQR9K4XxwSYsccV3RY5weRXEeOhiPOOOeaTE2eZudrHnrU8DAoGGfSqxbc2G6VPaAeWcngN8uKhmsdzWtPVT24zWxZyDyx13dORWLAwDKc8HmtW3H7sfTqKVrnUi7GxjkaMcA+vcVciGEyOvbNUGk/eKWG7n06Vdi5QjqeCOaLDuWUAKBmOQDyfepWb7pAAGOD7VFDuTersMFeM9M/407cpk2gnPb/CpY0X4JSo4IOR8xPGKmjkCvzgdyelZ8JYqMlQD14qdCSOccdB3FSVYsybd2MEjr0qaJkIAAz7iqBlZmAJCnuT3qaGQpyDnHTAp3KNKDODyTnnntT2k2MMKcnvVSOfcwZQMnrVoBJB97DjovrTJJM7vmJGR6VKQCRuIz7GoVUDkAg4/CpFCg5J+vHWgQ8jLBnPy+9PSZi5QqhU9DntTAsbxnkkE8g8UzARAABjoMc0AJcbAcL+R/nmmCVgdqkYAyc+lPdDuDEdO4HSo2UhSRkA89OtAxGkDtkk5HoeMVIJ1XGP1pqHHKYwfaopVG8HBOOSKQbk0EoyznapPTvUiyggsWz+FVGYhclMn0z3pNxJA4UZ6g/nRcZbU7eSB17GhpE385HtVRpCoOfXvzmopHYBncgdsCge5YuZg1wiop56+lU3fOVUL1xQWfBP3QeTmos4IOcZPGB+tIYxgdxwxHOfrRKyuPn3E/kKMZxnnniocLnJOcHnIpBcZIQr/MdzMcfhVCYSLuBxxwRVuZgygrwF/wAaoXMh3l1JyRg5PFAXKNxJnIAwfXHWqbKxIAII9PSrMhBXABJ67j3qs5O7aODjNPYRTlBLAD86p3LbUOAST096vn5lOMZ7YrLBMt8wHKKcCrWxhLcu2ke2L/aNX9Pi82Qpjr1qqp2jGORWz4YjWXUCpGRjpVIipsaun6aCBkc117NHcW8ReEi5UBWkHRgB6VBbW23HykD0rUt7QCMSTusUbfd4yzfQVaRy2J9Muvsyos0fmRqdy+q/SqcrDcxHQknntzV1rdPLZ7eQS7RllxhsfSs5jk8HOaYFMKVfGOlWQBtziokb1qQnNArjSR6YzSon1zSsBjP6ULkDJNAXH/dYDODTGUOw6evWopHySKfEQV6DFAiQR7eSMZ6U1sYAJDD0qR3GMY6U0LuwRjI6UDuEK5+YjkccUSzYOBx/WnAkLgetVZt24nNBRKkvbOCTXJ+N4y0JI966SMZYDvWH4vj/ANCY57UMTPIZV+Y8YNSW0mGKg4yPyp1wMSkD1pqgA59eKzZa3NO1YhRnnHU+ta1vLtUA52DOR61gW7gDkmty2Utb7gNwpHVE04PmBXqo/X3qeMuehHHbvVOznEfDgnH8quNsdBIuQe31oLsTxTDYiM24g8Me9PWXccOMEHnFUAxY7cj5amik5IK854rMDRUp5bBvvDofaneZlVxgpnFQWudw3HgngU5mwxUjv0FBRcU4yGBOBnmpY5GHynC4GeKpFvOXKltpPB71ZilVXCHJYZ7cGgaLceQMjjjJNWY8FgWAc4+96VWhbJTeAFJx06VdWMqcK2RjjNMGPEuU4XHPGD1qRGEi5HHbJqMxMj9Ad2DTwQDjGD1piJIQxyepOODTiHABAAPTpUce7rlQR7VLksPmJOOh9KBDwMA4AxjmoyFKnB/DNPDZ3D0HJqK5YJGWIBA6cUwEQZUADp39Ka4/eHaWOB0FKHDAMuRnnFJ5hUE849KQyIp+74J6fjTQox/eYc5xUz9Bzg/SoJW+QCM4xx7UhjH+RsbcnqcHpUYBbnjOM80CThcDjHXvSoykj5eQetACgZU5JGe5prBISQ+5mboOwoZlDHufU9vpUEj7skNSASQjD9QAKrTSKNo284zzTppGXAY81FOp3nOcY4GeMUiiErgrvPy9cepqtdKBGxJBZieKeTtHbJ/lVeVxJn26A0yWVpIyIz3OMVQmX5G2nFaFy/y7QMZ44qjMuMKBk4oWoim4Ckr1CjrVWyiJkaQ8bjVphgMDxxTraLbB+FaMyjq2NlwQfat7wcM6mo7Y7VhyY29K3PCDbNWHuKZNTY9HRtqkHORWzcRs6XKxIGf5Ao6ny8dvxrHQbjn0q4t0ojRJ1Ztg+V0O1lHp71qjjZPbiSNbcSpiTzgI8jBKH734VlhUWZyv3cnH51PLcopY26OHYYMkjbmx7elVV5Uj2pDP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous plaques are present in areas of striae in this woman with PUPPP. This disorder is also&nbsp;called polymorphous eruption of pregnancy (PEP).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37267=[""].join("\n");
var outline_f36_25_37267=null;
var title_f36_25_37268="Acute subdural hematoma in an abused infant";
var content_f36_25_37268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Acute subdural hematoma in an abused infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 544px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute subdural hematoma (arrows) in an abused infant with skin bruises and skull and rib fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cindy Christian, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37268=[""].join("\n");
var outline_f36_25_37268=null;
var title_f36_25_37269="Echinocandins target of activity";
var content_f36_25_37269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Target of activity of echinocandins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 592px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Fungal cell wall.",
"    <br>",
"     (B) Beta 1,3 glucan synthase complex.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Russell Lewis, PharmD, FCCP, BCPS.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37269=[""].join("\n");
var outline_f36_25_37269=null;
var title_f36_25_37270="Carbidopa-levodopa-entacapone: Drug information";
var content_f36_25_37270=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carbidopa-levodopa-entacapone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/63/40948?source=see_link\">",
"    see \"Carbidopa-levodopa-entacapone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Stalevo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6834694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Stalevo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F188060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, COMT Inhibitor;",
"     </li>",
"     <li>",
"      Anti-Parkinson's Agent, Decarboxylase Inhibitor;",
"     </li>",
"     <li>",
"      Anti-Parkinson's Agent, Dopamine Precursor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F188048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     All strengths of Stalevo&reg; contain a carbidopa/levodopa ratio of 1:4 plus entacapone 200 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parkinson's disease:",
"     </b>",
"     Oral: Dose should be individualized based on therapeutic response; doses may be adjusted by changing strength or adjusting interval. Fractionated doses are not recommended and only 1 tablet should be given at each dosing interval; maximum daily dose: 8 tablets of Stalevo&reg; 50, 75, 100, 125, or 150,",
"     <b>",
"      or",
"     </b>",
"     6 tablets of Stalevo&reg; 200.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patients previously treated with carbidopa/levodopa immediate release tablets (ratio of 1:4):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      With current entacapone therapy:",
"     </i>",
"     May switch directly to corresponding strength of combination tablet. No data available on transferring patients from controlled release preparations or products with a 1:10 ratio of carbidopa/levodopa.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Without entacapone therapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If current levodopa dose is &gt;600 mg/day: Levodopa dose reduction may be required when adding entacapone to therapy; therefore, titrate dose using individual products first (carbidopa/levodopa immediate release with a ratio of 1:4 plus entacapone 200 mg); then transfer to combination product once stabilized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If current levodopa dose is &lt;600 mg without dyskinesias: May transfer to corresponding dose of combination product; monitor, dose reduction of levodopa may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patients previously treated with benserazide/levodopa immediate release tablets (Canadian labeling, not in U.S. labeling):",
"     </b>",
"     <i>",
"      With current entacapone therapy:",
"     </i>",
"     Prior to switching to combination product (carbidopa/levodopa/entacapone), withhold treatment for 1 night, then initiate (carbidopa/levodopa/entacapone) therapy the following morning at a dose that provides either an equivalent amount or ~5% to 10% more levodopa.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F188049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F188050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use caution with severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F188051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution in biliary obstruction or hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F188034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stalevo&reg; 50: Levodopa 50 mg, carbidopa 12.5 mg, and entacapone 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stalevo&reg; 75: Levodopa 75 mg, carbidopa 18.75 mg, and entacapone 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stalevo&reg; 100: Levodopa 100 mg, carbidopa 25 mg, and entacapone 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stalevo&reg; 125: Levodopa 125 mg, carbidopa 31.25 mg, and entacapone 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stalevo&reg; 150: Levodopa 150 mg, carbidopa 37.5 mg, and entacapone 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stalevo&reg; 200: Levodopa 200 mg, carbidopa 50 mg, and entacapone 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F188020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F188036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Swallow tablet whole; do not crush, break, or chew. Only 1 tablet should be administered at each dosing interval. May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F188035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of idiopathic Parkinson's disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F12911124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Strengths listed in Stalevo&reg; brand names correspond to the",
"       <b>",
"        levodopa",
"       </b>",
"       component of the formulation only. All strengths of Stalevo&reg; contain a levodopa/carbidopa ratio of 4:1 plus entacapone 200 mg.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F188058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F188039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levodopa, carbidopa, entacapone, or any component of the formulation; use of nonselective MAO inhibitor therapy with or within prior 14 days; narrow-angle glaucoma; undiagnosed skin lesions or history of melanoma",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Clinical or laboratory evidence of uncompensated cardiovascular, endocrine, hematologic, pulmonary (including bronchial asthma), or renal disease; history of neuroleptic malignant syndrome (NMS) and/or nontraumatic rhabdomyolysis; hepatic impairment; pheochromocytoma; when administration of a sympathomimetic amine is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F188023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: Has been associated with delayed development of diarrhea (onset after 4-12 weeks); use with caution in patients with lower gastrointestinal disease or an increased risk of dehydration. Diarrhea may be a sign of drug-induced colitis. Discontinue use with prolonged diarrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyskinesias: May cause or exacerbate dyskinesias; may require dose adjustment; not recommended for use in treatment of drug-induced extrapyramidal reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hallucinations: May cause hallucinations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopamine agonists used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Ergot-derived dopamine agonists have also been associated with fibrotic complications (eg, retroperitoneal fibrosis, pleural effusions, pleural thickening, and pulmonary infiltrates); monitor closely for signs and symptoms of fibrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rhabdomyolysis: Severe cases have been reported (rare); may be related to severe, prolonged motor activity/dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Somnolence: Patients have reported falling asleep while engaging in activities of daily living; this has been reported to occur without significant warning signs. Monitor for daytime somnolence or pre-existing sleep disorder. Use caution with other CNS depressants, sedating agents, psychoactive drugs or ethanol. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: May cause syncope; incidence may be increased in patients with documented hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, including a history of myocardial infarction and arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endocrine disease: Use with caution when interpreting plasma/urine catecholamine levels; falsely diagnosed pheochromocytoma has been rarely reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with wide-angle glaucoma; monitor IOP carefully; contraindicated in patients with narrow-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment and biliary obstruction; use in hepatic impairment is contraindicated in Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients with a history of peptic ulcer disease; risk of gastrointestinal hemorrhage may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychotic disorders: Use with extreme caution in patients with psychotic disorders; observe patients closely for development of depression with concomitant suicidal tendencies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with history of seizures or lowered seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Catecholamines: Use caution with agents metabolized by COMT (eg, epinephrine, dopamine, methyldopa) regardless of route of administration; effects may be enhanced when used with entacapone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Levodopa/dopa decarboxylase inhibitors (eg, carbidopa): Avoid a direct switch to (levodopa/carbidopa/entacapone) in patients receiving levodopa doses &gt;600 mg/day or patients with dyskinesias; initiate adjunctive entacapone therapy and adjust levodopa dose prior to conversion to (levodopa/carbidopa/entacapone) therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sucrose: Contains sucrose; avoid use in patients with fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Body fluid discoloration: Urine, saliva, or sweat may appear dark in color (red, brown, black) during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on abrupt withdrawal or significant dosage reduction after long-term use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F188027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Atypical): May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Typical): Anti-Parkinson's Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Substrates: COMT Inhibitors may decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May decrease the serum concentration of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Levodopa. Only applies to oral iron preparations. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Levodopa may enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: COMT Inhibitors may enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methionine: May diminish the therapeutic effect of Levodopa. Probably only with large doses of methionine.  Data was generated using 4.5gm daily.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Levodopa. Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Levodopa. Only applies to oral iron-containing preparations. Management: Separate doses of these agents by 2 or more hours.  Monitor for decreased levodopa effects, particularly if doses cannot be separated.  Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May diminish the therapeutic effect of Levodopa. Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sapropterin: May enhance the adverse/toxic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F188044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: High-protein diets and increased stomach acid may delay absorption of levodopa. Iron may decrease bioavailability of levodopa. Entacapone has been reported to chelate iron and decreasing serum iron levels were noted in clinical trials; however, clinically significant anemia has not been observed.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F188030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F188040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed with levodopa, carbidopa, and entacapone in animal studies. There are case reports of levodopa crossing the placenta in humans. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit exceeds risks.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F188054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F188041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Distribute protein intake throughout the day to avoid fluctuations in levodopa absorption. Separate dosing of iron supplements and multivitamins with minerals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Carbidopa-Levodopa-Entacapone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5-50-200 mg (100): $374.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18.75-75-200 mg (100): $374.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-100-200 mg (100): $374.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     31.25-125-200 mg (100): $374.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5-150-200 mg (100): $374.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-200-200 mg (100): $374.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Stalevo 100 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-100-200 mg (100): $502.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Stalevo 125 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     31.25-125-200 mg (100): $502.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Stalevo 150 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5-150-200 mg (100): $502.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Stalevo 200 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-200-200 mg (100): $502.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Stalevo 50 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5-50-200 mg (100): $502.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Stalevo 75 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18.75-75-200 mg (100): $502.84",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F188032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of Parkinson's disease; CBC, liver function tests, renal function; blood pressure, mental status; signs and symptoms of neuroleptic malignant syndrome if abrupt discontinuation required (as with surgery); serum iron (if signs of anemia); IOP (in patients with wide-angle glaucoma)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Stalev (PH);",
"     </li>",
"     <li>",
"      Stalevo (AR, AT, AU, BE, BG, BR, CH, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PE, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F188022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Levodopa: The metabolic precursor of dopamine, a chemical depleted in Parkinson's disease. Levodopa is able to circulate in the plasma and cross the blood-brain-barrier (BBB), where it is converted by striatal enzymes to dopamine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Carbidopa: Inhibits the peripheral plasma breakdown of levodopa by inhibiting its decarboxylation; increases available levodopa at the BBB",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Entacapone: A reversible and selective inhibitor of catechol-O-methyltransferase (COMT). Alters the pharmacokinetics of levodopa, resulting in more sustained levodopa serum levels and increased concentrations available for absorption across the BBB.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F188038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2008, 5(2):164-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/25/37270/abstract-text/18394561/pubmed\" id=\"18394561\" target=\"_blank\">",
"        18394561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo;",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 2000, 15(5):869-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/25/37270/abstract-text/11009192/pubmed\" id=\"11009192\" target=\"_blank\">",
"        11009192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 2006, 63(7):969-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/25/37270/abstract-text/16831966/pubmed\" id=\"16831966\" target=\"_blank\">",
"        16831966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8688 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-211.167.112.14-B56043E255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37270=[""].join("\n");
var outline_f36_25_37270=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188047\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834694\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188060\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188048\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188049\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188050\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188051\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188034\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188020\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188036\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188035\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911124\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188058\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188039\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188023\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299593\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188027\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188044\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188030\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188040\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188054\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188041\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524637\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188032\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539887\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188022\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188038\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8688\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8688|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/63/40948?source=related_link\">",
"      Carbidopa-levodopa-entacapone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_25_37271="Scrotum anatomy";
var content_f36_25_37271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Scrotum anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 675px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The scrotal layers from external to internal include the skin, dartos, intercrural fascia, cremaster muscle, infundibulum, parietal tunica vaginalis, and visceral tunica vaginalis. Superficial lacerations of the scrotum (figure A) should undergo local wound care and closure with absorbable sutures. Penetrating scrotal trauma to or through the dartos layer (figure B) has a high rate of associated testicular injury and warrants prompt referral to a urologist for surgical exploration in the operating room.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37271=[""].join("\n");
var outline_f36_25_37271=null;
var title_f36_25_37272="Gram stain sputum 9A answer";
var content_f36_25_37272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82509%7EID%2F54384%7EID%2F67234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82509%7EID%2F54384%7EID%2F67234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain in pulmonary tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows no bacteria in an apparently good specimen from a patient with pneumonia. Some bacteria, including Mycobacterium tuberculosis, cannot be seen by Gram stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mycobacterium tuberculosis in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acid- fast stain of the same sputum (x1000). With this stain, the inflammatory cells appear blue and mycobacteria are red, thin, beaded rods.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power light micrograph of a lung biopsy from a patient with tuberculosis shows multiple granulomas (hematoxylin and eosin stain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37272=[""].join("\n");
var outline_f36_25_37272=null;
var title_f36_25_37273="Immunizations in HIV-infected patients";
var content_f36_25_37273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunizations in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/25/37273/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/25/37273/contributors\">",
"     Patricia L Hibberd, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/25/37273/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/25/37273/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/25/37273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/25/37273/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/25/37273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection, because of the immunocompromised state, is a risk factor for morbidity and mortality caused by a number of infections that can usually be prevented by immunization. A number of factors contribute to the HIV-infected patient's \"net state of immunosuppression\" including defects in cell-mediated immunity, B cell dysfunction, and suboptimal humoral immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/1\">",
"     1",
"    </a>",
"    ]. In the absence of effective therapy, the immunocompromise is continually progressive. On the other hand, patients who respond to highly active antiretroviral therapy (HAART) have substantial increases in their CD4 lymphocytes, suggesting improved immunity.",
"   </p>",
"   <p>",
"    In 2009, the United States Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America reconvened to update their previous joint guidelines to include information relevant to HAART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/2\">",
"     2",
"    </a>",
"    ]. These recommendations continue to focus on prevention of infection, including immunization, starting at the time of diagnosis (",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"mobipreview.htm?41/17/42263\">",
"     figure 1",
"    </a>",
"    ). Although vaccine efficacy is usually compromised in advanced disease, adequate responses can be achieved when vaccines are administered early after HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/3\">",
"     3",
"    </a>",
"    ]. Concerns have been raised about vaccine safety, specifically the risk of activating the immune system and the potential for increasing HIV replication and promoting HIV infection. As discussed below, the benefits of administering vaccines appear to outweigh the risks.",
"   </p>",
"   <p>",
"    Issues related to postexposure prophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7930?source=see_link\">",
"     \"Management of healthcare personnel exposed to HIV\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inactivated vaccines are generally acceptable and live vaccines are generally avoided in persons with HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/4\">",
"     4",
"    </a>",
"    ]. However, some live vaccines (eg, varicella) are recommended in HIV-infected patients with CD4 cell counts &gt;200",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    The specific recommendations for each vaccine are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INACTIVATED VACCINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients have similar immunity to tetanus as an age-matched normal population, but diphtheria immunity is lower than expected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/5\">",
"     5",
"    </a>",
"    ]. Since the immune responses to tetanus and diphtheria are T cell-dependent, the response to immunization is lower in patients with advanced HIV disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. One study noted a transient increase in plasma HIV-1 RNA levels after immunization with tetanus toxoid, but there were no long-term consequences of this upregulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Public Health Service",
"    <span class=\"nowrap\">",
"     (USPHS)/Infectious",
"    </span>",
"    Diseases Society of America (IDSA) guidelines recommend updating tetanus and diphtheria immunizations according to routine recommendations for adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/2\">",
"     2",
"    </a>",
"    ]. Waning immunity against tetanus and diphtheria is responsible for the recommendation for universal administration of Td boosters every 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/4\">",
"     4",
"    </a>",
"    ]. The United States Advisory Committee on Immunization Practices (ACIP) also recommends a single dose of a vaccine containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap; Adacel or Boostrix) 0.5 mL IM in place of Td for",
"    <strong>",
"     all",
"    </strong>",
"    adults aged 19 years and older who have not received Tdap previously to address waning immunity against pertussis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The appropriate vaccine formulation depends upon the age of the patient. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=see_link&amp;anchor=H6#H6\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\", section on 'Routine immunization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Poliovirus vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small number of HIV-infected patients at risk of exposure to polio (by travel or work) should receive a primary series with inactivated polio vaccine (IPV) if there is no documentation of vaccination status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/11\">",
"     11",
"    </a>",
"    ]. A single lifetime booster with IPV is recommended for adults at continued risk of exposure to polio although the duration of protection is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17223?source=see_link\">",
"     \"Poliovirus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pneumococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal pneumonia and meningitis are leading causes of morbidity and mortality among HIV-infected patients worldwide, and treatment is complicated by the increasing incidence of drug-resistant pneumococcal strains. The most important risk factor for developing pneumococcal infections is the level of immunosuppression (eg, CD4 count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11047?source=see_link&amp;anchor=H11160230#H11160230\">",
"     \"Pneumococcal immunization in HIV-infected patients\", section on 'Epidemiology of pneumococcal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumococcal vaccine is recommended for all HIV-infected patients. The use of pneumococcal vaccine is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11047?source=see_link\">",
"     \"Pneumococcal immunization in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Haemophilus influenzae vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fortunately, the incidence of Haemophilus influenzae type B (HIB) disease in HIV-infected adults is low. Adults with advanced HIV disease do have a significantly increased rate of infection with H. influenzae, but most infections involve nontypable strains for which the vaccine is not protective. HIB vaccine is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for adults infected with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with conjugate pneumococcal vaccines, responses with the conjugate HIB vaccine in HIV-infected children have also been disappointing. In one study, for example, only 37 percent of children seroconverted after administration of the HIB conjugate vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/12\">",
"     12",
"    </a>",
"    ] and another report noted a lesser antibody response than controls, particularly in children with AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/13\">",
"     13",
"    </a>",
"    ]. The duration of the antibody response in children is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Influenza vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the USPHS and IDSA, as well as the Advisory Committee on Immunization Practices (ACIP), recommend annual administration of influenza vaccine to HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/14\">",
"     14",
"    </a>",
"    ]. The inactivated vaccine formulation is recommended; intranasal vaccines should",
"    <strong>",
"     not",
"    </strong>",
"    be used in immunosuppressed patients. Despite this long-standing recommendation for routine immunization in HIV-infected patients, vaccination coverage remains low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/2,15,16\">",
"     2,15,16",
"    </a>",
"    ]. Available influenza vaccines are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Efficacy, immunogenicity, and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated the efficacy and safety of influenza vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/17-26\">",
"     17-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 328 patients who were advised to have influenza vaccine, 262 agreed to immunization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/17\">",
"       17",
"      </a>",
"      ]. Vaccination substantially reduced the risk of subsequent influenza infection (relative risk 0.29).",
"     </li>",
"     <li>",
"      In a placebo-controlled trial of 102 HIV-seropositive patients, influenza vaccination was associated with significant reductions in respiratory symptoms (29 versus 49 percent) including those with laboratory-confirmed infection (0 versus 21 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2012 meta-analysis that evaluated a limited number of studies also suggested that influenza vaccination is associated with a reduction in influenza-like illness and laboratory-confirmed influenza infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some studies, antibody responses following standard dose influenza vaccines have been lower in HIV-infected individuals than in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/27\">",
"     27",
"    </a>",
"    ]. Important questions are whether using a high-dose influenza vaccine will improve immunogenicity and efficacy in HIV-infected individuals. The question of immunogenicity was addressed in a randomized trial that compared a standard dose (15 mcg of antigen per strain) to a high dose (60 mcg per strain) of the inactivated trivalent influenza vaccine in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/28\">",
"     28",
"    </a>",
"    ]. Seroprotection rates following vaccination were significantly higher in the high-dose group for the H1N1 influenza A (96 versus 87 percent) and influenza B (91 versus 80 percent) components, but not for H3N2 influenza A (96 versus 92 percent, a non-significant difference). Further studies are necessary to evaluate the safety and efficacy of the high-dose influenza vaccine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link&amp;anchor=H384358#H384358\">",
"     \"Seasonal influenza vaccination in adults\", section on 'High-dose vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link&amp;anchor=H78880699#H78880699\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Reduced dose vaccines'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    The safety of the high-dose influenza vaccine is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link&amp;anchor=H21#H21\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Inactivated vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are conflicting results as to whether influenza vaccination leads to a transient upregulation of HIV replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/18-22,27\">",
"     18-22,27",
"    </a>",
"    ]. There are no studies to suggest any negative effect on HIV disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Risk factors for poor response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the antibody response to vaccination is critically dependent upon CD4+ T-cell help, a poor vaccine response can be predicted in patients with HIV, particularly those with advanced disease. Loss of CD4+ T-cells is associated with weak influenza-specific antibody responses, as measured by titers and influenza-specific antibody secreting cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/6,17,29\">",
"     6,17,29",
"    </a>",
"    ]. In fact, use of the vaccine has been questioned for patients with more advanced disease on a cost-benefit basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in other vaccine studies in HIV-infected patients (eg, hepatitis B), the presence of circulating HIV RNA has also been demonstrated to be an important predictor of nonresponse to influenza vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/31\">",
"     31",
"    </a>",
"    ]. This suggests that the immunogenicity of the vaccine may be improved with viral suppression on ART.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hepatitis A vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other individuals infected with hepatitis B and C, HIV-infected patients are at risk of decompensation of their underlying liver disease if they encounter hepatitis A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/32\">",
"     32",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     USPHS/IDSA",
"    </span>",
"    and ACIP guidelines recommend immunization of all susceptible HIV-infected patients who have chronic liver disease or are at increased risk for hepatitis A virus (HAV) infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/2,4,33\">",
"     2,4,33",
"    </a>",
"    ]. These patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with chronic hepatitis B or C",
"     </li>",
"     <li>",
"      Injection drug users",
"     </li>",
"     <li>",
"      Men who have sex with men (MSM)",
"     </li>",
"     <li>",
"      Hemophiliacs and other individuals who receive clotting factor concentrates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prevaccination screening for hepatitis A antibodies is cost-effective when expected prevalence rates are greater than 30 percent (eg, in persons older than 40 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/30/44518?source=see_link\">",
"     Hepatitis A vaccine",
"    </a>",
"    is immunogenic and safe in HIV-infected patients and does not affect clinical progression or levels of HIV plasma viremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. However, in general, HIV-infected patients have lower seroconversion rates than HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/36,38,39\">",
"     36,38,39",
"    </a>",
"    ]. This is particularly true in the setting of advanced immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/36,37,40\">",
"     36,37,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunization efficacy was studied in 90 HIV-uninfected adults and 90 HIV-infected subjects who were given the VAQTA vaccine at weeks 0 and 24 of the study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/36\">",
"       36",
"      </a>",
"      ]. Seroconversion rates at week 28 were 94 percent among the HIV-infected subjects compared with 100 percent in HIV-uninfected controls. The seroconversion rate was only 87 percent in HIV-infected subjects with a CD4 count",
"      <span class=\"nowrap\">",
"       &lt;300/microL",
"      </span>",
"      compared with 100 percent in those with a CD4 count",
"      <span class=\"nowrap\">",
"       &ge;300/microL.",
"      </span>",
"     </li>",
"     <li>",
"      In a study of 133 HIV-infected patients, seroconversion was demonstrated in 68 percent of those with CD4 counts &gt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      compared to only 9 percent in those with lower T-cell counts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 214 patients undergoing hepatitis A immunization, a multivariate analysis identified that the only predictor of vaccine efficacy was the absolute CD4 count; the past nadir CD4 count did not have any impact on immunogenicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are contrasting data, however, as to whether the presence of HIV viremia at the time of immunization affects vaccine efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/39,41\">",
"       39,41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that HAV vaccination should be given early in the course of HIV infection or after immune reconstitution with antiretroviral therapy. One randomized controlled trial of 99 patients demonstrated that a three-dose schedule led to higher levels of antibody titers, although rates of seroconversion were similar to the two-dose schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/42\">",
"     42",
"    </a>",
"    ]. A detailed discussion of the various hepatitis A vaccines is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hepatitis B vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients are at increased risk of hepatitis B virus (HBV) infection due to shared modes of transmission. Furthermore, HIV-infected individuals are less likely to clear HBV DNA and are at increased risk of chronic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/43\">",
"     43",
"    </a>",
"    ]. Routine screening and immunization is therefore recommended for all HIV-infected adults to prevent primary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/2,4,44\">",
"     2,4,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting data as to whether immunization prevents HBV infection in HIV-infected patients; one study demonstrated a 40 percent reduced risk, while another did not show any impact except for a decreased risk of chronic infection after acquisition of HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The latter study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/46\">",
"     46",
"    </a>",
"    ] restricted the analysis to vaccine efficacy in patients who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    after acquiring HIV infection whereas the earlier study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/45\">",
"     45",
"    </a>",
"    ] did not.",
"   </p>",
"   <p>",
"    Vaccine efficacy in HIV-infected patients is affected by advanced immunosuppression and presence of HIV viremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/47\">",
"     47",
"    </a>",
"    ]; however, the response may improve if immunization is delayed until after initiating HAART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. A study of 194 HIV-infected patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    found that a non-detectable HIV RNA was also associated with development of a protective antibody response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other methods for boosting vaccine responses in HIV-infected patients have included the use of immunostimulatory adjuvants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/52,53\">",
"     52,53",
"    </a>",
"    ] and doubling the dose of vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One double-blind, randomized controlled trial compared the use of a standard dose (20 micrograms) to a double dose (40 micrograms) of recombinant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      in 210 HIV-infected patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/55\">",
"       55",
"      </a>",
"      ]. A statistically significant higher seroconversion rate was associated with use of the double dose of vaccine, but only in the subgroup of patients with CD4 counts greater than 350 cells.",
"     </li>",
"     <li>",
"      In another study of 144 patients with a history of vaccine failure, double-dose revaccination in a series of three monthly immunizations led to the development of protective anti-HBs titers in 51 percent of study participants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study found that the use of a synthetic immunostimulatory adjuvant (CPG 7909) improved immunogenicity of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      , including subjects with prior failure of immunization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 63 prior vaccine nonresponders, seroconversion was seen in 16, 31, and 36 percent of patients after one, two, or three additional doses of vaccine, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since efficacy of HBV vaccine is impaired in HIV-infected patients, routine serologic testing after completion of the immunization series is recommended to assess whether the level of surface antibodies is protective (eg, &gt;10",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/2\">",
"     2",
"    </a>",
"    ]. Serologic screening and the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    in HIV-infected patients with isolated HB core antibody is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40104?source=see_link\">",
"     \"Prevention of hepatitis B virus infection in the HIV-infected adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Meningococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated meningococcal infections have been reported in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/58\">",
"     58",
"    </a>",
"    ]. However, response to the polysaccharide meningococcal vaccine is suboptimal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/58\">",
"     58",
"    </a>",
"    ]. Use of the meningococcal vaccine was not specifically addressed in the USPHS guidelines but, based upon the new CDC recommendations, the conjugate meningococcal vaccine should be administered to HIV-infected adults through age 55 with functional or anatomic asplenia, travel exposure, are of college age, or living in dormitories (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"mobipreview.htm?9/48/9999\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38965?source=see_link\">",
"     meningococcal polysaccharide vaccine",
"    </a>",
"    is recommended for adults &ge;56 years of age who have an indication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the current outbreak of meningococcal disease (in the fall of 2012) in MSM in New York City, we recommend meningococcal vaccination for MSM, especially if HIV-infected, if their residence, travel, or social interactions have put them (or will put them) in close contact with other MSM from New York City since September 1, 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Close contact includes kissing, sharing water bottles, sharing eating or drinking utensils, sharing cigarettes, or being within a three foot distance for eight hours or more. The appropriate formulation depends upon the age of the patient (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"mobipreview.htm?9/48/9999\">",
"     table 1",
"    </a>",
"    ). HIV-infected individuals should receive two doses, with the second dose administered eight weeks or more after the first dose, plus booster doses every five years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H2#H2\">",
"     \"Meningococcal vaccines\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H21#H21\">",
"     \"Meningococcal vaccines\", section on 'In adults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Human papillomavirus vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomavirus (HPV) vaccine is recommended by the ACIP for HIV-infected individuals through age 26 years who did not get any or all doses when they were younger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/4\">",
"     4",
"    </a>",
"    ]. It is not a live vaccine. Specific recommendations regarding HPV vaccination in HIV-infected individuals are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link&amp;anchor=H5968486#H5968486\">",
"     \"Recommendations for the use of human papillomavirus vaccines\", section on 'Immunosuppressed or immunocompromised hosts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ACIP does not recommend HPV DNA or serologic screening before immunization. A history of genital warts, abnormal cytology, or positive HPV DNA test result is not evidence of prior infection with any or all of the vaccine HPV types. Hence, the ACIP recommends that women with any such history who are within the recommended age range for immunization should still be vaccinated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The immunogenicity and safety of the HPV vaccine in these risk groups has been established in adult HIV-seropositive men for Gardasil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/65\">",
"     65",
"    </a>",
"    ] as well as in HIV-seropositive boys and girls aged 7 to 12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/66\">",
"     66",
"    </a>",
"    ]. Data from vaccine studies of HIV-seropositive adult women are not yet available. Clinical trials of HPV vaccines are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13480?source=see_link\">",
"     \"Clinical trials of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should discuss the potential risks and benefits of immunization with their patients.",
"   </p>",
"   <p>",
"    Cervical screening for HPV infection and disease continues to play an important role in prevention of cervical intraepithelial neoplasia and cervical cancer in these high-risk patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/35/16954?source=see_link\">",
"     \"HIV and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LIVE VACCINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Measles, mumps, and rubella vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measles can be a life-threatening infection in immunocompromised patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/67\">",
"     67",
"    </a>",
"    ]. In one review of 68 cases of measles in such patients, severe complications occurred in 80 percent and the mortality in HIV-infected patients was 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/68\">",
"     68",
"    </a>",
"    ]. Since the number of measles cases has been increasing in the United States, as well as other countries, prevention of measles in HIV infection is of major importance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/16/42246?source=see_link\">",
"     \"Epidemiology and transmission of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 1988, the Advisory Committee on Immunization Practices (ACIP) began to recommend that asymptomatic HIV-infected children aged 12 to 15 months be vaccinated with measles, mumps, and rubella (MMR), and immunization be considered for symptomatic children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/69\">",
"     69",
"    </a>",
"    ]. One series of 81 HIV-infected children found an overall 72 percent response to measles immunization, but only 52 percent had a detectable response one year after immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/70\">",
"     70",
"    </a>",
"    ]. In another report in which 10 HIV-infected children with symptomatic HIV infection were vaccinated, the serologic response was poor but vaccine viruses could not be recovered from any of the vaccinees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/71\">",
"     71",
"    </a>",
"    ]. In contrast, revaccination with MMR was demonstrated to be very effective in achieving protective antibodies in 51 children who had attained immune reconstitution with ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The great majority of HIV-infected adults, 95 percent in one study, are seropositive to measles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/73\">",
"     73",
"    </a>",
"    ]. The MMR vaccine response in such patients is poor, with only two of six patients responding to immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/73\">",
"     73",
"    </a>",
"    ]. Another problem is that fatal pneumonitis with vaccine strain measles has been described in an HIV-infected adult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/74\">",
"     74",
"    </a>",
"    ]. This patient had an undetectable viral load and had been immunized as required for college entry, almost one year before developing giant cell pneumonitis.",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics modified its recommendations in 2006; the MMR vaccine should be given to HIV-infected patients, except those who are severely compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/75\">",
"     75",
"    </a>",
"    ]. The ACIP has specifically recommended that MMR vaccine should only be given to HIV-infected patients with a CD4 T-cell count &gt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other live virus vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other live virus vaccines are available for possible use in HIV-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Varicella vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP recommends the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in all adults without evidence of immunity; however, immunization is contraindicated in HIV-infected patients with a CD4 T-cell count &le;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Zoster vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP recommends the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    in all adults &gt;60 years of age; however, immunization is contraindicated in HIV-infected patients with a CD4 T-cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Yellow fever vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     Yellow fever vaccine",
"    </a>",
"    is contraindicated in AIDS patients with a CD4 cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    due to concerns regarding risk of live virus vaccine in patients with advanced immunosuppression.",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    can be considered among HIV-infected patients with higher CD4 cell counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/77\">",
"     77",
"    </a>",
"    ]. Several prospective and retrospective data including approximately 450 HIV-infected patients (most of whom had CD4 cell counts &gt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    have not suggested any additional safety concerns in this patient population.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    appears to be safe among HIV-infected patients with CD4 cell counts &gt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    lower vaccine efficacy has been observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. In a retrospective study, 174 patients in the Swiss HIV Cohort were identified who had received yellow fever vaccine, including 102 with HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/79\">",
"     79",
"    </a>",
"    ]. Compared with HIV-seronegative patients, neutralization titers were significantly lower in HIV-infected patients.",
"   </p>",
"   <p>",
"    In one prospective study of 240 HIV-infected patients who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    after their HIV diagnosis, failure to achieve a significant level of neutralizing antibodies was associated with detectable HIV RNA at the time of immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/80\">",
"     80",
"    </a>",
"    ]. There are conflicting data as to whether the level of immunosuppression is associated with vaccine immunogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     BCG vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacillus Calmette Guerin (BCG) vaccines are administered to newborn infants in developing countries to reduce the risk of developing tuberculosis. Although HIV-infected patients are at risk of developing tuberculosis, disseminated BCG has been reported after vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/81\">",
"     81",
"    </a>",
"    ], with complications occurring up to many years after vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Since the efficacy of the vaccine in HIV-infected patients is unknown and there is a risk of disseminated disease, two CDC advisory groups have recommended",
"    <strong>",
"     against",
"    </strong>",
"    use of the BCG vaccine even if the risk of acquiring tuberculosis is high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary data from a randomized placebo-controlled trial among 2013 HIV-infected patients in Tanzania suggest that an inactivated whole cell mycobacterial vaccine (Mycobacterium vaccae) is safe and protects against tuberculosis infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37273/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PASSIVE IMMUNIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since HIV-infected patients are not able to make effective new antibodies as their disease progresses, the use of hyperimmune globulin preparations can be considered in some patients with severe infections such as cytomegalovirus. This approach has been best studied in bone marrow transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     IMMUNIZATIONS IN TRAVELERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunizations in travelers are discussed separately. The use of the different vaccines must be considered in relation to the issues described above. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36498?source=see_link\">",
"       \"Patient information: Vaccines for people with HIV (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=see_link\">",
"       \"Patient information: Vaccines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=see_link\">",
"       \"Patient information: Vaccines for adults (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"       \"Patient information: Adult vaccines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28307327\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV infection is a risk factor for morbidity and mortality caused by a number of infections that can often be prevented by immunization. HIV-infected patients have defects in cell-mediated immunity, B cell dysfunction, and suboptimal humoral immune responses. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inactivated vaccines are acceptable for use in HIV-infected patients, while live vaccines are generally avoided. However, some live vaccines (eg, varicella) are recommended in HIV-infected patients with CD4 cell counts &gt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      Live vaccines include measles, mumps, rubella vaccine, and varicella, zoster, yellow fever and Bacillus Calmette Guerin (BCG) vaccines. The rest of the vaccines are inactivated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumococcal vaccines (both polysaccharide and conjugate vaccines) should be administered to adults and children with CD4 counts greater than 200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      as soon as HIV infection is diagnosed. The immunization schedule is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11047?source=see_link\">",
"       \"Pneumococcal immunization in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although AIDS patients have a significantly increased rate of infection with H. influenzae, most infections involve non-typable strains for which the vaccine is not protective. Thus, this vaccine is not recommended for adults infected with HIV. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Haemophilus influenzae vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      is safe and effective in HIV-infected patients and should be administered annually for protection against seasonal and pandemic influenza. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Influenza vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All susceptible HIV-infected patients who have chronic liver disease or are at increased risk for hepatitis A infection should receive the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/30/44518?source=see_link\">",
"       hepatitis A vaccine",
"      </a>",
"      . These candidates include patients with chronic hepatitis B or C, injection drug users, men who have sex with men, and hemophiliacs. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Hepatitis A vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients are at increased risk of hepatitis B infection due to shared modes of transmission. Furthermore, HIV-infected individuals are less likely to clear hepatitis B virus DNA and are at increased risk of chronic infection. HIV-infected patients should have routine screening for hepatitis B infection and immunization, if susceptible. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hepatitis B vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The conjugate meningococcal vaccine should be administered to HIV-infected patients with functional or anatomic asplenia, travel exposure, or in those living in dormitories. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Meningococcal vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The human papillomavirus (HPV) vaccine should be given to HIV-infected individuals through age 26 years who did not get any or all doses when they were younger; it is not a live vaccine. HPV DNA screening is not recommended prior to immunization. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Human papillomavirus vaccine'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link&amp;anchor=H5968486#H5968486\">",
"       \"Recommendations for the use of human papillomavirus vaccines\", section on 'Immunosuppressed or immunocompromised hosts'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The measles, mumps, and rubella vaccine should be given to HIV-infected patients, except among those who are significantly immunocompromised (&lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Measles, mumps, and rubella vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       Varicella vaccine",
"      </a>",
"      should be administered in all adults without evidence of immunity; however, immunization is contraindicated in HIV-infected patients with a CD4 T-cell count &le;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Varicella vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"       Zoster vaccine",
"      </a>",
"      should be administered in all adults &gt;60 years of age; however, immunization is contraindicated in HIV-infected patients with a CD4 T-cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Zoster vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"       Yellow fever vaccine",
"      </a>",
"      is contraindicated in AIDS patients with a CD4 cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      Although yellow fever vaccine appears to be safe among HIV-infected patients with CD4 cell counts &gt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      lower vaccine efficacy has been observed. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Yellow fever vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacillus Calmette Guerin (BCG) vaccine is utilized in developing countries to reduce the risk of developing tuberculosis. Since there is a risk of disseminated tuberculosis disease after vaccination, and the efficacy of BCG vaccine is unknown, BCG immunization is not recommended in HIV-infected patients. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'BCG vaccine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/1\">",
"      Titanji K, De Milito A, Cagigi A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006; 108:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/2\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/3\">",
"      Glesby MJ. Immunizations during HIV infection. Curr Opin Infect Dis 1998; 11:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/4\">",
"      ACIP Adult Immunization Work Group, Bridges CB, Woods L, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/5\">",
"      Kurtzhals JA, Kjeldsen K, Heron I, Skinh&oslash;j P. Immunity against diphtheria and tetanus in human immunodeficiency virus-infected Danish men born 1950-59. APMIS 1992; 100:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/6\">",
"      Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994; 8:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/7\">",
"      Kroon FP, van Dissel JT, Labadie J, et al. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/8\">",
"      Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/11\">",
"      Prevots DR, Burr RK, Sutter RW, et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/12\">",
"      Peters VB, Sood SK. Immunity to Haemophilus influenzae type b polysaccharide capsule in children with human immunodeficiency virus infection immunized with a single dose of Haemophilus vaccine. J Pediatr 1994; 125:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/13\">",
"      Chadwick EG, Chang G, Decker MD, et al. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994; 13:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/14\">",
"      Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/15\">",
"      Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/16\">",
"      Gallagher KM, Juhasz M, Harris NS, et al. Predictors of influenza vaccination in HIV-infected patients in the United States, 1990-2002. J Infect Dis 2007; 196:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/17\">",
"      Yamanaka H, Teruya K, Tanaka M, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/18\">",
"      Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995; 182:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/19\">",
"      R&oslash;sok B, Voltersvik P, Bjerknes R, et al. Dynamics of HIV-1 replication following influenza vaccination of HIV+ individuals. Clin Exp Immunol 1996; 104:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/20\">",
"      Ramilo O, Hicks PJ, Borvak J, et al. T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr Infect Dis J 1996; 15:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/21\">",
"      Glesby MJ, Hoover DR, Farzadegan H, et al. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis 1996; 174:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/22\">",
"      Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/23\">",
"      Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011; 52:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/24\">",
"      Bickel M, Wieters I, Khaykin P, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010; 24:F31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/25\">",
"      Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010; 24:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/26\">",
"      Kajaste-Rudnitski A, Galli L, Nozza S, et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 2011; 25:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/27\">",
"      Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis 2012; 206:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/28\">",
"      McKittrick N, Frank I, Jacobson JM, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med 2013; 158:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/29\">",
"      Malaspina A, Moir S, Orsega SM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005; 191:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/30\">",
"      Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis. Am J Med 1993; 94:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/31\">",
"      Evison J, Farese S, Seitz M, et al. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009; 48:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/32\">",
"      Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/33\">",
"      Villano SA, Nelson KE, Vlahov D, et al. Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin Infect Dis 1997; 25:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/34\">",
"      Bodsworth NJ, Neilsen GA, Donovan B. The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up. AIDS 1997; 11:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/35\">",
"      Santagostino E, Gringeri A, Rocino A, et al. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemost 1994; 72:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/36\">",
"      Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004; 39:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/37\">",
"      Kemper CA, Haubrich R, Frank I, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003; 187:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/38\">",
"      Shire NJ, Welge JA, Sherman KE. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis. Vaccine 2006; 24:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/39\">",
"      Crum-Cianflone NF, Wilkins K, Lee AW, et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011; 203:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/40\">",
"      Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis 1997; 176:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/41\">",
"      Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS 2005; 19:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/42\">",
"      Launay O, Grabar S, Gordien E, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 2008; 49:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/43\">",
"      Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/44\">",
"      Brook G. Prevention of viral hepatitis in HIV co-infection. J Hepatol 2006; 44:S104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/45\">",
"      Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/46\">",
"      Landrum ML, Hullsiek KH, Ganesan A, et al. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2010; 24:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/47\">",
"      Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118 Suppl 10A:75S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/48\">",
"      Cheeseman SH, Davaro RE, Ellison RT 3rd. Hepatitis B vaccination and plasma HIV-1 RNA. N Engl J Med 1996; 334:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/49\">",
"      Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS 1994; 8:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/50\">",
"      Wong EK, Bodsworth NJ, Slade MA, et al. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS 1996; 7:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/51\">",
"      Overton ET, Sungkanuparph S, Powderly WG, et al. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/52\">",
"      Cooper CL, Davis HL, Angel JB, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005; 19:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/53\">",
"      Cooper CL, Angel JB, Seguin I, et al. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008; 46:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/54\">",
"      Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/55\">",
"      Fonseca MO, Pang LW, de Paula Cavalheiro N, et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23:2902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/56\">",
"      de Vries-Sluijs TE, Hansen BE, van Doornum GJ, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008; 197:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/57\">",
"      Bloom A, Jackson K, Kiviat A, et al. Repeat hepatitis B vaccination may lead to seroprotection in HIV-infected patients who do not respond to an initial series. J Acquir Immune Defic Syndr 2009; 50:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/58\">",
"      Nitta AT, Douglas JM, Arakere G, Ebens JB. Disseminated meningococcal infection in HIV-seropositive patients. AIDS 1993; 7:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/59\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011; 60:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/60\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/61\">",
"      Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     New York State Department of Health. New York State Department of Health expands vaccination recommendation in response to meningococcal disease outbreak among high risk HIV positive men in New York City. file://www.health.ny.gov/press/releases/2012/2012-10-05_meningitis.htm (Accessed on October 26, 2012).",
"    </li>",
"    <li>",
"     Commonwealth of Masschusetts Department of Public Health. Health Advisory: Meningococcal vaccine recommendations for men who have sex with men. October 25, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/64\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: serogroup C invasive meningococcal disease among men who have sex with men - New York City, 2010-2012. MMWR Morb Mortal Wkly Rep 2013; 61:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/65\">",
"      Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/66\">",
"      Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/67\">",
"      Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/68\">",
"      Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA 1992; 267:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/69\">",
"      Centers for Disease Control (CDC). Immunization of children infected with human immunodeficiency virus--supplementary ACIP statement. Immunization Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 1988; 37:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/70\">",
"      Arpadi SM, Markowitz LE, Baughman AL, et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996; 97:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/71\">",
"      Frenkel LM, Nielsen K, Garakian A, Cherry JD. A search for persistent measles, mumps, and rubella vaccine virus in children with human immunodeficiency virus type 1 infection. Arch Pediatr Adolesc Med 1994; 148:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/72\">",
"      Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/73\">",
"      Wallace MR, Hooper DG, Graves SJ, Malone JL. Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine 1994; 12:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/74\">",
"      Angel JB, Walpita P, Lerch RA, et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 1998; 129:104.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Measles. In: Red Book: 2006 Report of the Committee on Infectious Diseases, 27th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2006. p.441.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/76\">",
"      Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/pdf/rr/rr5907.pdf (Accessed on January 06, 2011).",
"    </li>",
"    <li>",
"     Goujon C, Tohr M, Feuillie V, et al. Good tolerance and efficacy of yellow fever vaccine among subject carriers of human immunodeficiency virus (abstract 32). 4th International Conference on Travel Medicine. International Society of Travel Medicine/World Health Organization, Acapulco, 1995, p. 63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/79\">",
"      Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009; 48:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/80\">",
"      Pacanowski J, Lacombe K, Campa P, et al. Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients. J Acquir Immune Defic Syndr 2012; 59:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/81\">",
"      Edwards KM, Kernodle DS. Possible hazards of routine bacillus Calmette-Gu&eacute;rin immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/82\">",
"      Armbruster C, Junker W, Vetter N, Jaksch G. Disseminated bacille Calmette-Gu&eacute;rin infection in an AIDS patient 30 years after BCG vaccination. J Infect Dis 1990; 162:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/83\">",
"      Besnard M, Sauvion S, Offredo C, et al. Bacillus Calmette-Gu&eacute;rin infection after vaccination of human immunodeficiency virus-infected children. Pediatr Infect Dis J 1993; 12:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/84\">",
"      O'Brien KL, Ruff AJ, Louis MA, et al. Bacillus Calmette-Gu&eacute;rin complications in children born to HIV-1-infected women with a review of the literature. Pediatrics 1995; 95:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37273/abstract/85\">",
"      von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Gu&eacute;rin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24:675.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3706 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37273=[""].join("\n");
var outline_f36_25_37273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28307327\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INACTIVATED VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Poliovirus vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pneumococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Haemophilus influenzae vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Efficacy, immunogenicity, and safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Risk factors for poor response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hepatitis A vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hepatitis B vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Meningococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Human papillomavirus vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LIVE VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Measles, mumps, and rubella vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other live virus vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Varicella vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Zoster vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Yellow fever vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - BCG vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PASSIVE IMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      IMMUNIZATIONS IN TRAVELERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28307327\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3706\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3706|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/17/42263\" title=\"figure 1\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3706|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/48/9999\" title=\"table 1\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13480?source=related_link\">",
"      Clinical trials of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/16/42246?source=related_link\">",
"      Epidemiology and transmission of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/35/16954?source=related_link\">",
"      HIV and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7930?source=related_link\">",
"      Management of healthcare personnel exposed to HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36498?source=related_link\">",
"      Patient information: Vaccines for people with HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11047?source=related_link\">",
"      Pneumococcal immunization in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40104?source=related_link\">",
"      Prevention of hepatitis B virus infection in the HIV-infected adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_25_37274="Inherited disorders of LDL-cholesterol metabolism";
var content_f36_25_37274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inherited disorders of LDL-cholesterol metabolism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/25/37274/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/25/37274/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/25/37274/contributors\">",
"     Sarah D de Ferranti, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/25/37274/contributors\">",
"     Paul Durrington, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/25/37274/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/25/37274/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/25/37274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/25/37274/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/25/37274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid disorders occur as either a result of one or more genetic abnormalities or secondary to some underlying disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/1\">",
"     1",
"    </a>",
"    ]. The former are discussed in this topic, which will focus principally on the inherited disorders of low density lipoprotein (LDL) cholesterol metabolism, which often lead to premature atherosclerosis in the individual and in family members. Secondary causes of lipid disorders are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43621?source=see_link\">",
"     \"Secondary causes of dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inherited disorders of low density lipoprotein (LDL) cholesterol metabolism are associated with overproduction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired removal of lipoproteins (",
"    <a class=\"graphic graphic_table graphicRef54329 \" href=\"mobipreview.htm?20/51/21307\">",
"     table 1",
"    </a>",
"    ). The latter defect can be induced by an abnormality in either the lipoprotein itself or in the lipoprotein receptor.",
"   </p>",
"   <p>",
"    General treatment guidelines for hypercholesterolemia and possible indications for the therapy of other dyslipidemias, such as low serum HDL-cholesterol (HDL-C), hypertriglyceridemia, and elevated serum Lp(a), are discussed in other topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further information on the approach to children with dyslipidemia is found in other UpToDate topics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43096?source=see_link\">",
"     \"Risk factors and development of atherosclerosis in childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=see_link\">",
"     \"Diseases associated with atherosclerosis in childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=see_link\">",
"     \"Overview of the management of the child at risk for atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE OF LIPID ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;One definition of dyslipidemia is total cholesterol, low density lipoprotein cholesterol (LDL-C), triglyceride, or Lp(a) levels above the ninetieth percentile or HDL-C or apo A-1 levels below the tenth percentile for the general population (",
"    <a class=\"graphic graphic_table graphicRef71803 \" href=\"mobipreview.htm?18/63/19453\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The prevalence of dyslipidemia varies with the population being studied. The prevalence is highest in patients with premature coronary heart disease (CHD), which can be defined as occurring before 55 to 60 years of age in men and before 65 years in women. In this setting, the prevalence of dyslipidemia is as high as 75 to 85 percent compared to approximately 40 to 48 percent in age-matched controls without CHD (",
"    <a class=\"graphic graphic_figure graphicRef59944 \" href=\"mobipreview.htm?15/40/16014\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disturbance in lipoprotein metabolism is often familial. In one study, for example, 54 percent of all patients with premature CHD (and 70 percent of those with a lipid abnormality) had a familial disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/2\">",
"     2",
"    </a>",
"    ]. In the great majority of patients, inheritance is polygenic and the expression of dyslipidemia is strongly influenced by factors such as obesity (particularly central obesity) and the saturated fat and cholesterol content of the diet. In nations with low rates of obesity and where saturated fat intake is low, both the incidence of CHD and the prevalence of dyslipidemia are low compared to North America and Europe. This polygenic type of dyslipidemia is the major source of atherosclerotic cardiovascular disease (CVD).",
"   </p>",
"   <p>",
"    There is a less common, but important, group of familial disorders that are monogenic. These require few or no non-genetic factors for their expression and carry a high risk of CHD at a young age, which militates for their identification as early as possible. The clinical syndrome of familial hypercholesterolemia is the leading clinical phenotype resulting from monogenic, usually dominantly inherited defects in LDL catabolism. These disorders are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056577277\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of the frequency of familial disease and the associated risk, screening lipid analysis is recommended for first-degree relatives of patients with MI (particularly if premature). Screening begins with a standard lipid profile; if this is normal, further testing should be performed with consideration paid to the measurement of Lp(a) and apolipoproteins B and A-I; approximately 25 percent of patients with premature CHD and a normal standard profile will have an abnormality in one of these factors. A larger discussion of screening for dyslipidemia is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33241?source=see_link\">",
"     \"Screening guidelines for dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     UNDERSTANDING THE GENETICS OF ELEVATED LEVELS OF LDL-C",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terminology surrounding the hereditary disorders of LDL-cholesterol metabolism can be confusing. Individual patients may have one or more genetic defects that lead to a particular phenotype.",
"   </p>",
"   <p>",
"    Most individuals with an elevated level of LDL-C in a general practice have a genetic rather than a secondary cause (such as liver or kidney disease). Of those with hereditary causes, most have multiple genetic mutations, each of which contributes in a smaller way to the elevated LDL-C level. These patients are described as having polygenic hypercholesterolemia. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Polygenic hypercholesterolemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Few patients in a general medicine practice have familial hypercholesterolemia (FH); heterozygous FH is estimated to occur in about 1 in 500 individuals in Europe and the United States, in 1 in 70 among Afrikaners in South Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/4\">",
"     4",
"    </a>",
"    ], and 1 in 150 individuals in French Canadians in Quebec [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/5\">",
"     5",
"    </a>",
"    ]. For the purposes of this topic review, FH is a clinical disorder characterized by substantially elevated plasma LDL-cholesterol (LDL-C &gt;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age and sex) from birth and premature atherosclerosis.",
"   </p>",
"   <p>",
"    Some experts further subdivide patients into definite and possible categories; individuals with tendon xanthomas fall into the former category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/6\">",
"     6",
"    </a>",
"    ]. However, not all patients with clinical FH (elevated LDL-C, premature atherosclerosis, with or without tendon xanthomas) have one of the three mutations described below. Using DNA testing, it has been estimated that about 95 percent of patients with FH carry a functional mutation of one of three genes: the LDL receptor (LDLR); the apolipoprotein B (APOB) gene which impairs binding of LDL particles to the LDL receptor; and gain of function mutations of the proprotein convertase subtilisin kexin 9 (PCSK9) gene, leading to decreased LDL metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/7\">",
"     7",
"    </a>",
"    ]. These three mutations occur in about 93, 5, and 2 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/6\">",
"     6",
"    </a>",
"    ]. FH (Online Mendelian Inheritance in Man [OMIM] number 143890) is generally attributable to one of three monogenetic mutations, each with an autosomal dominant mode of inheritance. The clinical manifestations of these mutations are indistinguishable and genetic testing is required to differentiate one from the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FAMILIAL HYPERCHOLESTEROLEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial hypercholesterolemia (FH) is a genetically modulated clinical syndrome in which the phenotype is characterized by a high LDL-C level from birth, a propensity to tendon xanthomata, and early onset CHD. CHD often develops in the absence of other CHD risk factors.",
"   </p>",
"   <p>",
"    In its most common form, FH is a monogenic, autosomal dominant disorder caused by defects in the gene that encodes for the apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The associated impairment in function of these receptors results in reduced clearance of LDL particles from the circulation and an elevation in plasma LDL-C. There is also increased uptake of modified LDL (oxidized or other modifications) by the macrophage scavenger receptors, resulting in macrophage lipid accumulation and foam cell formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link&amp;anchor=H15#H15\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Lipoproteins and atherosclerosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to LDL receptor defects, the phenotype of familial hypercholesterolemia can be seen with mutations in the PCSK9 gene or mutations in the gene that codes for apolipoprotein B. (See",
"    <a class=\"local\" href=\"#H780943178\">",
"     'Mutations in the PCSK9 gene'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Familial defective apolipoprotein B-100'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056577205\">",
"    <span class=\"h2\">",
"     LDL receptor genetic defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 1600 different mutations in the LDL receptor (LDLR) gene have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/13\">",
"     13",
"    </a>",
"    ]. The mutations at the LDLR locus have been categorized into four classes of alleles based on the phenotypic behavior of the mutant protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class I - Null, in which synthesis is defective",
"     </li>",
"     <li>",
"      Class II - Transport defective, in which intracellular transport from the endoplasmic reticulum to Golgi is impaired",
"     </li>",
"     <li>",
"      Class III - Binding defective, in which proteins are synthesized and transported to the cell surface normally, but binding of LDL is defective",
"     </li>",
"     <li>",
"      Class IV - Internalization defective, in which proteins reach the cell surface and bind LDL normally but the receptors do not cluster in the coated pits, thereby minimizing LDL internalization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with FH are classified into one of two major groups based on the amount of LDLR activity: patients with less than 2 percent (receptor-negative) and patients with 2 to 25 percent of normal LDLR activity (receptor-defective) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/14\">",
"     14",
"    </a>",
"    ]. In general, plasma levels of LDL-C are inversely related to the level of residual LDLR activity.",
"   </p>",
"   <p>",
"    A clinical presentation similar to FH can be seen in a rare autosomal recessive form of FH in which the defect appears to involve an adaptor protein for the LDL receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/15\">",
"     15",
"    </a>",
"    ] and with mutations in apo B, the ligand on LDL for the receptor. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Familial defective apolipoprotein B-100'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056577219\">",
"    <span class=\"h3\">",
"     Homozygotes versus heterozygotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;FH is inherited with a gene dosing effect, in which homozygotes are more adversely affected than heterozygotes. Homozygous FH (HoFH) is rare (1 in 1,000,000 births) unless there is co-sanguineous union in a family with HeFH. Cases are generally compound heterozygotes (a different mutation on each allele) unless parents are related when true homozygosity can occur. The severity depends on the extent to which the combination of mutations interferes with LDL metabolism. Coronary heart disease and florid xanthomatosis occur in childhood.",
"   </p>",
"   <p>",
"    Heterozygous familial hypercholesterolemia (HeFH) affects approximately 1 in 500 people in North America and Europe. Patients have high LDL-cholesterol levels from birth, premature coronary heart disease, a family history of hypercholesterolemia, and tendon xanthomata.",
"   </p>",
"   <p>",
"    In one report, for example, the fractional clearance of LDL-C was reduced by 27 percent in heterozygotes and 53 percent in homozygotes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/10\">",
"     10",
"    </a>",
"    ]. Some of the excess LDL-C is deposited in the arteries as atheroma and in the tendons and skin as xanthomata (",
"    <a class=\"graphic graphic_picture graphicRef52572 graphicRef50109 graphicRef71083 graphicRef67239 \" href=\"mobipreview.htm?22/49/23322\">",
"     picture 1A-D",
"    </a>",
"    ) and xanthelasma (",
"    <a class=\"graphic graphic_picture graphicRef67919 \" href=\"mobipreview.htm?23/14/23778\">",
"     picture 2",
"    </a>",
"    ). The prevalence of xanthomata increases with age, eventually occurring in 75 percent of FH heterozygotes.",
"   </p>",
"   <p>",
"    Coronary artery calcification, a marker of coronary artery disease, can be identified as early as 11 to 23 years of age in heterozygotes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Homozygotes with familial hypercholesterolemia also have a high incidence of aortic stenosis (about 50 percent) due to atherosclerotic involvement of the aortic root; the incidence is lower in heterozygotes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40774?source=see_link&amp;anchor=H5#H5\">",
"     \"Supravalvar aortic stenosis\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Determinants of CHD risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular risk in patients with familial hypercholesterolemia (FH) is determined both by the LDL-cholesterol (LDL-C) concentration and by other traditional cardiovascular risk factors.",
"   </p>",
"   <p>",
"    The serum LDL-C concentration is determined largely by the activity of the LDL receptor, which is genetically determined. Thus, for patients with homozygous FH, risk is related almost entirely to the severity of the genetic defect. These individuals typically have extremely low levels of LDLR activity, as discussed in the preceding section.",
"   </p>",
"   <p>",
"    In patients with heterozygous FH, risk is related to both the severity of the LDLR activity defect and, to a lesser degree, other risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/14\">",
"     14",
"    </a>",
"    ]. The following are examples of the variable impact of LDLR defects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 264 children with heterozygous FH as well as their parents and unaffected siblings, carriers of LDLR-negative mutations had, compared to carriers of LDLR-defective mutations, a significantly higher LDL-C (7.6 versus 6.7",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      [295 versus 258",
"      <span class=\"nowrap\">",
"       mg/dL])",
"      </span>",
"      and a significantly greater degree of carotid intima-media thickening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/13\">",
"       13",
"      </a>",
"      ]. In addition, there was a much higher prevalence of premature coronary artery disease in the first-degree relatives of LDLR-negative compared to LDL-defective patients (36 versus 7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Familial hypercholesterolemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Different mutations of the LDLR gene appear to confer varying effects on both LDL-C concentrations and on coronary heart disease (CHD) risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/17\">",
"       17",
"      </a>",
"      ]. In a study of 399 patients with FH who were free of CHD at study entry, LDLR-negative mutations (null alleles) (ie, complete lack of the gene's normal function) were associated with more severely elevated LDL-C and higher CHD risk than the",
"      <span class=\"nowrap\">",
"       N543H/2393del9",
"      </span>",
"      mutation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the widespread use of statin therapy for patients with heterozygous FH, the risk of premature CHD was very high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/19\">",
"     19",
"    </a>",
"    ]. In a 1974 study of over 1000 first and second degree relatives of 116 index patients, the risk of fatal of nonfatal CHD by age 60 was 52 percent for male and 32 percent for female relatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/20\">",
"     20",
"    </a>",
"    ]. In relatives without FH, the comparable rates were 13 and 9 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One useful set of diagnostic criteria for heterozygous FH categorizes patients into definite and probable FH (",
"    <a class=\"graphic graphic_table graphicRef61060 \" href=\"mobipreview.htm?35/7/35963\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66747 \" href=\"mobipreview.htm?6/33/6684\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/21\">",
"     21",
"    </a>",
"    ]. Definite criteria require hypercholesterolemia, usually normal serum triglycerides, and either genetic or cellular confirmation of an LDL receptor defect. The presence of tendon xanthomata in the proband or first-degree relatives has been considered pathognomonic of FH, but these findings can also occur in familial defective apo B-100, the normal ligand for the apolipoprotein",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/22\">",
"     22",
"    </a>",
"    ]. Supportive findings for one of these disorders include the level of serum cholesterol and premature CHD in either a first-degree relative or two or more second-degree relatives.",
"   </p>",
"   <p>",
"    One study in children of parents who had heterozygous FH found that an LDL-C concentration &ge;135",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.50",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    had a positive predictive value (PPV) of 98 percent (95% CI 96 to 99 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/23\">",
"     23",
"    </a>",
"    ]. This PPV would only apply to such children of parents with FH; a similar result would not be found in a general population tested for FH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendon xanthomata and premature atherosclerosis can also occur in two rare disorders not involving LDL metabolism: sitosterolemia and cerebrotendinous xanthomatosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sitosterolemia is an autosomal recessive disorder associated with hyperabsorption of cholesterol and plant sterols from the intestine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/24\">",
"       24",
"      </a>",
"      ]. The genetic defect can involve either the ABCG5 (ATP-binding cassette G5) or ABCG8 gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. These genes are expressed primarily in the liver and intestine and are upregulated by cholesterol feeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/25\">",
"       25",
"      </a>",
"      ]. They may normally cooperate to limit intestinal sterol absorption.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"       Ezetimibe",
"      </a>",
"      appears to reduce plasma plant sterol concentrations in patients with sitosterolemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cerebrotendinous xanthomatosis is characterized by a block in bile acid synthesis due to the absence of hepatic mitochondrial 27-hydroxylase (CYP27); it is associated with prominent neurologic abnormalities and usually normal serum cholesterol concentrations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/4/34888?source=see_link\">",
"       \"Cerebrotendinous xanthomatosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    FH also needs to be distinguished from the other two common causes of hypercholesterolemia described below: familial combined hyperlipidemia; and polygenic hypercholesterolemia. The clinical history and evaluation of the lipid profile are helpful in establishing the correct diagnosis (",
"    <a class=\"graphic graphic_table graphicRef61060 \" href=\"mobipreview.htm?35/7/35963\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66747 \" href=\"mobipreview.htm?6/33/6684\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lipid profile is similar in familial and polygenic hypercholesterolemia but xanthomata are not seen in the latter disorder.",
"     </li>",
"     <li>",
"      There is a reduced ratio of LDL-C to apo B (less than 1.2 versus greater than 1.4 in normals), and triglyceride levels may be above the 90th percentile in familial combined hyperlipidemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In initial studies, heterozygotes with FH were typically treated with multidrug regimes, which included less potent statins, to adequately control serum LDL-C levels. Such regimens retarded the angiographic progression of coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/28\">",
"     28",
"    </a>",
"    ]. At present, high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    should be the initial regimen since these drugs are more effective than other statins as monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of this approach was evaluated in a trial in which 325 patients with FH were randomly assigned to high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or conventional dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/29\">",
"     29",
"    </a>",
"    ]. High-dose atorvastatin produced a larger reduction in LDL-C (308 to 149",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [8 versus 3.9",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    than conventional dose simvastatin (321 to 185",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [8.3 to 4.8",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    High-dose atorvastatin also produced a significant reduction in carotid intima media thickness, measured with B-mode ultrasound, compared to an increase with simvastatin. &nbsp;",
"   </p>",
"   <p>",
"    The role of additional therapy with other lipid altering drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    , or probucol has not been established. These drugs produce a further reduction in LDL-C (the effect is greatest with ezetimibe) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/32-35\">",
"     32-35",
"    </a>",
"    ] but there have been no trials demonstrating either improved clinical or surrogate outcomes in patients already on high dose statin therapy.",
"   </p>",
"   <p>",
"    This point was illustrated in the ENHANCE trial of 720 adult patients with heterozygous FH who were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/36\">",
"     36",
"    </a>",
"    ]. Decreases in LDL-C were significantly greater in patients treated with combination therapy (58 versus 41 percent), but there was no statistically significant difference in the primary outcome of change from baseline in carotid intima-media thickness (0.0111 versus 0.0058 mm with simvastatin alone). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=see_link&amp;anchor=H9#H9\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Ezetimibe'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Homozygous individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 American Heart Association scientific statement on cardiovascular risk reduction in high-risk pediatric patients recommends that children with homozygous FH receive early initiation of combined therapy including LDL apheresis (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10329?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of drug-resistant hypercholesterolemia\", section on 'LDL apheresis'",
"    </a>",
"    ), high dose statin therapy, and a cholesterol absorption inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/37\">",
"     37",
"    </a>",
"    ]. We agree with this approach for both children and adults. Consideration can be given to the addition of a bile acid sequestrant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nicotinic acid as necessary, although compliance with these agents tends to be difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/35/23095?source=see_link\">",
"     Lomitapide",
"    </a>",
"    , a microsomal triglyceride transfer protein inhibitor, has been approved for use in the United States in adults with homozygous FH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10329?source=see_link&amp;anchor=H4096656#H4096656\">",
"     \"Treatment of drug-resistant hypercholesterolemia\", section on 'Lomitapide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16789?source=see_link\">",
"     Mipomersen",
"    </a>",
"    , a second generation antisense oligonucleotide inhibitor of apolipoprotein B100 synthesis, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10329?source=see_link&amp;anchor=H1142223#H1142223\">",
"     \"Treatment of drug-resistant hypercholesterolemia\", section on 'Potential future approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Heterozygous adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;While young subjects with homozygous FH require aggressive therapy, treatment of heterozygotes is often delayed until later in life. However, this approach may be inappropriate since heterozygotes have an increased risk of premature CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]; in one series, for example, the risk of a coronary event was 24 percent by age 40, 51 percent by age 50, and 85 percent by age 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/42\">",
"     42",
"    </a>",
"    ]. Thallium scanning in adolescents and young adults revealed abnormalities in 11 of 50 heterozygotes tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/43\">",
"     43",
"    </a>",
"    ]. Autopsy reports also have demonstrated atherosclerotic lesions in children at a young age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The NHLBI statement on comprehensive cardiovascular risk reduction in children and adolescents recommends that pharmacotherapy be considered for children 10 years and older when the LDL-C is elevated in the range seen in heterozygous children with FH; under the care of an expert, statin therapy may be initiated as early as age eight if the lipid abnormalities are severe. Dietary therapy and bile acid sequestrants have traditionally been the lipid-lowering therapies of choice in children, but the effect of both of these interventions is modest (approximately a ten percent reduction in LDL-C and total cholesterol with dietary interventions), and long-term compliance is poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Statins have been studied as lipid-lowering agents in children. Short-term treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    can reduce endothelial dysfunction in heterozygous children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/49\">",
"     49",
"    </a>",
"    ]. Two years of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    therapy produced regression of carotid intima-media thickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While clinical outcomes data are limited in children, short- and medium-term randomized, placebo controlled trials have demonstrated that statins are effective in lowering LDL-C and are safe in boys and girls with heterozygous FH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"       Lovastatin",
"      </a>",
"      (titrated up to 40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was evaluated in 132 adolescent males, ages 10 to 17, with serum LDL-C concentrations between 189 and 503",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.9 and 13",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      despite dietary therapy, and at least one parent with an elevated serum LDL-C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/51\">",
"       51",
"      </a>",
"      ]. After 48 weeks, serum LDL-C fell by 25 percent in the lovastatin group compared to control. Lovastatin did not affect growth, sexual maturation, testicular volume, serum hormone concentrations (testosterone, cortisol, follicle stimulating hormone, or luteinizing hormone), or serum vitamin levels, except for a reduction in vitamin E.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       Simvastatin",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      to start, titrated at eight week intervals to 20 and then 40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was evaluated in 173 children ages 10 to 17 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/52\">",
"       52",
"      </a>",
"      ]. After 48 weeks, treatment with simvastatin was associated with significant reductions in LDL-C compared with placebo (40.7 reduction versus 0.3 percent increase, respectively). There were no significant adverse effects noted with simvastatin therapy and no significant changes from baseline in adrenal, gonadal, or pituitary hormones.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       Pravastatin",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in children younger than 14, 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in older children), was evaluated in 214 children ages 8 to 18 with; the primary efficacy outcome was change in carotid intima-media thickness (IMT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/50\">",
"       50",
"      </a>",
"      ]. After two years, children who received pravastatin showed regression of IMT (-0.10 mm) with a significant difference compared with placebo (0.014 mm). LDL-C was also reduced with pravastatin (-24.1 versus 0.3 percent). There was no evidence of adverse effects on growth, sexual maturation, hormone levels, or liver or muscle tissue.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       Rosuvastatin",
"      </a>",
"      (at doses of 5, 10, and 20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was evaluated in 177 pubertal children ages 10 to 17 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/53\">",
"       53",
"      </a>",
"      ]. After 12 weeks, LDL-cholesterol fell from 237 to 117",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (50 percent) at the 20 mg dose. During an open-label, dose titration phase, only 40 percent of children achieved the LDL-cholesterol target of 110",
"      <span class=\"nowrap\">",
"       mg/dl.",
"      </span>",
"      There were no hepatic, renal, or skeletal muscle adverse events that led to permanent discontinuation of treatment and no adverse impact on growth or development was detected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials demonstrate low, tolerable rates of side effects and good efficacy in LDL-C lowering. However, no longer term larger studies exist to address the question of whether statins might have subtle effects on growth and development, increase the risk of Type 2 diabetes, or affect memory; indeed, whether LDL-C lowering during childhood will diminish or prevent future atherosclerotic disease has not been studied and is unlikely to be done given the methodological challenges of such a study. This effect is extrapolated from adult data and pre-clinical disease testing.",
"   </p>",
"   <p>",
"    Longer-term data in children are needed. However, these studies suggest that statin therapy is safe and effective in the short term for children as young as eight years of age and any potential risk should be balanced again the high risk of early atherosclerosis accompanying significantly elevated LDL cholesterol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of the child at risk for atherosclerosis\", section on 'Dyslipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in adults, the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    lowers LDL cholesterol to a greater extent than monotherapy with statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/36,54\">",
"     36,54",
"    </a>",
"    ]. In a study of 248 male and female adolescents with heterozygous FH, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/4/41031?source=see_link\">",
"     ezetimibe-simvastatin",
"    </a>",
"    combination did not lead to any significant increase in adverse events compared to a similar dose of simvastatin monotherapy during up to 53 weeks of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/54\">",
"     54",
"    </a>",
"    ]. However, there is as yet no evidence that lipid lowering with ezetimibe plus a statin improves clinical outcomes compared to a statin alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=see_link&amp;anchor=H9#H9\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Ezetimibe'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal age at which to initiate treatment of children with heterozygous FH is unknown. It is our practice, as is recommended by the NHLBI statement, to initiate cholesterol-lowering therapy in children with significant elevations of LDL cholesterol (&gt;190",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    without other risk factors, &gt;160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in children with family history of early atherosclerotic disease or two or more other risk factors). If the elevations are severe and the family history is particularly concerning, and lifestyle modification is not effective, treatment can be started as young as age eight years, although our preference is to wait until 10 years of age in males and after the onset of menses in females. Consideration should be given to the initiation of therapy earlier in children perceived to be at particularly high risk, such as those with tendon xanthomata, aortic sclerosis, or a particularly worrisome family history, features that might be consistent with homozygous familial hypercholesterolemia or more severe forms of hyperlipidemia.",
"   </p>",
"   <p>",
"    Previously, bile acid binding therapy was the first line treatment. However, compliance with these medications is particularly difficult, and statins are now an acceptable first line agent for children. Some are concerned about the theoretical risk of altering the steroid synthesis pathway by using statins in developing children; these concerns must be balanced against risks of early atherosclerotic disease; decisions about the initiation of drug therapy are best made in consultation with family members and in the context of the individual patient. We have reserved the use of cholesterol absorption inhibitors for children with intolerance to statins.",
"   </p>",
"   <p>",
"    This practice is consistent with the 2006 American Heart Association scientific statement on cardiovascular risk reduction in high-risk pediatric patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/37\">",
"     37",
"    </a>",
"    ] and the 2008 AAP guidelines noted above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Resistant hypercholesterolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;FH homozygotes and heterozygotes who are refractory to standard drug therapy have been treated with a variety of regimens. These include ileal bypass surgery, portacaval anastomosis, liver transplantation, LDL apheresis, and, in pilot studies, gene therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10329?source=see_link\">",
"     \"Treatment of drug-resistant hypercholesterolemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Investigational medical therapies, including microsomal triglyceride transfer protein inhibition, PCSK9 inhibition, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16789?source=see_link\">",
"     mipomersen",
"    </a>",
"    , are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10329?source=see_link&amp;anchor=H1142223#H1142223\">",
"     \"Treatment of drug-resistant hypercholesterolemia\", section on 'Potential future approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Fertile women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fertile women with familial hypercholesterolemia present special challenges to physicians caring for them, including the potential for pregnancy while on statin therapy, the risks of pregnancy in the presence of advanced coronary artery disease or aortic stenosis, and the use of lipid lowering therapy during breast feeding.",
"   </p>",
"   <p>",
"    We agree with the following recommendations made in the 2008 United Kingdom National Institute for Health and Clinical Excellence (NICE) Clinical Guidelines and Evidence Review for Familial Hypercholesterolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FH women who are on statin therapy and anticipate becoming pregnant should stop statins three months prior to attempting to conceive. The potential risks to the fetus of statin therapy are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link&amp;anchor=H19#H19\">",
"       \"Statins: Actions, side effects, and administration\", section on 'Risks in pregnancy and breastfeeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Contraceptive options should be explored with fertile FH patients. For those women who choose to use an oral contraceptive, the potential for an increased risk of a cardiovascular event related to thrombosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevated lipids needs to be discussed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H7#H7\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Cardiovascular disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An assessment of coronary artery disease and aortic stenosis risk should be made prior to conception, particularly in homozygotes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=see_link\">",
"       \"Screening for coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29097?source=see_link&amp;anchor=H9#H9\">",
"       \"Acquired heart disease and pregnancy\", section on 'Valvular heart disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cholesterol measurements should not be performed during pregnancy as no therapy is indicated.",
"     </li>",
"     <li>",
"      There are no contraindications to breastfeeding in these women, but no lipid-lowering therapies should be used, with the possible exception of resin agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues should be discussed in depth with the patient well in advance of conception and should be repeated periodically.",
"   </p>",
"   <p>",
"    The issue of whether pregnancy outcomes (mother and child) are worse in women with heterozygous FH was addressed in a Norwegian registry based study of 2319 births of 1093 such women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/58\">",
"     58",
"    </a>",
"    ]. Outcomes were compared to those of women (and their children) in the general Norwegian population for the same time period (1967 to 2006). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean prepregnancy total cholesterol was 370",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (9.59",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      The frequencies of prematurity, low birth weight, and congenital malformations were not significantly different between women with FH and women in the general population (6.8, 5.0, and 3.3 versus 6.2, 5.2, and 3.2 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H780943178\">",
"    <span class=\"h2\">",
"     Mutations in the PCSK9 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease that is secreted by the liver into the plasma that binds to an extracellular domain of the LDL receptor (principally) on liver cells. This binding prevents LDL receptors from recycling to the cell surface and ultimately accelerates their destruction inside liver cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/59\">",
"     59",
"    </a>",
"    ]. Fewer LDL receptors lead to less clearance of LDL-cholesterol and higher serum levels. Gain-of-function mutations in PCSK9 are rare and lead to higher levels of LDL-cholesterol and increased risk of ischemic heart disease; loss-of-function mutations are more common and are associated with reductions of both LDL-cholesterol and risk of ischemic heart disease.",
"   </p>",
"   <p>",
"    The following observations summarize the clinical importance of PCSK9:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated levels are associated with reduced expression of the hepatic LDL receptor and increased serum LDL-cholesterol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. There are polymorphisms in the PCSK9 gene that are associated with increased severity of coronary atherosclerosis in patients with polygenic hypercholesterolemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/62\">",
"       62",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Polygenic hypercholesterolemia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In multiple population studies, carriers of the loss of function 46L allele of PCSK9 have lower levels (9 to 16 percent) of LDL-cholesterol as well as a lower risk (6 to 47 percent) of ischemic heart disease compared to noncarriers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. In a meta-analysis of three large population studies, 46L allele carriers had a 12 percent reduction in LDL-cholesterol and a 28 percent reduction in the risk of ischemic heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/64\">",
"       64",
"      </a>",
"      ]. The observed reduction in LDL-cholesterol predicted only 5 percent of the reduction in the risk of ischemic heart disease. Explanations include a greater effect with lifelong exposure or other non-LDL-cholesterol lowering effects.",
"     </li>",
"     <li>",
"      Statins appear to increase serum levels of PCSK9, potentially lessening their LDL-cholesterol lowering effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/65\">",
"       65",
"      </a>",
"      ]. In a case-control substudy of the TNT trial of high- versus low-dose statin therapy in patients with stable coronary heart disease, circulating PCSK9 levels measured at randomization were predictive of major cardiovascular events at five years in the group assigned to 10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      but not in the group assigned to 80 mg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/66\">",
"       66",
"      </a>",
"      ]. At one year, there was no difference in PCSK9 levels between the two treatment groups nor was there any difference between randomization or one-year levels in either treatment arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infusion of a monoclonal antibody to PCSK9 reduces LDL cholesterol levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10329?source=see_link&amp;anchor=H1142223#H1142223\">",
"     \"Treatment of drug-resistant hypercholesterolemia\", section on 'Potential future approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Familial defective apolipoprotein B-100",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial defective apo B-100 is an autosomal dominant disorder which, like FH, is associated with impaired binding of LDL particles to the apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptor. This disorder differs from FH in that the defect is localized to the apo B-100 ligand on the LDL particle (mutation at residue 3500), not the apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptor. The net effect is that the clearance of LDL is reduced and plasma levels increase by two- to threefold. The frequency of the apo B 3500 mutation among patients classified as FH heterozygotes is as high as 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/22,68\">",
"     22,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study evaluated the frequency and clinical significance of the apolipoprotein B 3500 mutation in 9255 subjects from the general population, 948 patients with CHD, and 36 patients with FH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/69\">",
"     69",
"    </a>",
"    ]. The mutation was present in 0.08 percent of subjects in the general population in whom the mean serum cholesterol concentration was 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    higher than in those without the mutation. The increment in serum cholesterol above the general population was more pronounced in the patients with CHD (154",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.0",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and those with FH (172",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.5",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    Heterozygotes for the mutation were more common in patients with CHD (odds ratio 7.0) and FH (odds ratio 78) compared to the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FAMILIAL COMBINED HYPERLIPIDEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial combined hyperlipidemia (FCHL) is a relatively common lipid disorder. It occurs in 1 to 2 percent of the general population and accounts for one-third to one-half of familial causes of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/70\">",
"     70",
"    </a>",
"    ] and 10 percent of cases of premature CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/71\">",
"     71",
"    </a>",
"    ]. In affected families, some individuals will have hypertriglyceridemia, some hypercholesterolemia, some both, and some neither.",
"   </p>",
"   <p>",
"    One study of 63 families with FCHL found that, after adjustment for baseline covariates, 20 year cardiovascular disease mortality was increased among siblings and offspring in FCHL compared to spouse control subjects (relative risk 1.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/72\">",
"     72",
"    </a>",
"    ]. Baseline triglyceride concentrations were not independently associated with an increased risk.",
"   </p>",
"   <p>",
"    FCHL is thought to be a genetically complex disease and the phenotype is usually determined by interaction of multiple susceptibility genes and the environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Co-inheritance of two or more gene variants potentially affecting lipoprotein metabolism are generally required for the expression of FCHL.",
"   </p>",
"   <p>",
"    In many cases, FCHL is caused by overproduction of hepatically-derived apo B-100 associated with VLDL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/73\">",
"     73",
"    </a>",
"    ]. In these cases, there is an autosomal dominant pattern of inheritance. Apo B levels are strongly correlated with LDL phenotype B in FCHL families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]; LDL phenotype B levels are inherited as a Mendelian trait that is distinct from the apo B genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/75\">",
"     75",
"    </a>",
"    ]. LDL phenotype B is associated with increased serum concentrations of apo B and triglycerides, reduced serum HDL (",
"    <a class=\"graphic graphic_figure graphicRef63857 \" href=\"mobipreview.htm?35/37/36445\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/77\">",
"     77",
"    </a>",
"    ], and a three-fold increase in risk of CHD (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Small dense LDL (LDL phenotype B)'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/78\">",
"     78",
"    </a>",
"    ]. LDL phenotype A is associated with large buoyant LDL particles; in comparison, phenotype B is characterized by small, dense LDL particles.",
"   </p>",
"   <p>",
"    A study of 31 extended Finnish FCHL families suggested a novel locus on chromosome 1q21-q23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/79\">",
"     79",
"    </a>",
"    ]. A follow-up study that included an additional 29 families found that FCHL was linked and associated with the gene encoding upstream transcription factor 1 (USF1); USF1 encodes a transcription factor known to regulate several genes involved in glucose and lipid metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FCHL can be represented by one of three Fredrickson phenotypes (",
"    <a class=\"graphic graphic_table graphicRef54329 \" href=\"mobipreview.htm?20/51/21307\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Combined elevations of triglycerides and cholesterol resulting from increases in VLDL and LDL (type IIb)",
"     </li>",
"     <li>",
"      Hypercholesterolemia due to an increase in LDL (type IIa)",
"     </li>",
"     <li>",
"      Isolated hypertriglyceridemia induced by a rise in VLDL (type IV)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The phenotypic heterogeneity derives from variations in LDL subclass pattern and an associated impairment in lipoprotein lipase (mass and activity) in one-third of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/81\">",
"     81",
"    </a>",
"    ]. Those patients with abnormal lipoprotein lipase (LPL) function have higher levels of triglycerides (due to decreased clearance) and lower levels of HDL-C (due to reduced production from triglyceride-depleted VLDL remnants) than those with normal LPL activity. In at least some patients, a mutation in the LPL gene is responsible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because FCHL is phenotypically heterogeneous, and total cholesterol and triglyceride levels may vary within an affected individual over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/83\">",
"     83",
"    </a>",
"    ], diagnosis of this disorder or the possible variant hyperapobetalipoproteinemia requires family data. The presence of one of these two conditions is suggested by an LDL-to-apo B ratio of less than 1.2 (normal value &gt;1.4).",
"   </p>",
"   <p>",
"    A murine model with serum lipid profiles suggestive of human FCHL may provide some insight into the pathogenesis of the human disorder. Transgenic mice were produced by crossing mice expressing human apolipoprotein C-III (which have elevated VLDL levels) with mice deficient in the LDL receptor (which have elevated LDL levels) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/84\">",
"     84",
"    </a>",
"    ]. The double transgenic animals had very high serum concentrations of VLDL, LDL, and apo B-100; elevated levels of apo B-100 were found in IDL and to a lesser extent in VLDL. The development of atherosclerotic lesions was markedly enhanced when these animals were fed a \"Western diet.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment decisions are based upon the relative concentrations of LDL-C and triglycerides. As an example, patients with severe hypertriglyceridemia (triglyceride level &gt;500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.6",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    plus moderate hypercholesterolemia will benefit more from triglyceride-lowering agents such as a fibrate or nicotinic acid. These drugs hydrolyze the triglyceride core of VLDL and convert the large, buoyant VLDL to a particle mass more easily cleared by the apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to the patient with hypertriglyceridemia\", section on 'Pharmacologic therapy (including fish oil)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    does not reduce the level of apo B in FCHL, despite reductions in VLDL- and LDL-C and triglycerides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/85\">",
"     85",
"    </a>",
"    ]. To the contrary, gemfibrozil may actually elevate LDL-C levels when the baseline concentration of triglycerides is moderately to markedly elevated. This paradoxical response may be countered by the addition of nicotinic acid or a statin; alternatively, a bile acid sequestrant can be used if the triglyceride levels have normalized.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     Gemfibrozil",
"    </a>",
"    must be used with caution with a statin because of an increased risk of muscle injury. This risk can be minimized by using a statin that is not metabolized by CYP3A4 (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .) Dosing of gemfibrozil and bile acid sequestrants requires separation by two hours due to sequestrant-induced impaired bioavailability of gemfibrozil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HYPERAPOBETALIPOPROTEINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperapobetalipoproteinemia is characterized by an overproduction of apo B and may be a variant of familial combined hyperlipidemia. The clinical manifestations include premature CHD (particularly in patients with concurrent hypertriglyceridemia), xanthelasma (in 10 percent of cases), and obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/88\">",
"     88",
"    </a>",
"    ]. Coexisting diabetes mellitus or impaired glucose tolerance is more common in patients who also have hypertriglyceridemia.",
"   </p>",
"   <p>",
"    This condition is characterized by LDL species that are enriched in apo B-100. It is manifested clinically by an elevation in the concentration of apo B, but a normal concentration of LDL-C. In most cases, the LDL-C level is less than 160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.1",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the LDL apo B concentration is greater than 135",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and the LDL-to-apo B ratio is less than 1.2 (normal value &gt;1.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POLYGENIC HYPERCHOLESTEROLEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without genetic testing, it can be difficult to differentiate polygenic hypercholesterolemia from familial hypercholesterolemia (FH). Similar to patients with monogenic FH, these patients have familial aggregation of moderate hypercholesterolemia and the premature onset of coronary heart disease (CHD). The lipid profile shows an elevated LDL-C level, and (usually) a normal triglyceride level; tendon xanthoma are not seen (",
"    <a class=\"graphic graphic_table graphicRef66747 \" href=\"mobipreview.htm?6/33/6684\">",
"     table 4",
"    </a>",
"    ). A genetic study of over 600 patients with clinical FH and 3020 controls attempted to distinguish patients with polygenic and monogenic FH by genotyping for the three known genetic causes of FH (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Understanding the genetics of elevated levels of LDL-C'",
"    </a>",
"    above) and 12 common LDL-C raising single-nucleotide polymorphisms (SNPs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/6\">",
"     6",
"    </a>",
"    ]. In this study, only about 50 percent of patients with clinical FH had monogenic FH; of these, many had multiple SNPs. Multiple genetic mutations were often found in those labeled as having a polygenic cause (none of the three known genetic causes found).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetics of polygenic hypercholesterolemia are poorly understood but multiple abnormalities in LDL metabolism are likely involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These abnormalities in LDL metabolism include mild defects in the LDL receptor, defective apo B-100, increased synthesis of apo B, and the presence of the apo E4 phenotype. Apo E is required for receptor-mediated clearance of chylomicron and VLDL remnants from the circulation. Apo E4 has a higher affinity for the LDL receptor than the other apo E isoforms. The enhanced lipid binding leads, via negative feedback, to downregulation of LDL receptor synthesis and a secondary rise in LDL-C levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link&amp;anchor=H8#H8\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Apolipoproteins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple studies and reviews have evaluated the relationship between apo E genotypes (particularly the apo E4 allele) and both LDL-cholesterol and the incidence of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/91-93\">",
"     91-93",
"    </a>",
"    ]. However, these reports may have been both underpowered to detect the true relationship and also subject to publication bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest meta-analysis of the impact of the presence of the apo E allele on LDL-cholesterol levels and CHD risk came to the following conclusions using the",
"    <span class=\"nowrap\">",
"     E3/E3",
"    </span>",
"    genotype as the reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/94\">",
"     94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was an approximately linear relationship of apoE genotypes (when ordered",
"      <span class=\"nowrap\">",
"       E2/E2,",
"      </span>",
"      <span class=\"nowrap\">",
"       E2/E3,E3/E3,E3/E4,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       E4/E4)",
"      </span>",
"      with LDL-cholesterol. There was a weakly inverse relationship of these genotypes with HDL-cholesterol level and a non-linear relationship with triglycerides, with the",
"      <span class=\"nowrap\">",
"       E3/E3",
"      </span>",
"      genotype having the lowest triglyceride levels",
"     </li>",
"     <li>",
"      There was an approximately linear relationship of apoE genotypes (when ordered",
"      <span class=\"nowrap\">",
"       E2/E2,",
"      </span>",
"      <span class=\"nowrap\">",
"       E2/E3,E3/E3,E3/E4,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       E4/E4)",
"      </span>",
"      with CHD risk. Compared with the apo",
"      <span class=\"nowrap\">",
"       E3/E3",
"      </span>",
"      individual, the odds ratio for CHD was 0.8 (95% CI, 0.70-0.90) in E2 carriers and 1.06 (95% CI, 0.99-1.13) in E4 carriers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy in polygenic hypercholesterolemia usually begins with a statin; nicotinic acid and a bile acid sequestrant are alternatives in patients who cannot tolerate a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/34\">",
"     34",
"    </a>",
"    ]. The 4S trial, which followed 966 survivors of a myocardial infarction for 5.5 years, found that those with the apo E4 allele had a nearly twofold increased risk of dying compared to other patients; this excess mortality was abolished by treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further lowering of LDL-C may be accomplished by combining a statin with nicotinic acid or a bile acid sequestrant. Low doses of nicotinic acid (1 to 1.5",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    will also raise HDL-C, a desirable effect in patients with hypercholesterolemia and low HDL-C. However, the concurrent use of a statin and nicotinic acid may increase the risk of liver function abnormalities and myopathy.",
"   </p>",
"   <p>",
"    The Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II, or ATP II) had recommended that hormone replacement therapy be used as first-line therapy in women with CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/96\">",
"     96",
"    </a>",
"    ]. However, this recommendation was omitted in ATP III [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/97\">",
"     97",
"    </a>",
"    ], as a result of clinical trials such as the HERS trial that failed to show any benefit of hormone replacement for secondary prevention of CHD (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H11#H11\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Secondary prevention'",
"    </a>",
"    ). Thus, statins should be the first choice for lipid lowering therapy in most women with CHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SMALL DENSE LDL (LDL PHENOTYPE B)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, LDL particles are heterogeneous in size, density, and composition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/98\">",
"     98",
"    </a>",
"    ]. Individuals can be classified according to their predominant LDL size into one of three phenotypic patterns on gradient gel electrophoresis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phenotype pattern A &mdash; Large particle size, &ge;26.3 nm in diameter",
"     </li>",
"     <li>",
"      Phenotype pattern B &mdash; Small particle size, &lt;25.8 nm in diameter",
"     </li>",
"     <li>",
"      Phenotype pattern I &mdash; Intermediate particle size (mixed distribution), 25.8 to 26.3 nm in diameter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Small, dense LDL particles (phenotype B) are associated with increased serum concentrations of apo B and triglycerides, reduced serum HDL (",
"    <a class=\"graphic graphic_figure graphicRef63857 \" href=\"mobipreview.htm?35/37/36445\">",
"     figure 2",
"    </a>",
"    ), and an increased risk of CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Determinants",
"    </span>",
"    &nbsp;&mdash;&nbsp;LDL phenotype B levels are in part genetically determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/75\">",
"     75",
"    </a>",
"    ]. Studies of monozygotic and dizygotic women twin pairs suggest that one-third to one-half of the variation in LDL particle diameter can be attributed to genetic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/99\">",
"     99",
"    </a>",
"    ]. One gene that may contribute is the gene for cholesteryl ester transfer protein (CETP), which plays a central role in reverse cholesterol transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/100\">",
"     100",
"    </a>",
"    ]. CETP moves cholesterol from peripheral tissues to the liver by transferring cholesteryl ester from HDL-C to apo B-containing lipoproteins with triglyceride transfer in the opposite direction. Increased CETP activity may be proatherogenic and is associated with LDL phenotype B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LDL phenotype B levels are also influenced by acquired conditions. As an example, they are associated with obesity, type 2 diabetes, and the manifestations of the acquired insulin resistance syndrome such as hypertriglyceridemia, hyperinsulinemia, increased waist-to-hip ratio, low serum HDL2, and systolic hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High hepatic lipase activity is another factor associated with an increase in small, dense LDL particles as well as a reduction in HDL2 cholesterol. Interventions that alter hepatic lipase activity can affect the concentration of small, dense LDL particles. Among patients in the FATS trial with a personal and family history of CHD and apo B levels &ge;125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    intensive lipid-lowering therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    -colestipol or niacin-colestipol produced a significant reduction in hepatic lipase activity and an increase in large, buoyant LDL particles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/103\">",
"     103",
"    </a>",
"    ]. These changes were associated with a significant improvement in disease severity; in a multivariate analysis, an increase in LDL buoyancy was most strongly associated with regression of CHD, accounting for 37 percent of the variance of change in coronary stenosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of hepatic lipase may be related to a polymorphism in the hepatic lipase gene promoter, the most common being a C to T substitution. The presence of a C allele is associated with higher hepatic lipase activity; smaller, denser, and more atherogenic LDL particles; and lower serum HDL-C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The angiographic improvement with lipid lowering is most prominent in subjects with small, dense LDL and lower serum HDL-C, suggesting that hepatic lipase polymorphism might have predictive value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/105\">",
"     105",
"    </a>",
"    ]. This hypothesis was evaluated in a study of 49 men with established coronary disease and dyslipidemia; patients with the CC genotype had the greatest decrease in hepatic lipase activity, improvement in LDL density, and regression in coronary atherosclerosis (96 versus 60 and 0 percent for TC and TT genotypes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Increase in coronary risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small, dense LDL particles, have been consistently associated with CHD in case-control studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/78,107-111\">",
"     78,107-111",
"    </a>",
"    ]. As an example, the Stanford Five-City Project evaluated the association between LDL particle diameter with incident fatal and nonfatal MI in a nested case-control study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/110\">",
"     110",
"    </a>",
"    ]. The study included 124 case-control pairs (90 pairs of men and 34 pairs of women). The patients with MI had a smaller LDL size (mean 26.17 versus 26.68 nm, p&lt;0.001) and there was a graded association across quintiles of LDL size. Small LDL size was a stronger independent predictor of CHD than all other parameters except for the total cholesterol-to-HDL C ratio.",
"   </p>",
"   <p>",
"    The Physicians' Health Study used a nested case-control study to evaluate whether small, dense LDL particles and nonfasting triglyceride levels were independent predictors for MI in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/111\">",
"     111",
"    </a>",
"    ]. The study group included 266 cases and 308 controls that were matched for age and smoking status. The cases had a significantly lower average LDL diameter (25.6 versus 25.9 nm, p &lt;0.001) and higher serum triglycerides. Small, dense LDL was associated with higher triglyceride and lower HDL-C levels, and LDL diameter was not an independent risk factor after adjustment for the high triglyceride levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It may be possible to refine the risk associated with small, dense LDL particle size. In a prospective study of over 2000 men, for example, the ability to predict CHD was improved by measuring the cholesterol concentration in the small LDL particles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to determining coronary risk, LDL particle size is also an important predictor of the response to risk-factor reduction. The Stanford Coronary Risk Intervention Project (SCRIP) was a four-year angiographic trial of multifactorial risk reduction versus usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/105\">",
"     105",
"    </a>",
"    ]. LDL particles were classified by density into a \"buoyant\" (density &lt;1.0378",
"    <span class=\"nowrap\">",
"     g/mL)",
"    </span>",
"    or \"dense\" mode (density &gt;1.0378",
"    <span class=\"nowrap\">",
"     g/mL).",
"    </span>",
"    Cholesterol-lowering therapy produced a significant treatment benefit only in the dense-mode subjects. As noted above, an improvement in LDL density and regression of atherosclerosis appear to be most prominent in patients with the CC genotype for the hepatic lipase gene promoter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At any level of LDL-C, individuals with an increased number of small LDL particles have higher LDL particle (LDL-P) concentrations. In multivariate models, LDL-P size is not related to increased cardiovascular risk after adjustment for LDL-P concentration or its surrogate measure apolipoprotein B (apo B) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. Thus, LDL size represents part of the pattern of atherogenic dyslipidemia, and it is not a specific therapeutic target. In individuals with disorders of insulin resistance (obesity, metabolic syndrome, type 2 diabetes), LDL-cholesterol under-represents cardiovascular risk due to the discordance between LDL-C and LDL-P [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/113,115\">",
"     113,115",
"    </a>",
"    ]. Thus, LDL-P, or its surrogate measure apo B, has been considered a target of therapy, as this measure is associated with a twofold higher risk of cardiovascular disease events than LDL-C. Moreover, in statin-treated patients, apo B levels are more strongly associated with residual cardiovascular risk than LDL-C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the high residual cardiovascular risk in metabolic syndrome and type 2 diabetes patients who achieve current recommended LDL-C targets on statin therapy, we agree with the American Diabetes",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of Cardiology Foundation issued consensus statement recommending measurement of apo B (or LDL-P concentration) in patients at high cardiometabolic risk, as well as treatment of high levels of apo B or LDL-P concentration, after therapeutic interventions have been initiated for treatment of LDL-C and non-HDL-C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/117\">",
"     117",
"    </a>",
"    ]. Treatment targets for",
"    <span class=\"nowrap\">",
"     LDL-C/non-HDL-C/LDL-P/apo",
"    </span>",
"    B are presented in the following table (",
"    <a class=\"graphic graphic_table graphicRef52294 \" href=\"mobipreview.htm?11/35/11835\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Mechanisms of increased atherogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The atherogenic potential of small LDL particles has been related to both direct and indirect mechanisms. The direct mechanisms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enhanced oxidative susceptibility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/118,119\">",
"       118,119",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced clearance by LDL receptors in the liver with increased LDL receptor-independent binding in the arterial wall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/120,121\">",
"       120,121",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Endothelial dysfunction that is independent of the concentrations of other lipid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/122\">",
"       122",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These factors may interact. Less avid binding to the LDL receptor prolongs the half-life of small, dense LDL in the circulation, increasing the likelihood that they will undergo oxidative modification and subsequent uptake by the macrophage scavenger receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indirect associations between small, dense LDL and atherogenic risk include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inverse relationship with HDL-C (",
"      <a class=\"graphic graphic_figure graphicRef63857 \" href=\"mobipreview.htm?35/37/36445\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Marker for accumulation of atherogenic triglyceride remnant particles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/123\">",
"       123",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Insulin resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/101\">",
"       101",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LOW LDL-CHOLESTEROL LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two genetic disorders causing extremely low levels of LDL-cholesterol have been identified. These two, &ldquo;abetalipoproteinemia&rdquo; and hypobetalipoproteinemia,&rdquo; are referred to as &ldquo;familial hypobetalipoproteinemia.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180677128\">",
"    <span class=\"h2\">",
"     Abetalipoproteinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abetalipoproteinemia is a rare recessive disorder caused by a mutation in the gene encoding microsomal transfer protein (MTP). MTP is responsible for the intracellular assembly of apolipoprotein B (apo B) and lipids in the liver and intestine.&nbsp;Consequently, no apo B-containing lipoproteins are found in the plasma (and thus LDL-C levels are near zero), and this results in impaired transport of fat-soluble vitamins&nbsp;(A, D, E, K). This condition is manifest in infancy, and it is characterized by mental retardation and growth abnormalities.&nbsp;Some patients with abetalipoproteinemia can have peripheral neuropathies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=see_link&amp;anchor=H10#H10\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Abetalipoproteinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180677135\">",
"    <span class=\"h2\">",
"     Hypobetalipoproteinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypobetalipoproteinemia is associated with mutations that may occur at multiple genetic loci, and the best-described cases show linkage to mutations in the gene encoding apo B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/124\">",
"     124",
"    </a>",
"    ]. The clinical manifestations include intestinal fat malabsorption, hepatic steatosis, and fat soluble vitamin deficiencies.&nbsp;Monitoring for symptoms of fat-soluble vitamin deficiency is recommended. Measurement of fat-soluble vitamin levels is recommended with supplementation of the deficient vitamins as dictated by the magnitude of the vitamin deficiency. Patients have very low levels of plasma apo B and LDL-cholesterol (&lt;5",
"    <sup>",
"     th",
"    </sup>",
"    percentile of age- and sex-specific values; LDL-C levels between 25 and 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.65 and 1.03",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    as well as low levels of very low density lipoprotein (VLDL) cholesterol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2010 report of one family with hypobetalipoproteinemia",
"    <strong>",
"     not",
"    </strong>",
"    linked to apo B has not only shed light on the genetics lipid disorders, but has also raised the possibility of a new mechanism for LDL-C lowering [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/25/37274/abstract/124\">",
"     124",
"    </a>",
"    ]. In this family, premature coronary heart disease was absent. Four family members also had very low levels of HDL-cholesterol. Genetic analyses were performed on forty family members, including exome sequencing of two individuals with low HDL-C. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two independent, nonsense mutations in ANGPTL3 were found. The protein produced by ANGPTL3 region is thought to increase plasma levels of triglycerides, LDL- and HDL-cholesterol.",
"     </li>",
"     <li>",
"      Those individuals with only one affected allele had low levels of LDL-C (mean of 72 mg per deciliter [1.9",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      compared to those without the defect, and normal levels of HDL-C (mean of 43",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.1 mmol per liter]).",
"     </li>",
"     <li>",
"      The four siblings with two affected alleles had very low levels of both LDL- and HDL-C (mean values of 33",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [0.9",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      and 18",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [0.5",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No intervention to either raise or further lower the LDL cholesterol level in these patients with mutations in ANGPTL3 is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H183315699\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest referring the following groups of patients with a primary disorder of LDL-cholesterol metabolism to a specialist in the care of lipid disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All those with homozygous familial hypercholesterolemia (FH).",
"     </li>",
"     <li>",
"      All those with heterozygous FH or other primary disorders of LDL-C metabolism who remain above their low density lipoprotein cholesterol or triglyceride target(s) on maximum tolerated dose of a statin and a second drug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, health care providers should recommend lipid profiles for all first-degree relatives of patients with FH in order to identify other individuals at risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/30/5602?source=see_link\">",
"       \"Patient information: Familial hypercholesterolemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H451294160\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary dyslipidemias are associated with overproduction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      impaired removal of lipoproteins (",
"      <a class=\"graphic graphic_table graphicRef54329 \" href=\"mobipreview.htm?20/51/21307\">",
"       table 1",
"      </a>",
"      ). The latter defect can be induced by an abnormality in either the lipoprotein itself or in the lipoprotein receptor. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of dyslipidemia varies with the population being studied. The incidence is highest in patients with premature coronary heart disease (CHD), which can be defined as occurring before 55 to 60 years of age in men and before 65 years in women. In this setting, the prevalence of dyslipidemia is as high as 75 to 85 percent compared to approximately 40 to 48 percent in age-matched controls without CHD (",
"      <a class=\"graphic graphic_figure graphicRef59944 \" href=\"mobipreview.htm?15/40/16014\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence of lipid abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Familial hypercholesterolemia (FH) and familial combined hyperlipidemia are two of the most common types of primary dyslipidemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Understanding the genetics of elevated levels of LDL-C'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Familial hypercholesterolemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Familial combined hyperlipidemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Health care providers should recommend lipid profiles for all first-degree relatives of patients with FH in order to identify other individuals at risk.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/1\">",
"      Durrington P. Dyslipidaemia. Lancet 2003; 362:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/2\">",
"      Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/3\">",
"      Roncaglioni MC, Santoro L, D'Avanzo B, et al. Role of family history in patients with myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators. Circulation 1992; 85:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/4\">",
"      Steyn K, Goldberg YP, Kotze MJ, et al. Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations. Hum Genet 1996; 98:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/5\">",
"      Couture P, Morissette J, Gaudet D, et al. Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. Atherosclerosis 1999; 143:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/6\">",
"      Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/7\">",
"      van der Graaf A, Avis HJ, Kusters DM, et al. Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation 2011; 123:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/8\">",
"      Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990; 24:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/9\">",
"      Ishibashi S, Brown MS, Goldstein JL, et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/10\">",
"      Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/11\">",
"      Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/12\">",
"      Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/13\">",
"      Guardamagna O, Restagno G, Rolfo E, et al. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr 2009; 155:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/14\">",
"      Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/15\">",
"      Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/16\">",
"      Gidding SS, Bookstein LC, Chomka EV. Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. Circulation 1998; 98:2580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/17\">",
"      Koeijvoets KC, Rodenburg J, Hutten BA, et al. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 2005; 112:3168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/18\">",
"      Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002; 106:3031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/19\">",
"      Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004; 160:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/20\">",
"      Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974; 49:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/21\">",
"      Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/22\">",
"      Defesche JC, Pricker KL, Hayden MR, et al. Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. Arch Intern Med 1993; 153:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/23\">",
"      Wiegman A, Rodenburg J, de Jongh S, et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 2003; 107:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/24\">",
"      Gregg RE, Connor WE, Lin DS, Brewer HB Jr. Abnormal metabolism of shellfish sterols in a patient with sitosterolemia and xanthomatosis. J Clin Invest 1986; 77:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/25\">",
"      Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/26\">",
"      Lee MH, Lu K, Hazard S, et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001; 27:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/27\">",
"      Salen G, von Bergmann K, L&uuml;tjohann D, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004; 109:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/28\">",
"      Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/29\">",
"      Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/30\">",
"      Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 79:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/31\">",
"      Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/32\">",
"      Aji W, Ravalli S, Szabolcs M, et al. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 1997; 95:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/33\">",
"      Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/34\">",
"      Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994; 154:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/35\">",
"      Yamamoto A, Matsuzawa Y, Yokoyama S, et al. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986; 57:29H.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/36\">",
"      Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/37\">",
"      Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006; 114:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/38\">",
"      Colletti RB, Neufeld EJ, Roff NK, et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993; 92:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/39\">",
"      McCrindle BW, O'Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J Pediatr 1997; 130:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/40\">",
"      Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ 2006; 174:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/41\">",
"      Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989; 79:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/42\">",
"      Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969; 2:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/43\">",
"      Mouratidis B, Vaughan-Neil EF, Gilday DL, et al. Detection of silent coronary artery disease in adolescents and young adults with familial hypercholesterolemia by single-photon emission computed tomography thallium-201 scanning. Am J Cardiol 1992; 70:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/44\">",
"      Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999; 281:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/45\">",
"      McGill HC Jr, McMahan CA, Zieske AW, et al. Association of Coronary Heart Disease Risk Factors with microscopic qualities of coronary atherosclerosis in youth. Circulation 2000; 102:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/46\">",
"      Tonstad S, Knudtzon J, Sivertsen M, et al. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996; 129:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/47\">",
"      Groot PH, Dijkhuis-Stoffelsma R, Grose WF, et al. The effects of colestipol hydrochloride on serum lipoprotein lipid and apolipoprotein B and A-I concentrations in children heterozygous for familial hypercholesterolemia. Acta Paediatr Scand 1983; 72:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/48\">",
"      Lauer RM, Obarzanek E, Hunsberger SA, et al. Efficacy and safety of lowering dietary intake of total fat, saturated fat, and cholesterol in children with elevated LDL cholesterol: the Dietary Intervention Study in Children. Am J Clin Nutr 2000; 72:1332S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/49\">",
"      de Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/50\">",
"      Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/51\">",
"      Stein EA, Illingworth DR, Kwiterovich PO Jr, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999; 281:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/52\">",
"      de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002; 106:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/53\">",
"      Avis HJ, Hutten BA, Gagn&eacute; C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010; 55:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/54\">",
"      van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008; 52:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/55\">",
"      Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/56\">",
"      Thorogood M, Seed M, De Mott K, Guideline Development Group. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG 2009; 116:478.",
"     </a>",
"    </li>",
"    <li>",
"     www.nice3.org.uk/nicemedia/pdf/CG071FullGuideline.pdf (Accessed on March 18, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/58\">",
"      Toleikyte I, Retterst&oslash;l K, Leren TP, Iversen PO. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation 2011; 124:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/59\">",
"      Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50 Suppl:S172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/60\">",
"      Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res 2008; 49:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/61\">",
"      Abifadel M, Rab&egrave;s JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009; 30:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/62\">",
"      Chen SN, Ballantyne CM, Gotto AM Jr, et al. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005; 45:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/63\">",
"      Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/64\">",
"      Benn M, Nordestgaard BG, Grande P, et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010; 55:2833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/65\">",
"      Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004; 24:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/66\">",
"      Huijgen R, Boekholdt SM, Arsenault BJ, et al. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol 2012; 59:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/67\">",
"      Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/68\">",
"      Tybjaerg-Hansen A, Gallagher J, Vincent J, et al. Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 1990; 80:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/69\">",
"      Tybjaerg-Hansen A, Steffensen R, Meinertz H, et al. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 1998; 338:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/70\">",
"      Williams RR, Hopkins PN, Hunt SC, et al. Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah. Arch Intern Med 1990; 150:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/71\">",
"      Goldstein JL, Schrott HG, Hazzard WR, et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/72\">",
"      Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000; 101:2777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/73\">",
"      Venkatesan S, Cullen P, Pacy P, et al. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 1993; 13:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/74\">",
"      Brouwers MC, van Greevenbroek MM, Troutt JS, et al. Plasma proprotein convertase subtilisin kexin type&nbsp;9 is a heritable trait of familial combined hyperlipidaemia. Clin Sci (Lond) 2011; 121:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/75\">",
"      Jarvik GP, Brunzell JD, Austin MA, et al. Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype. Arterioscler Thromb 1994; 14:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/76\">",
"      Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/77\">",
"      Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/78\">",
"      Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/79\">",
"      Pajukanta P, Nuotio I, Terwilliger JD, et al. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet 1998; 18:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/80\">",
"      Pajukanta P, Lilja HE, Sinsheimer JS, et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 2004; 36:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/81\">",
"      Babirak SP, Brown BG, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb 1992; 12:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/82\">",
"      Yang WS, Nevin DN, Peng R, et al. A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. Proc Natl Acad Sci U S A 1995; 92:4462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/83\">",
"      Veerkamp MJ, de Graaf J, Hendriks JC, et al. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 2004; 109:2980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/84\">",
"      Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, et al. A mouse model with features of familial combined hyperlipidemia. Science 1997; 275:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/85\">",
"      Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 1993; 13:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/86\">",
"      Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/87\">",
"      Forland SC, Feng Y, Cutler RE. Apparent reduced absorption of gemfibrozil when given with colestipol. J Clin Pharmacol 1990; 30:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/88\">",
"      Kwiterovich PO Jr, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged &lt; or = 50 years) and women (&lt; or = 60 years) with coronary artery disease. Am J Cardiol 1993; 71:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/89\">",
"      Teng B, Thompson GR, Sniderman AD, et al. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia. Proc Natl Acad Sci U S A 1983; 80:6662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/90\">",
"      Grundy SM. George Lyman Duff Memorial Lecture. Multifactorial etiology of hypercholesterolemia. Implications for prevention of coronary heart disease. Arterioscler Thromb 1991; 11:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/91\">",
"      Walden CC, Hegele RA. Apolipoprotein E in hyperlipidemia. Ann Intern Med 1994; 120:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/92\">",
"      Wilson PW, Myers RH, Larson MG, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994; 272:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/93\">",
"      Frikke-Schmidt R, Tybjaerg-Hansen A, Steffensen R, et al. Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol 2000; 35:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/94\">",
"      Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007; 298:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/95\">",
"      Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study. Circulation 2000; 101:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/96\">",
"      Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/97\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/98\">",
"      Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992; 38:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/99\">",
"      Austin MA, Newman B, Selby JV, et al. Genetics of LDL subclass phenotypes in women twins. Concordance, heritability, and commingling analysis. Arterioscler Thromb 1993; 13:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/100\">",
"      Talmud PJ, Edwards KL, Turner CM, et al. Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size: use of a novel tetranucleotide repeat within the CETP promoter. Circulation 2000; 101:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/101\">",
"      Selby JV, Austin MA, Newman B, et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993; 88:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/102\">",
"      Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 1996; 45:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/103\">",
"      Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999; 99:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/104\">",
"      Zambon A, Deeb SS, Hokanson JE, et al. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 1998; 18:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/105\">",
"      Miller BD, Alderman EL, Haskell WL, et al. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996; 94:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/106\">",
"      Zambon A, Deeb SS, Brown BG, et al. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 2001; 103:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/107\">",
"      Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/108\">",
"      Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis 1991; 90:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/109\">",
"      Lamarche B, Tchernof A, Mauri&egrave;ge P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/110\">",
"      Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/111\">",
"      Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/112\">",
"      St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001; 104:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/113\">",
"      Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 2010; 213:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/114\">",
"      Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009; 119:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/115\">",
"      Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/116\">",
"      Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/117\">",
"      Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/118\">",
"      de Graaf J, Hak-Lemmers HL, Hectors MP, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/119\">",
"      Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/120\">",
"      Galeano NF, Al-Haideri M, Keyserman F, et al. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 1998; 39:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/121\">",
"      Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991; 32:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/122\">",
"      Vakkilainen J, M&auml;kimattila S, Sepp&auml;l&auml;-Lindroos A, et al. Endothelial dysfunction in men with small LDL particles. Circulation 2000; 102:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/123\">",
"      Slyper AH. Low-density lipoprotein density and atherosclerosis. Unraveling the connection. JAMA 1994; 272:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/25/37274/abstract/124\">",
"      Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010; 363:2220.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4567 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-2F27AEB7FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37274=[""].join("\n");
var outline_f36_25_37274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H451294160\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE OF LIPID ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1056577277\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UNDERSTANDING THE GENETICS OF ELEVATED LEVELS OF LDL-C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FAMILIAL HYPERCHOLESTEROLEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056577205\">",
"      LDL receptor genetic defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1056577219\">",
"      - Homozygotes versus heterozygotes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Determinants of CHD risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Homozygous individuals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Heterozygous adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Resistant hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fertile women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H780943178\">",
"      Mutations in the PCSK9 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Familial defective apolipoprotein B-100",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FAMILIAL COMBINED HYPERLIPIDEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HYPERAPOBETALIPOPROTEINEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POLYGENIC HYPERCHOLESTEROLEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SMALL DENSE LDL (LDL PHENOTYPE B)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Determinants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Increase in coronary risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Mechanisms of increased atherogenicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LOW LDL-CHOLESTEROL LEVELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H180677128\">",
"      Abetalipoproteinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H180677135\">",
"      Hypobetalipoproteinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H183315699\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H451294160\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4567\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4567|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/40/16014\" title=\"figure 1\">",
"      Lipids and premature CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/37/36445\" title=\"figure 2\">",
"      LDL phenotypes and HDL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4567|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/26/17825\" title=\"picture 1A\">",
"      Tendon xanthomata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/29/32208\" title=\"picture 1B\">",
"      Achilles tendon xanthoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/39/10866\" title=\"picture 1C\">",
"      Subperiosteal xanthomata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/22/31074\" title=\"picture 1D\">",
"      Planar xanthoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/14/23778\" title=\"picture 2\">",
"      Xanthelasma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4567|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/51/21307\" title=\"table 1\">",
"      Fredrickson classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/63/19453\" title=\"table 2\">",
"      Normal values for lipid levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/7/35963\" title=\"table 3\">",
"      Cholesterol criteria for heterozygous FH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/33/6684\" title=\"table 4\">",
"      Causes of hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/35/11835\" title=\"table 5\">",
"      Suggested apolipoprotein B or LDL-P treatment goals",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/4/34888?source=related_link\">",
"      Cerebrotendinous xanthomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=related_link\">",
"      Overview of the management of the child at risk for atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/30/5602?source=related_link\">",
"      Patient information: Familial hypercholesterolemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43096?source=related_link\">",
"      Risk factors and development of atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43621?source=related_link\">",
"      Secondary causes of dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40774?source=related_link\">",
"      Supravalvar aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10329?source=related_link\">",
"      Treatment of drug-resistant hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_25_37275="NCI CTCAE hypertension";
var content_f36_25_37275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    National Cancer Institute Common Terminology Criteria for hypertension (CTCAE v 4.0)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"90%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td>",
"        Prehypertension (systolic BP 120 to 139 mmHg or diastolic BP 80 to 89 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td>",
"        Stage 1 hypertension (systolic BP 140 to 159 mmHg or diastolic BP 90 to 99 mmHg); medical intervention indicated; recurrent or persistent (&ge;24 hours); symptomatic increase by &gt;20 mmHg (diastolic) or to &gt;140/90 mmHg if previously within normal limits; monotherapy indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td>",
"        Stage 2 hypertension (systolic BP &ge;160 mmHg or diastolic BP &ge;100 mmHg); medical intervention indicated; more than one drug or more intensive therapy than previously used indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td>",
"        Life-threatening consequences (eg, malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis); urgent intervention indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BP: blood pressure.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Common Terminology Criteria for Adverse Events, version 4.0, June 2010, National Institutes of Health, National Cancer Institute. Available at:",
"     <a href=\"file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\" target=\"_blank\">",
"      file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf",
"     </a>",
"     (Accessed December 14, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37275=[""].join("\n");
var outline_f36_25_37275=null;
var title_f36_25_37276="Some genes of interest in schizophrenia";
var content_f36_25_37276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F69865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F69865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some genes of interest in schizophrenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gene name or product",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hypothesized function",
"       </td>",
"       <td class=\"subtitle1\">",
"        Notes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catechol-O-methyl transferase",
"       </td>",
"       <td>",
"        COMT",
"       </td>",
"       <td>",
"        Catecholamine (including dopamine) metabolism",
"       </td>",
"       <td>",
"        <p>",
"         At position 158 in the resulting protein: a VAL/VAL allele is more active than a VAL/MET or MET/MET allele.",
"        </p>",
"        <p>",
"         The VAL/VAL allele is associated with greater risk of psychosis in cannabis users",
"         <sup>",
"          [1]",
"         </sup>",
"         . Position 22q11.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disrupted in schizophrenia 1",
"       </td>",
"       <td>",
"        DISC1",
"       </td>",
"       <td>",
"        Wide array of hypothesized functions from cell migration during development to dendritic outgrowths and cell adhesion",
"       </td>",
"       <td>",
"        Discovered from studying a Scottish family with many members having a severe mental disorder and also a translocation disrupting the expression of the gene. Position 1q42.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dystrobrevin binding protein 1 (dysbindin)",
"       </td>",
"       <td>",
"        DTNBP1",
"       </td>",
"       <td>",
"        Axon stability",
"       </td>",
"       <td>",
"        Also associated with skeletal muscle. Position 6p22.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gamma-aminobutyric acid (GABA) A receptor subunit beta 2",
"       </td>",
"       <td>",
"        GABRB2",
"       </td>",
"       <td>",
"        Inhibitory neurotransmission",
"       </td>",
"       <td>",
"        There is evidence of GABA signaling system abnormalities in schizophrenia. Position 5q34.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuregulin 1",
"       </td>",
"       <td>",
"        NRG1",
"       </td>",
"       <td>",
"        Signal transduction related to cell growth and differentiation",
"       </td>",
"       <td>",
"        NRG1 undergoes alternative splicing into several proteins. Position 8p12-21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc finger protein 804A",
"       </td>",
"       <td>",
"        ZNF804A",
"       </td>",
"       <td>",
"        Unknown (may be transcription factor)",
"       </td>",
"       <td>",
"        <p>",
"         Identified in GWAS study",
"         <sup>",
"          [2]",
"         </sup>",
"         .",
"        </p>",
"        <p>",
"         Also associated with bipolar disorders.",
"        </p>",
"        <p>",
"         Examination of rare alleles of the gene found no difference in rates in schizophrenia compared to controls",
"         <sup>",
"          [3]",
"         </sup>",
"         .",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      References:",
"     </p>",
"     <ol>",
"      <li>",
"       Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-O-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006; 31:2748.",
"      </li>",
"      <li>",
"       O'Donovan MC, Craddock N, Norton N, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008; 4 :1053.",
"      </li>",
"      <li>",
"       Dwyer S, Williams H, Holmans P, et al. No evidence that rare coding variants in ZNF804A confer risk of schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2010; 153B:1411.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37276=[""].join("\n");
var outline_f36_25_37276=null;
var title_f36_25_37277="Analgesia for labor delivery";
var content_f36_25_37277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Systemic analgesics used for labor and vaginal delivery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Class",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       Onset",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Meperidine",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Opioid",
"      </td>",
"      <td>",
"       25-50 mg IV",
"      </td>",
"      <td>",
"       5 min IV",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       2-3 hr",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Active metabolite is normeperidine a potent respiratory depressant;neonatal effect most likely if delivery occurs between 1 and 4 hr after administration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       50-100 mg IM",
"      </td>",
"      <td>",
"       40 min IM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Morphine",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Opioid",
"      </td>",
"      <td>",
"       2-5 mg IV",
"      </td>",
"      <td>",
"       3-5 min IV",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       3-4 hr",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Infrequent use during labor; greater respiratory depression in neonate than meperidine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5-10 mg IM",
"      </td>",
"      <td>",
"       20-40 min IM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Fentanyl",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Opioid",
"      </td>",
"      <td>",
"       25-50 mcg IV",
"      </td>",
"      <td>",
"       1-3 min IV",
"      </td>",
"      <td>",
"       30-60 min IV",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Short-acting, potent respiratory depressant; best used by PCA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       100 mcg IM",
"      </td>",
"      <td>",
"       7-10 min IM",
"      </td>",
"      <td>",
"       1-2 hr IM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Nalbuphine",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Mixed opioid agonist/antagonist",
"      </td>",
"      <td>",
"       10-20 mg IV",
"      </td>",
"      <td>",
"       2-3 min IV",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       3-6 hr",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Agonist/antagonist; less nausea and vomiting than with meperidine; ceiling of respiratory depression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10-20 mg IM",
"      </td>",
"      <td>",
"       10-15 min IM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Butorphanol",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Mixed opioid agonist/antagonist",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1-2 mg IV or IM",
"      </td>",
"      <td>",
"       5-10 min IV",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       3-4 hr",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Agonist/antagonist; maternal sedation similar to meperidine + phenothiazine; ceiling of respiratory depression; dysphoria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10-15 min IM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Pentazocine (Talwin)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Mixed opioid agonist/antagonist",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       20-40 mg IV/IM",
"      </td>",
"      <td>",
"       2-3 min IV",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       2-3 hr",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Agonist/antagonist; ceiling of respiratory depression; dysphoria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5-20 min IM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Promethazine (Phenergan)",
"      </td>",
"      <td>",
"       Phenothiazine",
"      </td>",
"      <td>",
"       25-75 mg IV/IM",
"      </td>",
"      <td>",
"       10-20 min",
"      </td>",
"      <td>",
"       3-4 hr",
"      </td>",
"      <td>",
"       Commonly used with opioids to mitigate nausea &amp; vomiting; may produce hypotension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hydroxyzine (Vistaril)",
"      </td>",
"      <td>",
"       Antihistamine",
"      </td>",
"      <td>",
"       25-50 mg IM",
"      </td>",
"      <td>",
"       30 min",
"      </td>",
"      <td>",
"       4 hr",
"      </td>",
"      <td>",
"       Commonly used with opioids to mitigate nausea &amp; vomiting; not used IV (painful on injection)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pentobarbital (Nembutal)",
"      </td>",
"      <td>",
"       Barbiturate",
"      </td>",
"      <td>",
"       100-200 mg PO/IM",
"      </td>",
"      <td>",
"       30-60 min",
"      </td>",
"      <td>",
"       3-6 hr",
"      </td>",
"      <td>",
"       Hypnotic; used only in early or prodromal labor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Secobarbital (Seconal)",
"      </td>",
"      <td>",
"       Barbiturate",
"      </td>",
"      <td>",
"       100 mg PO",
"      </td>",
"      <td>",
"       30-60 min",
"      </td>",
"      <td>",
"       3-6 hr",
"      </td>",
"      <td>",
"       Hypnotic; used only in early or prodromal labor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Ketamine (Ketalar&reg;)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Phencyclidine derivative",
"      </td>",
"      <td>",
"       10-20 mg IV",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       &lt;1 min",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       5 min",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       IV dose should not exceed 1 mg/kg per 30 min; psychiatric effects may be prevented with concomitant benzodiazepine; sedation for vaginal delivery; potent amnestic and analgesic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5-10 mg/kg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Midazolam (Versed)",
"      </td>",
"      <td>",
"       Benzodiazepine",
"      </td>",
"      <td>",
"       1-5 mg IV",
"      </td>",
"      <td>",
"       3-5 min",
"      </td>",
"      <td>",
"       1-2 hr",
"      </td>",
"      <td>",
"       Sedation and anxiolysis for vaginal delivery; non-irritating when given IV; potent amnestic; rapid onset/offset; used for eclamptic seizures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Diazepam (Valium)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Benzodiazepine",
"      </td>",
"      <td>",
"       2-5 mg IV",
"      </td>",
"      <td>",
"       5 min",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1-2 hr IV",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Sedation and anxiolysis for vaginal delivery; potent amnestic; rapid onset/offset; prolonged half-life; used for eclamptic seizures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 mg IM",
"      </td>",
"      <td>",
"       3-4 hr IM",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37277=[""].join("\n");
var outline_f36_25_37277=null;
var title_f36_25_37278="Episcleritis IBD";
var content_f36_25_37278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Episcleritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 181px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with episcleritis associated with inflammatory bowel disease showing the characteristic injection of the ciliary vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner- Fenwick, Inc at 1-800-432-8433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37278=[""].join("\n");
var outline_f36_25_37278=null;
var title_f36_25_37279="Survival by residual tumor vol";
var content_f36_25_37279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Estimated five-year survival for epithelial ovarian carcinoma by residual tumor volume after adjusting for age and international federation of gynecology and obstetrics (FIGO) stage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tingulstad S, Skjeldestad E, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003; 101:885.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_25_37279=[""].join("\n");
var outline_f36_25_37279=null;
